var title_f30_23_31088="MUNE multiple point stimulation";
var content_f30_23_31088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 649px\">",
"   <div class=\"ttl\">",
"    Motor unit number estimation (MUNE) by the multiple point stimulation method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 629px; height: 441px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A group of single motor unit action potential (S-MUAP) waveforms recorded from the thenar muscles of an ALS patient using low intensity multiple point stimulation. The amplitudes of these potentials can be averaged to obtain the representative S-MUAP amplitude for calculation of the MUNE. Note the higher amplitude motor unit (waveform 2, left column, middle row) in this patient with motor neuron disease, a correlate of the collateral reinnervation. The following waveform data appears above each tracing (left to right): Waveform number (1 to 10), onset latency (milliseconds; time base varies from tracing to tracing with settings at 5, 10 or 20 milliseconds/division), peak-to-peak amplitude (microvolts; sensitivity 100 microvolts per division), negative peak amplitude (microvolts) and area (microvolts-milliseconds).&nbsp;",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Clifton Gooch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31088=[""].join("\n");
var outline_f30_23_31088=null;
var title_f30_23_31089="LS SCC 1";
var content_f30_23_31089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus (LS) and squamous cell cancer (SCC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAP8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDJj1GbT9Sns9TLKokxDcE/eHbf6H3/ADrooZSRjc3PvVHxXpxnvGCFfIZT8si7tzA9j261zml3d1YXLQljJa9URvvIPY+nsefrXme0s7M+milJXPQrWVkI+c/nWrBMSPvHNctY3aXCB1bP1rVt5l6E1tGVxSgbBZ2BGT060nITqc/WooJVPvUr4bpz+NbJmViq4JbIY5HvVuMB1XBINReRnkGp7SP95t9OaE9RTWgku9cBieKqyqXwATk+9bLwF1wRVKWMRuD1xVMyTVjg/HGnNc6Pd4TdIq9PXBz+dcPo2pzQOlpeNJvdCI95w24Y4z36frXst/CWGSuQeuRXk/xO0fBtpbSM74nDnDfdPA4z6j+lc1SPUuEr+6a+k3ojuRPI80yMjeYhG0hSSQffgVZuJmgtJbaHc00kBlDA8rzyT+dc54UuZb+4hW4dRHHu8xSeoHTnuMnpW5dlrq9nlQYZoWj4GCFAOSOwyTj8M1hfQ2tqalrd7LJCjOyAbmGeWz0/Kr9ldtAskDl96n5sZIBJPeqUccRnW3iZAIo0U54yw6cfXn8Kdptz9nu8JM06zu4DkYXtzhv84q10E7GtbJ5aE7mLSsAShPH+RVueaOFNkcpDSELuBwQO549qgt3Pn4VC4jQuTuAHPT1A4BrNknludQYt5aQQJvYv3PQcfn9ab90ndm/PdhvLS3Vi23v/AAj6f0pyGLzI7Q3DBQN7sTncT/8AXzWZp0M7SF5fMjL84cZOPfFX4CkephfJLkp8xB6YP/16V29SeWxpLILfcUO1NoO48Y7DirNsDJb7pgXnmywDDoDwOPpisjUZPMuFt4xlpVAC46DJ3Mfw4/GtLT7qGSJZIpnYnI5U9uOvpVpmbWlyzIsaQxwO7F0BYl/YdfrUiSeWm3JyqDbnuT/+qqV3OypKIsGTGMkdcnBqS/mSKz8xZAWfCqVOevf60XItcuySZWJFkLs/BIOflxyf8+tZrzb9cLKyrbJH5fB6uCP/ANVQPI+nQKzjE0vyRqOqKOg/qTUsKQR7TcKRFHEwAJyeoyxx3zmhu40rF+f52jQt8pOSc+gzXG6g4/tK4MbZXf8Aw9OgrdS5u54ISIgxb5o4+mPTc3fj/JrBvzKupSx3OxZsByinJGc8mmncdNWZoac2TtOfxrXSNowCCdvpWHYE7wRXQRTBlA9K1SKk+xYhJxnJqTDbxtJqsZMHjinpP8w5pk6o4rxIFNkd3L7wU2+vQj8iax/sCzWMkURJXb9455HpWpqtuzMqqSzZBy3zHOf0/Cq2yS3tGVOImBG0tyhPYd64JNcx1x0icx/pOmSRhG38Y2scHjtnvW3pWtW93HuVwCOCPQ+ntS/2bHJCWkLMzA7txJNcV4ksZrW4SXTpRFLuw0h/i9mHeiMnHc1jJPQ9Qt7wKMhs1ow3quPevLLDWbu1KxX6FHwCGwQp/Oui07WEcAqwJ74NbxqFOCep3kM4bA6Yq/EACHXkiuVtb3zcbSMetbVpKuBvJP1Nac1znqRVjfSUyQuIwOnJquYsoR61DFPGqbY1UevHWpHYBMj5fpWik2cUtCtcqiRFXzk+nNcT4o0w3lpLAhBM/Dk9lHJP6AfjXU6herbkKw8yUjKoDgn6+g965vS7q7vHmuLpTGrvlBHg4QEYAz2PXoetTUa+EqnF35jC0y2ntraytrmK3T7OzIk7Eh+RkHOOD0/Srl7amCSSdtyRlCIstzI/qe/b9M8VoQzW0epotwzfvYAclCTuz0/Ifoav3SWstvuRAFUHMkhI49BmslTvE6k3e5iWcPlwTbpMXE7mMy7BnJ+8Vxg9M4/+vUlpp9w9+007RJGoHlkR4K/rx0Fa/hi0We3SZm/fAbcMMBTn5jjtz/Krd7bAai0SFywQB9vIBPf0pqF43YnO0nFDY9OOJHlkUgn8xjjkf1z1rOsTcTzAhY5GjkZHyMgbehP6VeR5xAyyswt48r+6Gc/WobAi01FYC+RcIZFYfxOPvL+WMfQ1Mt0Sk9SxZS+dcO8TuVjbYTg4L567fT/GppJAtx96IyqCT1BJPAH9aZo12qw3wkCkrcyNg8HBwQfpzWPegJNaXJUK00zNls4A2E/nwP0pN2Qku5aNwttLJO8jh5ItkGRycnrz6nmtKx3xwxCFuchU3emf59azNZs1kuVkt5FaWJQqDOQrc9R7cfnVuwd5LCzmWVCwiEhJj5LYxj69anZ2G2mrkl1cm4byhIn2iSZRgH7oBJz+gNXEnjN9GXiLQQRk7s/hmuPsGmbUWm3wuH+4+cZXHzHr7AVrWImvmeTAW3bBwjfwDjGff/Gkp36BKFjdimOp6kZRGBFF8qEHI+tR3UUt9qAiRiLGPEcnYMDn5fzGKpNILa3ItyBcSnCIW4A7E+gA5/Cr1nC2GkePDNsCgtyAccn3OM1TZna2xsSgrhlBYnnk9a5S7hCSyMwHmmRt3cnoRn8CPyrqwAmT/Co64rktWLPrxlBXymiAAGc8E/hVroRDcmsQN5PtWpag8DNZFu22QVpW05HUYrco0VjyfWpI4x5gzioo5d2KtQryOaBepx92qLcbdyvO2SQBnAqCNQs5bashYHGeG/EVjxG/SeWd5I3BY5WRSDjsAe35d6uRzy3Dg7WRQpJVhnOOvIPv9a8+92dTjYgvGkcyhCwB6qew+ucZrlGEseoOk9s/lZBG9wdv15/HFdDcs0k7CMKjYwfm6envzVHxARaWy2cflt5pAbC9DkcfjkfnQ1fVmtPTTuY9xZSy2MSxypslO0Rk53DPOO+AOOO9ZBuvL1F4oIMxQ53lGztIHQEj6DFat5exwQSi1bbIV2Quf+Wcan7w/wBpj0/Or3h/S4Hs4poomSbGFU4OB6/7x6n61UW+hW2rNXw9N9sUrBeHzcfKkmFI+nrXSw2mpmAMJAXUgdOCPf3rl7Jbe+8l7oIpBIKKoHzA4JX8j9O1bkV5PHiKCd3gVhhSxy3610QqRtqjlqQlf3WdRp0P2eBp764GV5bPCrWTrOsXlwrLo8ZWM9bll3Nj/YTj8z+VUMXk7ETlpY93yA9APXHrWzZQmK3/AHe4kDp3ArTmctI6GXJy+9LVnL/ZLr7FujkWV5m/eSksCQepyScntWrBDJbIE2gsMAbeB+FWrS0ErTO27a0hcKf89zzUjIZQQpwjd8c//WNRGnymspXMeFRLcXDzKAhO0AnqF9/rmtAQp9kijkZm2ncQScAdsCprjTCzw7MhAemOgFWGtiIdxkCOPuk9/wAO9aRja43UTsX4YktbdWTbJE5LgjqCe9Z9rM/2r7QqkiZixQnpyQP0FIlvcXqIqoI4lOTISRk4xkDsOvueKv2toBGxmIZk+7sG0D6ev41pvsYbJ3LUcduD5Tjaw5bHGT/nms3VdLJgnmt8pPCvmR89QAcj271s29u4G5vmHJ55puofLYzHp8u3Ge1ROKa1JU7PRnEQSubxoZV3CVVww7jaAfx+WrniXyn05JNpDwEkHPAypXH45FT68hNxBdxweXHGx3SE8gHjOPQ+vuabMpuLee3iHmQuNhlU/L9c+tckotXRvzJ2ZjRhZrlEhLM24AgjJPH8zj9auokvntpkbyxsZ2dyAeI8BsD6lgPpmsrTIXtNT8udwWzywJ+Y8AEH1xz75NW76Xy/FTXjysUtrIELwRvZsA/kD+dRB3V2VLeyKtp5MSpbtIoCREM3TGW5A9+gFbsFrPFYgTBYzgKEQ/xE4AP0yOn51m+F7BZmtLqRfkQ7mcnOWIBH0wMH6kV0Ny8t3cwpEAkW4srEZEhAPQ+mcc/lThHS4py1sZdzzeiC3j2iNCoXPJbKjn65Az6ZrZmKC48u4JyVXAyRzzWXY2wuW/tMRSL5LFl5JyOd2fpk/lWnLse7BliIkzheeJEPUZ9e+PaqS0IlvYlczFFRJhCyHkgKdw/H/Oax7pHF6S8kj/LxuxjGfYVc1GwkS8tmtppYVIILZzjvjnjsazIzIl46XDbnVQc79xI559q0iveIst0aFuEQ7mGTV8SZIAwOM1nKQ2MHirAY793YYFdPQlamjCCeuDVhN4cbSQKitWBXNWgybhipG2efcG5eKOzfaPm+XbtOO+SRUQulQ4MMsQHVSnJ+mKq6nqVpCZHWeIJnJjMi5PvweCKWXXImsRMTHOuOGUjg9z/9euJWTOqzsV76e3F1NM0iRuIw0e75SRgkjB69K5ebURdy5aQcAqnOSM9cDueSB7/SodZ1eXUrp0gVv3uYgTgMFzzj0zzz9K2/DPh5II3ll2u4CklhwueAB6n2/lUNOTsjeCUFeQzSNCedftt0AqIQqwggsPr2yf0HHSuhgWCGC3WHAJTIzz265pbwrbwy2sUv7xFy5P3owR94/wC0ecCotOXfbW77PmjAyMYPt+H860ULaITbkr9BNLt4kmuI5WAImLYIxwef5mult4bSecyQx4ZVxhTkf/rNZVwVF9cTuQ8gCEqCOhAB/H5a3dJjVUkEOFGQQe/IrSEHexhUelyZQUjJ52ngU6HeG2oPl6EmrP2dgdgbP8XPamxHziArDGOcHvXTYyWxKiYXCqAariHyy4PEeTnPOau2wGSCeOxPpVadZJZXt7dwXPLsRkID0/E9vzpk9bFRwTMIIG2kfelPIT29z/Lv6VagtVg5chpCMNK3zFvqe306VKlgsKL5YZAOOuR/+upGeSMFVMEpxjn5T+VCv1B67EodoEZSmBjH7s9aRYw1qzodpz0qiZ2RGMkbIRyTGwIz9Knj3ywMySKSw3bVPUdaL3DlaL0bTQoyzIcjByBUN9LHPDJkbFxwD+tSWcr/AHZlcZ5Oec1Y1GOI2EhdAAV/yKb1Whi1aWpW1pAbSWLZ5u5cEDuO4/EVzdnILdFt4T58SgbGTg7McAdjjp2rrjZcl45GXnkdQa5y90y588TWoUMDz7nscdj7/nWU03qODS0M/VraCdiyYZGXZJvyCvIKkjqMHv27Vx014zXepyTFmeDMZ5A3bVAGfzIJ9+1dfczNIHgnQibtu+Ug/wCye3PbOPQmuU3Il9LBKj3AeZvMyP3i/dzkYGeB25571xVVZnXSO00XT/J0eG0mkBj2jBBxk98+v41cuBIxW3mT/SIwWWQZIZSMZB9ex+hrOsAjL5STN9mijUsVOGYHIC56rjB/Sprm3hWZXghMpVcMW3YIPv14IrRPQye5d0q2W1ElvARH8oO3PBBHII9yDzTrTaYmguSSYRtYNnBI6H8sc1nIbi2u4ZBbQlHjwAJMEYOeNw96W6uLkI0/2drdCMMzNu2+/Hb19vpVJ26Ba7LOoT+Q0cayuyD5sFSSPoa5ua7E2tz4jkTcoHzZxwB0z9TWnLb3F7iSaXyJM8SRkEHHQHsfxqLV9Kkt3a/kl3so3EAkg8c8Zx0qo3buhqy0ZYtcmNcHnFalsMD1J7Vi6ZcpNChX+IZXHet21tpAhLnBPf8Au/8A166U7oykrbjwwWXCfjipSWZhxge9PjiSIcdfWlARW5zRYaZ5JEs1ztms5bVXkzzsHmSLyTwOAPrTL+ATDyxEkpUEMw+bnGSAcAD3wPxNVbiA6dq81sscirMC0cvmYxzyo4z+tbVpAsn3pJ2HG8OyqAB/CSF/E/4muFxudu2pl6bZQWOm291cxJ50rR+VuXhUzzjHrzkmt2G43qxjUPydrZ/dqT1PH3iOmB/9epdO0wSWpNxDGqSfu40PLkA/ebP3enQYwB3q9EbJV8pod0oYAMPlD+uD2A/x96qMbEuV2Zw06Q2c2PN+0Pkuzn5m6Zb64wPy6VoabNGoMZVWZ02xge3v+HWpYlAiaV3d95AiX1HZsd+TnmryabHbQJuGJsYYkfdFaRjrdDc76MzJLLN+YXIJmiG7jkAE5P5N/Kuq0+yWMSEZCgjv1NZ1vb+bqKXAB2xBoQp69RlvzXH4VeuJfs43MGMCg8r2HoR6VvFW1MJyc3ZF6RFYHJ9s1m24Ecj+WpPb8Kh07UTqMjGEFUXjBHLZq6GMbADnseeam92aKm6d4yMXW9VktbYmNMhSRtHVuwH54q3pFy0KpDuUyffkOfvE9SaoazbPdyWsbcIHLuG64UEgfniodPtpI5Fmlb5c5z7UR5rnU6UJU/M7Dzd0Y5I9waqToAMsxK+pqjY3cfntF5rM33hzyPyqzfSFLfJBcA9BW2h58oOErGfdxkh1hkZXxkcVa0xWMABYK3Tk45rO0+RnlYbmyx+9nOK2bfyyiMxVT/EAMDgfr+FTbS5rJte6zVs7oo3lTr06bqk1CCOeMIoZFZlB2nryM8VSMLRxh2jJU/xKelOWeR/liZX46Dg/lS6WZyuOt0aapKh+Uhh6DrVdmCuc/KzcccUK8u1WZXwBTPtCyRsCwJzwMUJkWKWpW8E8LrLs24J3Efd98H+XevPbqwlh1tJFxE1xwqOD8u3AwD16EEexx2r0SSM7B5kLYBByDxnscVzXiK2aaSO4VtskMMrkdTgYOR2yP6kVlWhzK50UnZkdsksd7c3E4ZjtjDMo3qMAkEgdcg+xHrWjGwubfzLYmN/4micFW5/zxgfjSaFMiWwmVxI7/POhGGDHk4Ht0x7fnYv7eGVDNCAr8fOnynnvnv8AjUcmmgX1KqmYSKCQRnJDKOPcc9f51pwNPs2loiSM8Z5rnriS7t0MmwyKhP7xRuyPQr1/LNOtNUMqhoyGHZl9f1wahNrcbp32LslwbFmKFBEfk2licHBx2/L2IFZus3sht50LRC3wd21TyOecnp9Ko6/J9rkgEECfaJWAMm7Yw2kEnI7cd6imuFtnt47udTC8m11PI+n54q0xqnbU3/Blmkel2s8w2sYwUUjlRj+ddEZFZPlPfArItbnz5FHRP51KtwsbMM8DoK2TUVYycXKVy7JLhyBzUXmsGBNZU1w6nzAf/wBVFtdNPPnqopKdzZ0rK5y3iiya+gY6cdtxC2+ObOAHHYH+dZ3g+73RyJcRtNOBiRDxhsnqTxwa67yVZ/L4CL6cVzuv2a2dyNUtojI0Y/exj+NfXHcis3HW5qndcptWBe4S5DFQzZYqOpz3J9K0rq3S1sWdostJhBjr9AOw9BXI6XqMkhlMUQ82RV8pTxhecsT+Vdna2kshR7udp5ANqKPlCcck/wCNEFe4pxcdx9vGqTfcO8gEAj7o9f5YqzIx37mcNBDyx69B0H06U2S22xfMSxJHJ6tz/KpL2J7ZBbI6MW2lsfyreKsZpJtahYMFtwvCEjJx2J6iql6zsI4ldArkDJGfxp9rGSzLKw2j5iq/yqzPDvBKj5+oo6GiioSuJFaR2kKNCYAwYl8Hv9KoXtwybw0hOe45A+lV7LTzZys0uS7Esc9Dk/0rRtbRdQ3hGHyHkjuKVuY092Du3dGLA7TXsCL/AKtgzBmHLHjgVf8ANQWTxLsz5m1snnH0q7qFr5SwPayB/KO50VeSpBDfU4OfwqRIrZwhYbogrOpxxyP1HFUotDlXUtbGDd2P2cwXMJU5PzYbkgn+dauMQqrnaCOc/wCNSnbHBGXdfLjJKp6GnRbZ7djg5HY1okjmr1pSSuR2ltGkodGB3Y3Z71oyx2/kIrLz/L0rLCyRMI2XkdD1rWtIvNtNzBcZwAw5z7UraGLet7ksCSG2+YysnQEdCKVrONiJELI3TI9KS3aSONokHzDnB44p0MvkpvkbLCpaTMnJ30Iy8qYQSblH1Bpj3QTacqW/P9aW7zIoLDbuOcVmyW5JYL8qZ4rNuxvCKluWJLoyMcMzY6Y6GqWpxmazuVA3O8Lx8HnkVYm/0eBQTjPYU6DLKC/fkiiza1KslqjKllOYLmEkxEYlAGeMcMD6j/61DSzxRCPbujUtgheCP4e/v29K0re3S3l8l2wjgmMeo9KdHbNLbWxbhFXy2B5+n8h+dS4O2gnNJ+RhPNtjP7qQ/OD8vTrzzTJogJS0Vu8Mp/jUgFvr2I+tbd1afu5FHJIKj0rHvJRb2L3MzBW28BRnn/8AXWDTRpGXNsc+bw3mqT+Yrx3MKhVUj5WGSGI9sgZp11E9zH+8RZ12kEDAIH1qtAreYXCbjneX64J4Yfj1rTuV+bMm4rgYHQ5pQd1c6GraE3hrVo3svLkljE8XDrnkDsce9X5LgB2cMHTrjvXCarDG7NcRLLFcK2A3fH19Pasz+0dTVViinEu/IO4BcD6j/ClKT2Kjh9eZHpN1dIEyWAB7VlT6jHA43MUT681yVzd61NEESOJQo++CX/Aepqquk3U1zvu5pXPVI278d8cUuZl8iS1PU5gUlyepNJLEHOCODSXALzFuoycCrEGGi+fp2NdW5x7HOWdvHpepzlmby5OIc8hcclB7c5FdNY3bFYsMGDHc3+FZ2r2pmt/Jxhm53d1bsarafIfssOSUO3kA8A9801oaO01qdVvW6uEDOVA4GO34VLLs81VYZJ7n+E1kaNMrPl+vY57VfnvFhnji2h++atWauZcjUrIvWypEjjGdxyW9cU1ZCzyblwMYXNMt7iOaUsSytklh1AqS52iVc8I3TFNA+zKtwdtxGWX7zA4HNaUkQkdFihxnk44z9aqz28o8tkbcqKWIx/WtKW53QWht9ocnLjHJ9q0irGc27Kxi3On3NpdB5lLBn37l4G3uMfj2qS5sIJLkR2xaGJgJJRgkHJ6gdAOnPTJNbF3sucLJ55n8zcuzPB4J4pkCvZzywXcJZUQTbg+WCkkFf93OaOUn20mk+pC9rbyeZ5G2QvGDmTO5WHcdsfX0NUlVoHZgFD5GeO9amlLg7ZGOShZSw+8uSR9O4qGVFfdjBfGf/wBVMzlNq6ZmoxkujvO3jIwOpFaqNGoZXdVVjkFQeSBVNoCQJlAAA7mhLiNlVnRztbAUHt6f/XoIvceZMBmWUD5uMj+dRMscrruffITk4ogiUxzbwwZycr1x7VFagxSlg5Kjv6fjWTLirlxosuU2sCOvrS+WgDlskJ1Yim211KGcwEgkkMcZ61DdXEkZ2MVIPO0joaWhtGMm7DZVD5YqzBBnO3NEe6SIs/XgBQajhL3Mgh84qo9T94/yqzEUtI5hli6nbjOcH696pIclbTqU7olWjyOEdSO554P4YJq+reXZMHOGAJBxxn3rPuQIg0ru4zyR6/59Ku6W5vI9si7MjIUnt70lvYU4+7caCZJicEeo96xvGqr/AGZEkSKSZlDe/f8ApW3eRgMqQNgjjK1iatZXk8XlW4hL7lZnYnsRwT9Kid2mgg0pKRztiqAgyoDjkHrz249aLg+ZcjD+U456Z/nVy5hjsWEN8H8w/wCrEZ+Qn3zz+ArOv7czzsN2MH5WU/e9Tj0rBe6rHXH3ncoahE0rjDrkk8k4z781Xht41lbfCjgnaCh4OOpwR9Pyq1c2+LM/ZpyShyQ4xz2/WomskCRJPI0kg+6FZimB1IHTPU1FrnQthivbq+JDIEDH5Ixu59yOBVy1uZTMgEexMfwoVH/66SIRS7dscsfmMVCnhR2HFP8AsrC7WPzWyMgg4VeKaTFJLqdRMQHcKOMkU6AZiGei81auEVpnYYC5OKhIDqUXC8E/X2roSOLoQ3RWRy47VlW8kK3d1bNGBIkhIA43KeQf1q3KMEqDyOuDUd9pw1C1DwsI7yIfI56H2PtTKhZblvTVVCQQN2MLntk1PL5c10seQH65P1//AF1j6Tdk6cSySJfQviRXPoen1rVltJ1R9SMm1Ix5gBGT9M1UUb2tLVl6WOS2u2kQHyCw4xVyWT7RIJYoxjcDgn7tczp3jFJXlg8tlVWzzySDXX6XJA9sGhyUfLdvlPpWis9jLEU6lL+JHUg824kEw27FQE4I7VLpjK7KXQiRR94Dg8VPvEcW9imzpk+tSTzSQQwyWkYbnJ+nHP6/pVHLKV1ZIfefLPHdJKzXIGAcE8dPT1ot8nTpSNvnrGVuQx+YnPB9xzViNbqdOquxwPMRcdc/KaoR3Mj3AM0eVVCkmMhnX/DNM54t7dhpzG6wyoySDPO3g9xj2xj86S4nxtxjf6VM4KSC5uptzSAbAc4Awe/r0/MVlXMqo5ZMnJz7ClY0+J2LkcpuP3PIKjgegqtdJ9nIJkwBg56dqNPDKzSuxLqCcfWpNZyIyu0bnVABnuQD/Wgxek7It6XB58LO7nL5PHYVWvFW1thGgYvuyc1asnaCIBcODwTnlaz5J/OmKzY3sGIBOAnP/wBapexvSTcr9B9rMWWPcwjUAjPctQ4EjDqR0JI6mo7ZoBEZt+85IAxnJA4PtUfnsk8e/wCdXbO0dSB/Spt3Oi2rsXo4UkjPlHGecnrxVwopePMfVskY44qlpzbp/NEZWJjtZj91ew5rWASRyFD7AuB2z3J9hWljmqNp2ILq2iuXbeMAdAo4X/GswweVEyo37yU5D45UetaEdywUrbx9FJJbpiqqxyTQoZwcdcY4H0/+vSaQ4cy06ECXEMREcmGYdSD1P1/pWlp1urwh3BO75iKzXtYpFAEahmO3aB1ya6GxhNu6xuf3ZHyk9vbNZ2uxVrJaFO9sLa5XZPGjqezrXA6vYNpt64WKBY+Fj3gsWU/3TnGfrXrF00UUI3sCSM7a4Hx1MnlRG3wVBywxwPb61FRK1y8HOTny9GcfI2bIxQwYmDDe3UZB5OemKsJFLuEX7oJjAkB+/wCpz6Uthcy3sTwGGUI4KlemR3xxz9BVxnWW0xBD5IhGxnKsRnPbJ7/1rGOp6cnZ2sZVxCUt3AnRijEDg5/QcVBdafIkoDTwyBH5CZ2sMHucE8mtu4nnkQeWI4SrLGhiUKCeuTnjtUccNzcXizTvLcO5bczYP45Oev0ppdjPme5tytyw96bFEcFjuIx0AxVpgrXBCscE9jVryzu2qePWtlG7OWUraGFLDk9AM0tvmETbuqrurpotPiJzIct1xWZexx/bGWJfl2Yq3GwozvoYqeTcSQ3S7R5wCOffsf6flWzaSwy6FdWszZlGQAT1HrXPzsiXCW23CyKenYjoa1NFBQq91jaoKkmhGnS5zllZRwG53IGkR9m4P+XHpWxoly1tqC5baGB2g929Ky/EKx2dybmxRpyTgJHz/ntSxXBkjheSMRyMAdpGCKz2Z6006sOZ7M6j7VPMXhd1UBuhUcYqeyvJ7NzHc4aNxsAB5APp7Vz8uqbp8bfLcrhSfYVPpV3JcgiWMSNghVB5JHatEzz6lBqN2tD0qziiWx3AZbggjuKqatpwu4ZGgleKQDPljIz7/hjGK53R9WdWWNWbaeiOeV9we9dfDJtjVgQ+4YLcdK1vc8icJUpXMOCydoox84QcLnvisrU7OaInkmMnOR2ro72VrS5V8/uG4Yjt71FcXMTR5UBlPc0xqck7nO6a2PMjbJ5698e9TyJLe6g6xLhYsNyOM0kklukcksKgKeGZak8LXqzwXEmQuZSqnPXGKTWhLbcnKw6ZX2GM5Ur8zFRVGWFhuVNvPLuzc/Wtq/uEWSQrjJG3IHrWbb2JmkMkz4A/h9PrUNHXSnZXZVmlIRY1UsByWAxUVgsl1K7KGT5sbm7A1oXUMsrBYI8x4wCe+e9bNlaS/Z0aV1LRrkDhQMD360bsuVVRj6kNvarEiKAojUkFv7x9q1YokljDSOqRgZIY4AHvVPLNblgdi4JJxkt+FRyuJrRfIUmBcNwMlmqzkacxHcShCsR285J/i5/lUuwFFVycE5I7YqW3CraiSYFc9jTEkAZwoLAnjHTAoKXkK8KGaFsYHt3xVydkRdjlsEct3FJaITKS+Gxipp7ceVdysSMDgnnnsKWxm2r2ZhStJNI7McqehHpVW7soblwjqcKNxAPBPQcfnWutuQiDjb0FSQ2W92JHBPX2rmtdm3tFHY4y/wBNhiCrNButF5YxybH74OTwMZrPigWKJHEsfyZbYSGUkdz9fSu9v7GN1aJk3I3G1ueP8a5SKCCw1QxSQnIHyA5Ixngc9qHA66VXni+5kw28l1ePNJBLKrYfM7be2N3bNaMlsUCFvKbtkktj6DpWndbr64895VhVBhSDgr7CsO7v5I5yiIjIDzOSFH0xnn8M0kuUXO2akMBaclOmavxQuccc+taCR21qrLuUj+8T1qMhGbdGwwemDW0VYwlPmZHcKYZ1PIHfnrWRINpc4+Y1tS8p+8ZSPesq5ClsRHd+HSmxwOfuIP8ATA3OTxUjTyLJNCv3cBgfqOlXLi0LZO4rg8nHFV7dUZiWJz0J7kdjSimbqSuUbV1juQGTETLtOR90/Sr0cUMytC4DN2I6Y7EVQkDR3sm5vk6qcVZs2CxNI67SjfpULsdktroiudMd+jqV6Zx0zUVvFJpqESEsoYFGAI59K04rpjOymMEdQwb+dW7mFpisKosjsuVUD73sPetFFdDGdaS92WxD5kF2wubaQRyfxIV4fnPboff/APVWra315BbXEUEaEHAHmt905OCPXjHvWPY2qK4li4KkMVAwy4+vatezsrmWANJKkkJJKhTyPf2NUjlqKC06HTWts40yIzt5khXLN2Pr+dc7r8nlWjIhEStwDjpXXQTCWwjwgBC8445rz/xRdSPezxuuYicL6U2zkw0XOpqZLXbwWpCbSr9ic4qj4XvriXUbzT4AoUf6Ru7KOhFO3R48ssMYz7g1n+GZltfF8pALpPCV6dMEf4mi+h2TpWu7HfRFBGsy7pXwcse1WrOKSWF5NpCbSfm4H40aXBGtrKS/O88A8gdhWnZRbowjHCAE9e+ahysckp20Qy13FoYhGxUL1U8t60t9HLKhkWRRBGd2zOAf/r1ajiePO1eD3HWsjWJbldsUeVV8gnPWknfUUPeloXzMktlJ18s/KckjOeKtWk9vGGRACFXAwMBaxYpJFtyo34UjJxwDV61tJXUtMRGhwfdqtMqUElZsledWmCMofHXB4NNsnHnuSmF3dM8DnpTLny/OY7wUQqpT+L/69WrHyVMCsP3u4kr6ehpjdlHQ04ICVKkYduTVW7HmssQZi5fcwzwMe1a8qgRhud3H5VmWMfztI3QknNDOaMt5DREGdlJwEq5ACUVWChR+tN+zNKQU6H5nx1+lWEGxjwDnsaxSsyXK5CY48EYAb19fauf8QaYZrN2iYrLg4ZetdXJAjIGUEE9PSsi/Vol3Ebs9MVRdKo4u6PObiB/sUBdjJMmWbd0H+feuavtWLTpaWaJcXLsTg/d6ZP6V2OrqLi2eNBtDAgjHU+9cj4U055dcvbiVAiRfuY1HT1Y/yFZNq9j1YSTi5S6HRWUz3B2lya1oCqIQWO8GvIo9X1bQ7lRdgvbOTsnX5lJzyDx8p+tdbo+utfTZjG9sA47/AJVKlqaVaWl1sdqgedsMTgdh3qYW7/dVMcdB1rJtfEdpaxlL+B4n6hsdaz9X8dtJmHS7aSMEcysBn/61bJqxx8lSTtFF3XLjyFEDsGmfoAfuD3qhArhSy9McDuawITNdhpYS0hdv3koOW+nNdFp7SHyw214+z+1aI2VPkRZW2Ei75FBIGSB3pYIVlSWIcZBOT+WKtlAVPl8kjBANFv5EcbGfcGXJK5xSe4KbsY2nx3FtI8bIMjo3qO1W4mLZaPcsw5HzYINSwiXzCX2LkZAY4yPb3qO9uBC4AB83+IMOtPoXKXM7FmznkE7zuxaVuGZu5xiteziiRSzgknBLRnj/AAzWNbunlZIJYnhSOB/9erC3DwQ58zEQYHbuxye+P60I56kb6It6nrIsLKWGF5fNY7V3Dp61xUurCIETMWU8ncM4rfu4RdNzESxXcD6j1rAmsJpZSoQbT/EazlJpnXhoU0rMgsG+1XomgUPEBhyvofaqJdY/HFolo48p1ZTvTB46AflmnreWVo0tpC7C4X5WAygB+vcViafIYPH+mtNJuUykHcOY2KkYP+NCqRtubVaUk27aWPXtJZtzkKSCuC+eCc9v89q2odywlD8zEcDPWsO08uytIYvMHJxhTnByeK2PNBs18sEy7wqgHvU3vc8Wa1GpqTWziAwtI8a4O0DJ+tSWsMl3KZZVyz87R0H/ANemQWsW5mHEhbbuB/P8TWqEOOM7sYAHAzUwZMpJbFeC1VjyMKOcD1qa+WNpIVLn5OevGc96I0lPmRnJO4Nx2pmos6Anyx8vy4yM8/rW0JXJTbkUZbdBfS7mbH8J29snP/66kuHktbi2EhUogOMdck85qWCUtLua33fu8He+PxzUV9AjtbGPmSSNpG+Y4A5x19hVmyld2kdBJcF7UmMhuBn6UgiEdruLfMBwBWPatJDZnJ5IJIH8qs6fcPcFQTlcBm9qmT0OeULLQ17FJVskf/loPvrjv3psbb5pDtPBzkUs7sqtJB8zH7yg9R7e9RWlykse5D6gjoQfQ+9Zt2djJbNkjlvuqTyMkCswlgrgg5JPzE5wKtXkjgb4iBIBgZ6GsyO48uKaSWTgsTg8U00XFOxy+sOEiaTaNwJAA7nJ4rOsrb7N5YHDHJb6nrSarcC41BTBL8sSeYV/2i3GR9M1atgWY+b68H0rLdnfFNROAZlk2xSIDHJMN644IXkg5+mPfNSJohtR9s0acxK3BXhgvsQe1RSSpHqNzKgHkbjGGPIBJyePwH5U9Jpo3KwxyksOAw+U/gf/AK9SpK+p6duZaFHUZb9WjNyluT0DquMflVyyZpFDuF56Iwx+R6Uly9x5hANtnG1VRi3B7+/eltzIPmh8mMfxoykr+Wf5VpGWolFcppq8+UNuI4m7qcDP+NT288by+XJEsUw+Yg9GPqKzfMljYAogDHBVQWH1AxViKP7UzJgFgOI2PH/ATWlxcqtqdXp04ReEXPYLxV2QiWJd77SG/u8YrltPuzEw84lgOvHzL/jXQW9wGRSrA5GW2nIA9Ke5yVIcrNizSKeYs4EYVcR9CBnjnH+RWfe2YmAgllTCkbHzjI/z6+lTSQNbhJbaVXAUSMP4SD/+rr2NMjvLK9EchjKLGMbV4KH2PbnPXiqT6HPr8S2Ks1vLZ7vMXhSCDggj04/wrPjuJYLrzQEIwV+YZHPp71uXWGZooXYwhiFEijI9iO1Z91bOImUx+VLH8jowwH9D7GhlU520l1K8t08mERcBjkjPH4Dt3pLi9WS63WkccYACuFGTwMEk1AjLvwcq4PBxzVdruJL1w5VZmOTjgvWerO6nFW2FW3jkaQTW4d3XbtYAg81zniWzS0ksXEaoRMCnOWAIIxmurvW+1SxMkijywreh9CAa5rxz9htraGYSeWzTKzKTzjOD+dJx0ZpCbcku5uaNflbIuwVyrgrIc5NdCtsupQSSGWTDtlNjYBUHqPriuQs4sqqxsx5ywHHH1rudDk/0coRt2jci9PlPSs6qstDgrOzujTh2RExNtEZHOO1XxJlARg/U9qguY1+xF3C7lHBqot2qMMEEEcAnminFtnHbm2LcV2EDoHfcTx7euaablrmQxwld4JB3Dp71k30x81JNzDPGN33auac6xMrrGxbOQT1966OVFuCS5jo4YYreA7ysh6/OOM1l2/2ZHJRck5BwTT7qSSWIbBtCjls8H8Km09YwnA3EjO4jtTv0MFeKuyRmjZApUrkZG4YzVbT2WLzwOMvjjtVu6uVfZBHGrZy2WOFGPz68Vj2hkie4MpREMhwQCwyMDrUy12COqNb7R5a5HA7ZPJrJ1S6a3k+1RkRuMb1zgOvv7+n5VV1W/dZwlsWaUjG48nH9BWPNbvcTB7hEldOVLnOD61HJc2hS6s6G612C2RmlLMR0IGa4nXtdubzTAYUkt48BTvX5pGPCqB2yfWrmyORjHxMw+8zHCD1Gaw9deUMW8xw8Ss0Earjc2MF8dlUE8nkk8UOHc3p0oxfmV/D1r9ntpTIZHmnmJldz8zEcflxwOwrsbZiWVsZz1Fc3osBitbKPJYhdxLcknHU/ia6WD5WGOtZpamtTc5o6RpWnqTDeLnP7tncMcZ5BHasDWbq1nult47hYUjAM7hwCR/dU+vqf6muljsVLhYrC18ps/wCkmPgAd0Pc++cD3rWj8P2yWsflQpLEAV2qAGJ6k/Xr9abi2tEaQq8rvJ3OOkjsfsgEU8D2agKqhgTH9D6Vl3W0yr9mvEZj0bIya7o2VtFF+5txISNrBEAYjOeR2P6fSq15YQyWrTxZkhJ5CHLJ7lf/AK1HLc1hVa6HNaZc3ISQLGtwoGflYEir1q0dwRndDL/zzk+Xd9D61FANhZryOKUjIWYIFO0jjlfrUxgS5jMUTyW74KqWb5JPbJyA3sad2aSd+liaKQQiTzM4Ixlhk/j/AI1NaNNFIXRwA5GQSMc+v+NY15pt5aARzXEjW45DR8lffBz+Q/KlC3toqutxG+OYztBU++emD3GPrzTUn1QOnFrR7nR232uRy1nctFKrbtpORn2q/NFJxO8AjlZcSGI4Rs9cD0PpXJaTI2myeZKqG0kbLor/ADQsf4l9Vz1HXkH1NdgPEHlW6mYrt5Ubcbj6YHf6c/hVRs9zjquUZWSuMhl8x8tIQ4XAVmz0pn25WupUcsQOpbrn3qxFb2927TSbokBG0IvBbuCe1VNY0xURkkkYZwysjcjPTBHeruJRhJ2M+6lLbnR8pnI/2aqzCPUI0mUqWh5J7g4qhdw3dpv/AHplVhwxXH5+lZS6vd2bDAULgBgB0rNtrU9GhQ5tIs1hdyWyhkYlwcqDjIXrz+Vcp4qZ9VjNzLIWkJCkfwoo/mf8aku9WluZRKiBlztK8Dim3sge3HkriMEFgSTk+n0qedT0OyeHdFc3VnaeG7hdR0+2nAWMyKnmAdiOD+FdsJ45HW3C7ZIgDwMgj61578OXivNMmt512tGTGCOMeh/pXYWbfY7CaSUs0keTu68VduZang4mFpuPY2by7dQsbvkYyAMVlGRXk4b5xwoHasB7/wC1R+e7GOUnhAe1a3hSx+0O81/II1J+VSec+5pxSWgezVKLcjQsrQyyOP3jHbuJ/vDvV2zkcTmEklkPEmM1cljTCeR5cioeTULwK6SlyQpXBC9xV2Od1Obc1AFCF2nG0jqTWfc3sEJGyZ5XzwADgfjWMn2iWEQySNIo5Uj+MD+oqwYEZVUkqMgFC2P5UWF7NJ6svz6vFEY5WniXYdrKG5AbA/niqUGoSz2gNurBWZmLNxnLGqurx26afdmGPDGMkA47DI5qWzu2i0sxtGd+904H+2ealb2GoK10hfJljmLebH5ZxkEnaT7VEHWWUiR28pTjjvUpQqBLOyONuQmc7frVSceZdtNxDb98HOTjPHt1/Knsax1HagghiVYApkmbZEmeT3J+gGSa57W4pIY9jOS0zBmJ4MgH8l9B/wDrroI4pjO07RGS4dP3cPXy17Z9+5/+tXP6grzaifOO6XgHnNJ7Fw0Zb09gwjKdEjxn3P8A+qtWGU7wM4NQRR+XagAcmp4F+cGshuzOf+3ayWWFZ4Lja37tWXy8fTJ/rV+z8Q6kzNBJprLdkYVkYlWUdiMY/WnLZWqsM/KsfygBiR9B6e1NvPMtJXVotzMPkfHI79ayTlHW5p7stLFqHUIp3Ms4aOcna4RgGz02kMefwovJIrjYGtJY5YzuNw6Ebj6Z/wAfzpkFysqhZHEVwQFA35WXH+9xn8qcut+QBBewKARj94uN30YZU/zra6ZNpJ6IqzjTZZmLTiDoz5UojHpg5GBVOGMeRIYvLmzkKUbO4Dseo6V00Atp9PlRIkcbPk8pgQufQDHH4VlRWkUUriaAzZb5CVUup7A5HzD6U7alRlozO+0RtbKjgI23CFuVPsc9PSqgl83zbaOzbeil5Ye+O5H8/wD61TXVtAN6RFoYnfht5KqTxyGzge/5+tSWZMsYjufKE8PyRTp1I9D9PrSTOiPKlexjX0McQiklTfG/ClhtEg6EEev8jVvTrooNlwoxgqFJwG7c+je/Q0/VS8rsuUVM/NHgcH+8PQ//AKqzruNUVGBj88LvjdGysg9D6dxg9KHLqi3TU4pM6W3NvB+8iaWUKBlZGPBI/ujjH0ra0kRTR4HzoR8wbk49jXJWNyjxRzRSLkdV/ii/xHt2rTs7iWGZg+zDtlNh4P09DTutzllTdmlub99pKiJmgPmpjJQ9fw9a4DxFoBLrcWaMQTllHQV6Lpt/FcpskYK6nBPofequqpJbTiYKPLPB9G+vvQ2miKNapSl5njFxE4uFikBjZTyGGCRXRaTYQjSrmRmEhX5cgcfl610+t2Frqts3lIElHoOVNcLdandeGVlt5LXz1lI2NuwFb3NKNk9TvqYmVenyrR9iDwpdNaarJsO9SSCrHGRn+dejxXjSyBGVcvwMHj8a8w8O3EoLzziJpjvjk2/MuScgg/hiuz0wtPaiQiSOQcjAOMe1KMraGVeCnafkbtpptvDemSU/uguUAH3TWzbXEDuAqYKc565rn7e5+2yiLDmbHzKgxketaemKIJ9z8KPvc54rdWtocNRN/E9TSuJmmXCnZGvZaks7j5TDMzc52v6e1UXnJJCKNp6Z7fhUF7GqxK88+GJ+43FNkKKasRahfRWRMMUu6ZnygVi21vU+lNj1Fp4ibqFiCMMFGNvr/wDrqKCGHf51sgcg45OBTIjcSXcwdgoDjCKMtyB09e9JKxq4xLau7IQsLAOu3c3XB9RSWsrWbXcN3MZIkVZUYjDBcYP1+6easSrcbx8p3dsjp+H+NZmvAiaUOwkd7N+FXOMH9epqZK2pEVzOxr2VtcXmx5njhtiAzKM7+R0GeCff/wDXTdTtXNxaiwXEZkBlaR/vAA4Ck9/XtVizilmjWe5QxxsAwQHrkd6dO/mTwIF/dKrMHJ6ZwOP1oewtVIiu9RWO2nS0Rt6j53IIOfQ1lafaAnzJOTVrVrcEr5TMrsQCT1I9xSj91DtYbT69jQxXtsK0m+XYvQVahA3CqVqQWOOo9auRZyC3AqLajctLGEolkkaQscuzE7F4x2J/TpWrZyo1uBKBtYZBx7etZdlcF4oklYBcbBjvjp70Xk0kEW2NcOJCArjhsnIyO3fmsNtToceZ2L81pFsOI90XOWBJx9P1qKK3j8kIoZV5wxPDfX0NSaZekQiG4BQj5V3cg/jU8gMmPKCgngBu/wBfWmmkyfeWjMeIqsv72VkjVskhcke5A/n0rYtWkljDebE7D7ssHy7vquMH6iqNzGVJEkMjMMZUDDD6Hv8ASp1gEAjNnKkMzAlQxyk2T91vQ479a1i9RzV0R3Cu8ihY/mwS4UYDL3yO/wCFYktoROBZnzIwSShP3eckep/mK6+1cTRFWzHcJ95GXDofp3HuO1c3fQ3JPnoMSIWBaMfe5OQw705xuVRqO9jMvZFDL5q/KwB3g5/WkbTo7mF2MiMCN0UiMOfYjt/nNX/tkd2nCjeRu+UYDDuQMdP6+9Tx2G1Q0ZGw/MXHG09j9O1QkdSqOK7M5HzpLG73gj513F+OR0z6cc5/+tXQaXcfabcwvjB+YgdV/wBpfb2rM1ONvtCiQgopOd3ftjjpkce9VdMuZLW5/drvWPGAAA4HY+/HBx6VMXZmlSPPG/U6yzMy3zJfbVC8CaP+MdjXR2lwJFMEgDgggDsw9v8ACuOe6jup4XztA+7k9DWzpjOxKuPmU8DPQj0q7djz6ybV2Gpo2mp50Zyvr3HsfUVyWtKmt2VxsQFlXlf8K6zVpWkhljfhSM5rg4Hlt5pPLQsrgjA7+496T006F0U5R5uqKPhmJrW5mtJYlCMMFS3Y9K6Wed9KsmZd0ig4wD0Heub0tZnvXktMs4ABMhyenIPpXZTWT3NjAkjBXx85UZDE/wAhS66G6abXNsUdD1hIL6O/gdTAQVYN1P8A9fiukOs2l/bhrVJFkB5VhwPpWBJo1np8KNGcEjnvWfDdyx6qfskRkYIoCMcLjJ61rFtEVaMKj5o9DurUSTWW4NgZ6CqZtoYZTLezAjOTuNYjXV3HIfPu47VSPnRPmYAegpbS8hEDTvEzxg/LcXTZIPsP/wBVaGCoyWqOjsCt80ptmMUcY+Ukcv8ATP8AOrNuRZX5MrLIXjyzhh/Cf/sqwI7m4OJLQlgfvMBhR9fasy+tbm81W0kdgzb8eXCMIRg5yaG+wRw/M3zOyOzm1QXwNvpoWWUD7xPyL+XWs7VIpLGNftTrLLcQvGQOPmOwYFTaLEYIDDDFHAQMHHQ+nJ61FdRpc6nbxzO0iIshY7sEthQAB2AznPXOKlu6IsoO0djfLNcEq/3AcHPb2/8ArU+1iQRszbjuJ2luxqjPOYYkD4aUr9xOFFUrnUXlKwb0PmceYM4xnBx69f8ACk2kZqEpLQsJK95O7N92M7QAOn40XEYkxHgnuRjtS6fFJa+bE4+YseAMHHapY0Y/OxK7iST7dhVLYxm7S0KE0ElntZGzGf71WbYPO67iyjtiobySSaXgDyl6LnrUkF2LdA8oVRUuwXdjg/D2rw3U0hdyhZ8IjnlD/d571100QmgEqPFnHG7lh9K85a3XS9fdm/1N229D1KyZ5Htnr+ddpptxLbS5fc5Iwy9Sfp6VyRkejKPY6KBFktv3hBVgcj1Pv+NVzbSQMrxMzBiVKHkAY7H1qOC7h80LDndnO0n86vi7UTojMq5y35f/AF6ejIV0Qm5wifaBJHH2kBwPz9j61Wu4Lm1jMsiRXMTksrbflPOenY/j/OrtzcKkqKzIEkz5ikZx05x/OnCF4o3iT/UufmjI46Y4qk7aBe3QozTLd28ZLPsVAYpc5eH/AGWPXHofpmpLG4MVwbW/faZG3RTsM7uMEZHfjp3B49KlnhiaFngZldciVMYIX2Hc47VWu7eG600JDIk4+VtsysGxg8grwfrgEVpGTuTJJq1ipqOnrbTCaONtpYyYj6hu5X27/wCNMctCn2q1kV7ZicqOwI6+n/6qqrf6lbXEcNzCZxuwskUqsTxnI6E/ln61GNRQ3Bkhf90+d0TDaynPUA+vcfjVcyZpGMlvqR/ZEv5HCA7v7rHGfas3VNHmVhcxBnKHLdiy55H1FdBHPaXN2pjkVLlcZjzhnB9M9fp14rT1OI+Ushbgjh14wfep5Ezf28otI4wRtvV0lDHgjj7w9frXRabIpiBBzg5xnqO4rO8tEZrcKBkGQY6g55x7dD7ZNSRtJblZFUMpOGHb/P8AWiOjIqrnVjXmVZoyQSS3v09vr/OuX/s1o9Vg7LuIA9R/Suo06dGuDGMDcoIz3FQ6va7pRIVKnGCehFU11OWnUcG4nIadcMNXu9qbd7kkKOhrcW8jSRYlEjO/3APX0rnHgNtq8nmn5myrRk8Z4wRjnvVyxmuBrNtCAHUsNsmOhoirOzOqLTjddjqm0y5vf3cbKZCmSqjkema5Fra4t9aMV6HR0Gw87QD1H9a9h0doYGAkTEqrh5WABPtXM6vplrqGp3FyoyrDazZxn3+tbcqOKhjXdxlscrbKkt2VigXa38SD0HcmtKJbaWOSGYJu5+ZgSF+lQTRPbyQrF8uzepGOB07fSrFgkao0NtJEJX/jk+Y/QGhHU3dXHLZSOI2a4Yqp6uNiMPXHUmtWWaExwrBFveJ1+ZhjAzj8OtU7dzayk3MZlY8YySW9s9h9OKbcAzSC0hTykYAyc8qvpkdzjgfWok7EyXNuXJb430xhtXA2ErLcj7q+wP8Ae/lTSUhum8sGLyoVjEh4LZJJx+QpEEcJMcaKkcIG1MYUE9z+X60klrHNvnkO3d8zlz14x09MAVF2Qor5EUFo93+/ckW45SI/xj/Cnm8FkX2RoXYZBAy5HooH0qvJJK8JNs4W3f5ftL9/9z1+vT61VN/BarILCCSZ1O15wuWJ9CT39uvtU81tipa7iLea3HdNcLBFb2X8SzMTIwPc4zg/5xVm78TW8SsJ5PJUHGWqG+mvzbwK0SwLI+CZcM57jAzwfrx9axNQt1vJJRCv2i4YYLOeAfUkY/wpczS0MrRm9V9xtW3iHTrlwlvcLLKf4BkMfwNXobea8nX7TmMYyEHOKzfDvh2DTSqwxq07/wCsmbqeO3oPaut0u0X7QHZyPf8ACp529xOEYu6POvEVoLy1ZBgPnejejDpUPhPVALcRyKXUnDIx5HqPzrVuYd6yLnnJ249a5m1iht9cxJ8i3J3K+cfP3H9a51udcbOOp6MohaLfHnfG25cjkjnrUyQg4lkCZPOMbhjuKy9HuPMkfcVIjIUOv05yPxFXlcwTyQq37yXiNAMgEn+VamV2jSitLduDGGyoBI7jtUyQ+ZIIXkYoD8j9yAOh/rVMQtbovzsrrgcnr+FWbeQzxbXiMUmATzxnsQafqKV90wu2eKc79m5yR8q8c9/UVmXMbQTG4WXDD7ypnkj29e/4VqtdQqPLvkMY3bVlB4bjoR2PXnpVa8hRHdYYhLHuyCWwcH39P8apq+oQlbRmfcQwXcxSZxE5IIOMDcenToabYxRTSSJMIzOmUkjYcuuPlbHfuPzqvfWsf2iJ1Mvz8Oh+Yqc9D6jqR3GPbNZuoXAtLyOUOnmqMElsBh3Gfrznt/NqbW50KnzKyZb1rw/btGXsnaF2I3QsxZfUED09CMYqEajqOmoReIL62z87oCJAuP4lPXHqOfrUkd+13taKQswHy5PKn0xVu1vTPkT5GMZOOnpzTum9NAako2lrYbazWt1biSBsA8rkdAff0pjxNv8AlB2McMp7H1qNrF4Z2nsnC7ifMtm+4/v/ALJ/T2p8U8XlSALLCyHLRyDlCPQ9CPxp+TM2+qIL5XhRZo22sufl68dxWnb6tZ6vZmGRwGVRuOcGquUfa8xymCSPWuZ1a1ht9RRVleG3nBKtGMknGQKE+wowjP4t0Ub2/wDM1UwShiyMQGXPz/j06AV0Gn3kEVpLBLGVnByp54/+vXGLOBfCWWBnJAw3bP8AStw3l1Pl5EQb+pBIp+Zuqa+Hoao13UjEsQuZFUrklwCQPrWpZ635+mSJbLI8sY5YD5R7k1zsVvHHFvLGQ9Mtz+lamnSSJagRR+ZEZADEDjJHQf1q+fTUznTpvWKGMLia8tZJ8Nt+Yoer8cjH9TWils15ceXZBI42+6WHzn2Hp/SqzXJS5tnMStK5ZltoyW2jgfMfzrUsPtgkkdfLBz80hGWA4woqVO7FKTWq0H2CMkZt/KMW3ILFtzN9TUmmIiwG7cAeedwOOi9FA9eMfiTU14VeK4tcH7RMp3eq5HBP+FUZY5gI7WBsygbd/URKB+pxj86GYOXMWYXjie5fYZ52lwqdcAKMcdu/JoZY5p1F5m4dV3m2jbKD0LdB/nvUWI7CIx2/J5ZyR09WJ/zmooL6OxgCyShrqYl2bqWz7Dt2/Cp9Ra/ZGai1zqd0LUOkMaH5yvJ/3Qe3HcVNcXGn6TGAPLVUQLGFGMcdh7nNYGpa08MBitY5C82RwMFz6euOlLY2jySqb0l5wMlV6L9Pf3qedIbptpdiOdr3WNRQMpittu1QvLsAOfpnv9BXSWVmltbpGiZz7df/AK1XbRRDbeVHGil+Wb+6PSrtpDvXLBWyc5LdAKhsTdkLbQJGC8qrsI4H9au2yJGqhRz6U1rdnkC7jtIwMDNT24KSqnB9Caa3IbPPJcqW3D+PPHpXP+IrYJJ5kWVAZZVP91x0/D/GukdAXYufvZHPY1UnjW6tXVwCApUjHUVzo6YuzLnh+4WfT4biSMhZTuYkcD0P14xV/ar3ZliYqqnEeBkBu9ch4Tv/ALI9zo87fuxJ+49TnnH55NdjKTBDG6gBABkY6H1/P+dbtqxnqpWNiO8XzU89NzHrnBDZ/wA9Ke8mWZ1Hy9CRwcdsis9JgnzLtLDBGRyOf/r/AKVbk3eX8xxu5yB/nFLmFypEcl00qshTJbtt4IHWoI4WjMggulBcBwpHH51BNCfmZ5m+U8bSB+B/GnSQO0Csg8scYZRkH2NO5ordCpfwXDtMSWE5TLMo54HfsfbkHiufaZJ5ib6PttBb/OK6OWaQZIjfzUBwFBIP19sc1Qmnt2iP7oQZcHy3BwQTnHTr/Sh2Z1UpNK1jKlsIIYEmt4THKBkFOFYenHeoE1C5tLxLqGJJYmXa6KcOy+ucYOPT61qm5VYHtmhCuBlRngiqLwqjMjcI/IYrwD359KjbZmqSa95GvFdiaNbi2jYA/KcYK8/jT5JpbadTcIhicYDoScH0II9B78fnWfJancu1tjMOSMhT7gjv+lSR3DxyxR3SfIjZEucgk5AB44PNbqRxTh2I5o5BDcQ2bqTjdFuPQHsfpgj8B71y/m3KrsYGSOKYOszj5kYHocdua7HUWWOE3MZU7F2sM4BXOcfXNYChr03a71Mb8AjryO/4/wA6WzKpSte5z5e4u/t1xFGfsySB5AOAmSQv0GSR+NaNves9kYIxllIOVGf1rm7ae4gubmyZsyPhXA/iGcjI/D9K2raWWzVY1hVnkICgNjJ7U7s6FbWP3G3ps8KIVvDggZCinz3EnkiWE+TbFwu4cMTnoPTiuaQXM9+yn/WrwYwOc+/p9a7C2s42gtFe4V3XbKHfBjAxyuP73pmo1k7BKMYNS7m1pVon2w3FvEY7cxIAMfPJuycsfyrelQWsHmkYkUYRR0BPYD1zWN4clkgjaW4ZpGnPmJls7U6An04Aq9K/nSmaQ7YIwSpYfeb2HoK0T7Hm1W3LUhkYi4TbKiiNGaVmHC5xkn1PHSmRkpFJcsTBbiP+I4dxknJPbPHFIkP2j95KVQMQwSQ4AUdM/wBfrVDV7+OW8gtgzTCJxJIRwrsPur9M8/gKp6K7JSu7IguFu3sgMrbxsSSoXBbnjvk+/T6VlXJkhXaZwrOP+Wa5JP1OTV7VtQkRnEhy7clV5P0GO1Joentd3nmXgMaAZf8A2U9B/KsJPWyOiKtG8tippemyxMo2O05OWJOTn3NdTZWcYC4JLDO5umT7U+O0VJC1uTHbEZCnglc9M+tX7WP7QdkWFjQ4yfSpQpTvqKQsrYVegxx2qxaKkfLfe9KI3SJpEj2yDpmnCHzV3LgN256VSMW+5ajuFRFOSDnqKtQNlh0UdiRVGFdiAybc5+6f51eTkqe3pVpGbaOCuITMxK4HB4zVBG2ScgYIOR71pyoy3Eik4ySRWZdb45htGRw39DXNszojqcnqCRw+NLMSZ8qQZOOOh/8Ar131rdfugtw+UIGTj5gOxx6VxXjQCKWwmRDJiQhsdcY7Guv8N3Q1HSoJnCeagEe7aOvfP1rWHYKj2kaMIKZcNuD9QvPOP8Oa0PleEEEnGDkHPHvWUm6EPDHt27uQp+6R/dNXdMcGQxb+WBYfXPNHkQ21qJIyeYTs3xOvp396kKOpkGJVgbkAnIB+tXjbpu2uAFZgM9D+dL88EgAPmwgEbWOcf/W56VQlPsZb2zEo8x3c4bnH54NVtUt38pUjK+UTkEAKOhxntx3OO1boMlu+2XBU8Icce31rDvwZJhJuQc9R0P8A9ek9Eb0ptyMB4onl8uSQxzAlSSckccDPQg9jU1jtMoSSUCcfcwOvsO1XJ7QJI0vleahIBA4z7U648s2wKnzB0bHUe1ZrfU7JTutDJvtWiLCA4MkbY+Tr+XpU0Go2kpuILoMFdcBCpO7jtjOe1UNUiSQ/aoIXLgYbCYJqtbRyF1lRWCE/Mvoa0jJp6jlSjKF1oW4UH74vEQmdohYcA9NxHQE+1V4mS3vFeRPLVh5cmOns1aCMq37GQ/K0YPPqMD+X8qp6xGouEIBKsVPHpkA5/WtLaaHG3Z2ZyGtj7P4kmaMZkf5o3Bxt6Zz69xVa8n2JlW33Dn73YVs+IrXGq2oHA5U+p7/yxWW0Ef8AaiQNxEmWf1PPTNOS0NaU1z/I2fCtrPdafIkamE+Zkzk8yAjkeuc10Vtp/k2ZDICyEqgA4Uk4De556Va0COJIS7qqrj5E/ugdzWhDGkkkMz5EG8ybSPvYGAcdhn86XLczrYl8zSLcYithbxy52spIXPLYwOfzqPUJ5J9kWPmY59go5x/L60l1cCSQPj52GAfQegrP1HVEilUQAFkUrkdSTj/CrdkjlinJ36kmp3BgcjcNwUHJwTn69qxZbqQBzarudQWDNk4z3ptwZZP3lw3LNkITwPc1f0m2ebczq+1eeR0x0rnnK7OqMVFXY/RtLDIrzks7AM8jjn6AV0sSwIrRxZ8sYJHvVWyjV48MDntk1agSPcWVSV6D3NTEiWr1JyPMREKBcceuT71YjiKEKB8uDk0icgAgYPp3NWUXC5ztX361Rm2JFbJGcqeOv1qcvtgzjjHGKasbMBgnHvT12wx/vB06VUTKUrkBuCxXjhRlQ3eljlMs7LCxGPf2qlduz3PQ7ccAGpo2JKRxjb1JPoKd7Ao3VzAuH89fNHXJXNZupo0durjqpwcdxWoiMkLR+pOao3Kl4zHnAaufdG0dDn9bRI44jIgdEdTyeMHj+taGnzLYarBFCT9mnXG3tVPX4vtGjOGzkRsMD6VgaJ591awXG8SPDwoY9OPX1zWkJacpThza3PUEijFy7AqUPOelLLCYtksLDcMbTjA96g0nUY76wilH39uGX07Z/P8AStG0mSMyQhN0RO7djoPT8/507pswd1uEd4kqqjk55G3vnHrUojmbJ3IpHqCT9apTRr9sYxnED4AGc7SPSrSlxNuSRuuFNIa8iyiTSW4SWYyDOMFRjisqWKR3fzYyUz8wGCOOhHf/AOtWhFebH2YYc+n3T/hQJYfMLtiRRkHafamnfQpXi7mJd3AiQxzLIitxuAymOx4qjLA1pteVPlDnecdfQ/lWrPLGyqrbWGCMHuP/ANWaq6hdC4tFjDHcBtAJzx060tGrnXTk9rFKEF590QxCTyxGRip5oY1ZWOQ2cAj+eKu6YmbNBj/ZJHao9TX97tUfMoB478VrFaEyn71jIuNiu244bGSB6VQvZlksj5f3ncIpI6ZIFXtRXavmN1I7Gs5o3kLmMKUjfI7ZPf8AL+pqtdiWk9TA8QXDxxW0ufMuraRVxjO9T0b8sVzt5fG41tGg+cvkfLwXbI7dutbHi23cWkys2xlw248kleQP0x+NYHgUJfahDPKCqeYVZmzgDGcfp+tX9mzEpqErrsep6VA0duGuUA3EFo92cnsPp7VtI/mhmf8A4Dgda52K6ikleaKMJJg7D0CoD3+takWqItmk0cUryFchgAFA9s9eOc0o2Rzzu3cjv5Y4Zf3hOMYwDz6n8Ko2shnka6mU7m4jXHX/AAAqpCZNQmM75EWcDd1z9K04Ywy5bKxAduuPT2zWEpHTGKSs9x1pbGebc3Oefr7V0tpb/uVBJAPLAf1qnptswQMwAwPlX0rZjT5Ru47mpSInLUr3W1IwkfyvM34qPX8qdbOodIkOQBwCO3qahukke4ZkXO1CeR0qfS7fyArbTlx35ppXKSXLdmkkaoobduJ7nrSTSopIXjsM07erp8vBz+OB3qLyAZfOlGcdEqmrGHqTRXGEDY5HQUy6lJznO3HPrSMCEMknBI4X2qtJKSoxk8YwKG9CVC7C4PyDYu7d1YjpUlqCJOjYI4B4NOVQYNqHBxx7VF5rBgoRuO9SaLaxmzgeb+75Urgg1UnT/RRwcbgB7Vbuxh2ZAMNyKgk/49mKngH0rMDI1C33WUsJwFZDz3rzzwlN5P8AoscjJcpJtAYZ8xc9fwr0u4+aJWJ+XYea4Xw/aZ8Tzs7BVifdknG3P+NCV3oaRejudfpUgspS8PGOGX+8p6flzXS2kqySiUYKuCCMcHH/AOqucIX7TIFBIPzqR345q3prtFI8QU+WfnVlP8qG+VilHmVzfeMJ2+UZDgdVz3psOZIfLf5snGf61DDIZAQwZychiO/1qXcYpMOBtA5IGO/Bqr3MbNDzCJl2OvJPVu+OlT26bcxSIAGPTHapFZSAQOCMhs1Dc38USLgBm7BRzVXSLu5aGfLYESyiMKWiO7Y3Qg9D9KowxrsbzQBt4B9Kv/ap3eTy40XA+aSQ+p6YFZd3aT+bJ++YqTngADNS9NUdFO+zLlvdGKP7PFGZGHLkEDr6ZqK4nl80sYJ/n42lQf1zUljCrvDJGu0rkOP9qrl9EG2yDJAypAPetYXtqY1WoyOZvLSRmF1I7FgpBRTwo9vX61U09WSKSORdz/O2zPXPb9RW80RjlCn5kwRk1jBGgnkkXnyzkD271YKd1Y5bxTIJrO6kkHCFX5+nP86peDILWOxtbfzgmcXDt64OQP8AGtXVbeK6EryDI8kyMBnG0D+f+FY3hK0N9aQRSjClskY+6uSf/rfjTuw0Z11naNOgm27YWclAOhGTyf6Us88ly721mzi2+65zkYHb9asz3BVRbwH0Gc4wOn8hVm3SC1gQRoisBg4GM4H8yev40puwo92PitYkgJ8zywxyqoOlWIIo/KViN7FuD6VUthJMEe4yAW6H+VbdpGGc5BIUfLkfrXNfmdzX4USxl8lOOTxkdPatIsEjCnGcAZpmE3bsEBRnI/h5qMt5rqhBG3nP8qtGe5ZDLmRTwu0A+9QXMrAqV3YByoHeklXEx+bKhcY96kjwRuY428AH0p3sC0LNsrxlXY/N1O3+VSFDjMh6n9KZDcqxZgCfQD0pk+4KDJ1JyF9alyvqQ07hcsxBVcbRz0qokZG3zCfr3p7LIzl3O0jkKD0qC43spIcKoP40kUl0LLNDH1OGPOAc4qsblpJVSIOUbkN04qmkoORF87A5Z26fStC0DuVy3NK9y3Hl1I71RG8QAy44Iqs0RNuMZznkVbuFMlyG7CgYQ4H4UPUwvY56diImhIJUZNchbhhdXxCsVHJwM85ruLuL/SJMjhufpXKZEXiG5ttu4OvAA6kUR3NU7rQ3Hule6RhuAROcdxgcVZaN0HnA/wCqYBhnHBH/AOr8qyYy1uXVkJdIwh3dCD0P862YlciMKVYvHsLEZGcE5rOV29S0rI1rcgTDOADhgVqSSVM4bIIyv9azIGbydvRkbp0PvV8oDiU4LkfL9auMrohxHCIhAVcmM8gA449KZAFXdGiDcT83rVqAoYShyMZxnsaiysdw2/HmngN2p6E63sQ3kTRhNhGBwR/OlaeNoeEJXlQueccVMxAbg5wMge9Uru38iRXQ4L/fAPTNPZaGsWnoy9YBTkqfu/rUt2hYbkXljxim6VCO7fKV4+voatfcZvTrzW0Njnqv3jIuome3fIAZf51zmqOYpldBjOcgH2rqr8oPMXrvG0D1rmfEMKLHKFLPKAJBtHT3PpVvyIhLXU5WC4hkivjOCBFG3BOMDYQOvu1VvC1xHaRgFyjTDJJ6Ljv9KzNQlCpLHGrSyXaCJMHG1iwHP4Vs6FpkZmiL5b5tpb/ZHqPc0dEdCteVza0yJmDzOOOikj8qnjMkt58mWQDCt09s/wA60kj/AHflcADLED0AwP5/rUtpb28UULLkgLluOhrCY4z6j4Y/mJfPy98dBitWAHO5BwRhR61nwhZEYchG61pRS+VDwQSFAqUNkmMhVzkkgn39qjmJUscZDHtRNN5eHVSCeVHvSlVRAFGXAyT6k0wQxC8s8YVCFGetaMcIVS7Nu7KvqaqRrgb87ccYHp3q2pw6ygAKT8tDFLyCCBopHZ+Aeid6c6E3Ssx5HQelOTDPvcZOetRXQfzA6sQGGOKlmbbbEndt55CgVTmIugyxn5c8nHP4U+RWuJFiGcHqQama2MTKMgZ444pbmiSRQjt8xtj5Ix09/rWhZ7WRUHDj37U5YTLyPujoDUJgeNhLn5+mB3FNaCb5tCzsIiJKc5Paqki7pPkUhQcfpRRQYLqzKuI3Egzn722uMvOfF1vlpI45QwLhM5x2/H1oooN6fU2/ELKk9pJGrG4XqF6bT0q94dV2t5FJYhHPP49qKKiXxmi0pmz9mbzWYj5TxwKUgrbiM7uDxxzRRSWjM07k1quNzAEAn+dRzRmI/MGJHQ4JzRRWgr+8NYEocrkr0PqM0ySLzgvL46gj+tFFC7FeZHpzXMLN5gOFOORyR61pyF9xO0k4x9KKK1p7GVV3dzOvNkSCUoxkOQAB1J7CsO8hdNOuQ5LTsNznb19B9AP89aKK0W5m+h5yIE/tW0yWEas7sBwcjGP5n8q63Q1KW0e1TyNxGMZY8gfUUUUSehvbc1oJG89lKv8AM23gcYHX9TWhDExt5FOX3r8pHA/zxRRXPIrYtWcchsR5ykNn06VDM778GPcF9Tjk0UVK6FQ6ly3g8xQ8mSoHBqwq/M3BJ74FFFUK5ZSFhs80bSeSTVSPzVkVSpyCTuPcUUUNEJ3Lp8/7m3jPpS3KuybRkKBkkCiikyUxsCgoCVIYHJ4qfy2cjzEIHqRRRSWoSZIflXbtxUMUiNIBgjb04zRRVCS0Z//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severely itchy vulvar LS with scarring, loss of vulvar architecture and thick indurated areas of SCC.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31089=[""].join("\n");
var outline_f30_23_31089=null;
var title_f30_23_31090="Cold stimulus headache";
var content_f30_23_31090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cold stimulus headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31090/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31090/contributors\">",
"     Ivan Garza, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31090/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31090/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/23/31090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold stimulus headache is a generalized headache that follows exposure of the unprotected head to a cold environment, such as diving into cold water. In addition, cold stimulus headache can be triggered by passing solid, liquid, or gaseous cold materials over the palate and posterior pharynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review clinical aspects of cold stimulus headache. Cranial neuralgias and central causes of facial pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=see_link\">",
"     \"Overview of craniofacial pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32904?source=see_link\">",
"     \"Central craniofacial pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6917?source=see_link\">",
"     \"Nervus intermedius (geniculate) neuralgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16243?source=see_link\">",
"     \"Nummular headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31509?source=see_link\">",
"     \"Occipital neuralgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of cold stimulus headache is not completely understood. Cold temperature seems to be a trigeminal trigger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/2\">",
"     2",
"    </a>",
"    ] that is followed by possible reflex vasoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a Danish cross-sectional general population survey of people 25 to 64 years old, the lifetime prevalence of cold stimulus headache was 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/4\">",
"     4",
"    </a>",
"    ], while a survey of 13 to 15 year old adolescents from Taiwan found a prevalence of 41 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/5\">",
"     5",
"    </a>",
"    ]. Some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/3,5-7\">",
"     3,5-7",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/8\">",
"     8",
"    </a>",
"    ], suggest that cold stimulus headache is more common in migraineurs than in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After exposure to the cold stimulus, the pain begins within seconds, peaks over 20 to 60 seconds, and then subsides in approximately the same time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the pain can last up to five minutes in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/9\">",
"     9",
"    </a>",
"    ]. The headache location is most commonly midfrontal, followed by bitemporal or occipital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/3\">",
"     3",
"    </a>",
"    ]. When cold stimulus headache occurs in patients with migraine, the pain is more likely to be throbbing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/6\">",
"     6",
"    </a>",
"    ] and referred to the usual site of the migraine headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current International Classification of Headache Disorders includes the following two subtypes of cold stimulus headache and requires that all of the following diagnostic criteria are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache attributed to external application of a cold stimulus:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diffuse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonpulsating headache fulfilling the last two criteria",
"     </li>",
"     <li>",
"      Presence of external cold stimulus to the head",
"     </li>",
"     <li>",
"      Headache develops during cold stimulus",
"     </li>",
"     <li>",
"      Headache resolves after removal of cold stimulus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache attributed to ingestion or inhalation of a cold stimulus (previously known as \"Ice cream headache\"):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute frontal nonpulsatile headache fulfilling the last two criteria",
"     </li>",
"     <li>",
"      Cold stimulus to palate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      posterior pharyngeal wall due to ingestion of cold food or drink or to inhalation of cold air",
"     </li>",
"     <li>",
"      Headache develops immediately, and only after cold stimulus",
"     </li>",
"     <li>",
"      Headache resolves within five minutes after removal of cold stimulus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria have been criticized as inadequate because a substantial proportion of individuals with cold stimulus headache have throbbing or pulsatile pain, and the pain may localize to areas other than the frontal region, particularly the temporal region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold stimulus headache is best prevented by avoiding the known stimulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although often benign, headache after scuba diving can be associated with serious neurologic disorders, including those related to barotrauma and decompression sickness (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4633?source=see_link\">",
"     \"Complications of scuba diving\"",
"    </a>",
"    ). Divers can prevent the headache by using a neoprene hood when exposed to very cold waters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31090/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cold stimulus headache is a generalized headache that can be triggered by exposure of the unprotected head to a cold environment, or by passing solid, liquid, or gaseous cold material over the palate and posterior pharynx. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two subtypes of cold stimulus headache (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Headache attributed to external application of a cold stimulus",
"     </li>",
"     <li>",
"      Headache attributed to ingestion or inhalation of a cold stimulus (previously termed \"Ice cream headache\")",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain begins within seconds after exposure to the cold stimulus, peaks over 20 to 60 seconds, and then subsides in approximately the same time. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cold stimulus headache is best prevented by avoiding the known stimulus. Divers can prevent the headache by using a neoprene hood when exposed to very cold waters. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31090/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31090/abstract/2\">",
"      Cheshire WP. Headache and facial pain in scuba divers. Curr Pain Headache Rep 2004; 8:315.",
"     </a>",
"    </li>",
"    <li>",
"     Boes, CJ, Copobianco, DJ, Cutrer, FM, et al. Headache and other craniofacial pain. In: Neurology in clinical practice, Bradley, WG, Daroff, RB, Fenichel, GM, et al (Eds), Butterworth Heinemann, Philadelphia, PA 2004. p.2055.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31090/abstract/4\">",
"      Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a general population. Neurology 1992; 42:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31090/abstract/5\">",
"      Fuh JL, Wang SJ, Lu SR, Juang KD. Ice-cream headache--a large survey of 8359 adolescents. Cephalalgia 2003; 23:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31090/abstract/6\">",
"      Selekler HM, Erdogan MS, Budak F. Prevalence and clinical characteristics of an experimental model of 'ice-cream headache' in migraine and episodic tension-type headache patients. Cephalalgia 2004; 24:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31090/abstract/7\">",
"      de Oliveira DA, Valen&ccedil;a MM. The characteristics of head pain in response to an experimental cold stimulus to the palate: An observational study of 414 volunteers. Cephalalgia 2012; 32:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31090/abstract/8\">",
"      Bird N, MacGregor EA, Wilkinson MI. Ice cream headache--site, duration, and relationship to migraine. Headache 1992; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31090/abstract/9\">",
"      Cheshire WP Jr, Ott MC. Headache in divers. Headache 2001; 41:235.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3332 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31090=[""].join("\n");
var outline_f30_23_31090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32904?source=related_link\">",
"      Central craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6917?source=related_link\">",
"      Nervus intermedius (geniculate) neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16243?source=related_link\">",
"      Nummular headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31509?source=related_link\">",
"      Occipital neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=related_link\">",
"      Overview of craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_23_31091="GI peptides and cell function";
var content_f30_23_31091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Mechanisms by which gastrointestinal peptides regulate and influence cell function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31091=[""].join("\n");
var outline_f30_23_31091=null;
var title_f30_23_31092="Butabarbital: Patient drug information";
var content_f30_23_31092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Butabarbital: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/37/20054?source=see_link\">",
"     see \"Butabarbital: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Butisol Sodium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to butabarbital sodium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 to 60 minutes before bedtime if using for sleep. Do not take for more than 2 weeks in a row.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (elixir) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695756",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take elixir with water, milk, or juice.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11546 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31092=[""].join("\n");
var outline_f30_23_31092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143477\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011569\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011571\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011570\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011575\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011576\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011578\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011573\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011574\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011579\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011580\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/37/20054?source=related_link\">",
"      Butabarbital: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_23_31093="Prilocaine with epinephrine (dental): Drug information";
var content_f30_23_31093=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prilocaine with epinephrine (dental): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Citanest&reg; Forte Dental",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Citanest&reg; Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Dental anesthesia, infiltration, or conduction block:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Initial: 40-80 mg (1-2 mL) of prilocaine hydrochloride as a 4% solution with epinephrine 1:200,000",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum dose (weight-based) within a 2-hour period: Prilocaine hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;70 kg: 8 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;70 kg: 600 mg (15 mL) or 8 cartridges",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The effective anesthetic dose varies with procedure, intensity of anesthesia needed, duration of anesthesia required, and physical condition of the patient. Always use the lowest effective dose along with careful aspiration prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F213774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dental anesthesia, infiltration, or conduction block:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &lt;10 years:",
"     </i>",
"     Doses &gt;40 mg (1 mL) of prilocaine hydrochloride as a 4% solution with epinephrine 1:200,000 are rarely needed for procedures involving a single tooth, in a maxillary infiltration for 2-3 teeth, or for an entire quadrant with a mandibular block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Children &gt;10 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [for dental use]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Citanest&reg; Forte Dental: Prilocaine hydrochloride 4% and epinephrine 1:200,000 (1.7 mL) [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15162770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amide-type anesthetic used for local infiltration anesthesia; injection near nerve trunks to produce nerve block",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F213776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Degree of adverse effects in the CNS and cardiovascular system are directly related to the blood levels of prilocaine. The effects below are more likely to occur after systemic administration rather than infiltration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiovascular collapse, edema, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Apprehension, confusion, dizziness, drowsiness, euphoria, lightheadedness, nervousness, seizures, unconsciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blurred vision, double vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremors, twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Respiratory arrest, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions (rare), anaphylactoid reactions, sensation of warm/cold",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to local anesthetics of the amide-type or any component of the formulation; congenital or idiopathic methemoglobinemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia: Use caution in patients who are very young or have glucose-6-phosphate deficiencies. Use caution in patients taking concurrent drugs that can cause methemoglobinemia. Methemoglobinemia has been reported with local anesthetics including prilocaine; clinically significant methemoglobinemia requires immediate treatment. Use is contraindicated in patients with congenital or idiopathic methemoglobinemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; should be used in minimal amounts in patients with significant cardiovascular disease (because of epinephrine component).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Familial malignant hyperthermia: Prilocaine may potentially trigger malignant hyperthermia; follow standard protocol for identification and treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; amide-type anesthetics are hepatically metabolized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Should be avoided in patients with uncontrolled hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vascular disease: Local anesthetic solutions containing a vasoconstrictor should be used cautiously. Patients with peripheral vascular disease or hypertensive vascular disease may exhibit exaggerated vasoconstrictor response, possibly resulting in ischemic injury or necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill patients; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: May contain sodium metabisulfite; use caution in patients with asthma or a sulfite allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate dosing: To avoid serious adverse effects and high plasma concentrations, the lowest dosage resulting in effective anesthesia should be administered. Repeated doses may significantly increase blood concentrations of both the drug or its metabolites; tolerance to elevated blood concentrations varies with patient status. Reduced dosages, commensurate with age and physical condition, should be given to patients who are debilitated, elderly, acutely-ill, or pediatric.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Dental practitioners using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: EPINEPHrine (Systemic, Oral Inhalation) may enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F213758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14287328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F213765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usual infiltration doses of prilocaine with epinephrine given to nursing mothers has not been shown to affect the health of the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14634279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs and consciousness after each injection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F213766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Citanest Adrenalin (FI, SE);",
"     </li>",
"     <li>",
"      Citanest Forte (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F213752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Epinephrine prolongs the duration of the anesthetic actions of prilocaine by causing vasoconstriction (alpha-adrenergic receptor agonist) of the vasculature surrounding the nerve axons. This prevents the diffusion of prilocaine away from the nerves resulting in a longer retention in the axon.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Infiltration: &lt;2 minutes; Inferior alveolar nerve block: &lt;3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Infiltration: ~2.25 hours; Inferior alveolar nerve block: ~3 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ayoub ST and Coleman AE, &ldquo;A Review of Local Anesthetics,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1992, 40(4):285-7, 289-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/23/31093/abstract-text/1397990/pubmed\" id=\"1397990\" target=\"_blank\">",
"        1397990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blanton PL and Roda RS, &ldquo;The Anatomy of Local Anesthesia,&rdquo;",
"      <i>",
"       J Calif Dent Assoc",
"      </i>",
"      , 1995, 23(4):55-65.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaffen AS and Haas DA, \"Retrospective Review of Voluntary Reports of Nonsurgical Paresthesia in Dentistry,\"",
"      <i>",
"       J Can Dent Assoc",
"      </i>",
"      , 2009, 75(8):579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/23/31093/abstract-text/19840499/pubmed\" id=\"19840499\" target=\"_blank\">",
"        19840499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garisto GA, Gaffen AS, Lawrence HP, et al, \"Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2010, 141(7):836-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/23/31093/abstract-text/20592403/pubmed\" id=\"20592403\" target=\"_blank\">",
"        20592403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/23/31093/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacKenzie TA and Young ER, &ldquo;Local Anesthetic Update,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1993, 40(2):29-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/23/31093/abstract-text/8185087/pubmed\" id=\"8185087\" target=\"_blank\">",
"        8185087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1994, 42(1):16, 18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/23/31093/abstract-text/7911769/pubmed\" id=\"7911769\" target=\"_blank\">",
"        7911769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yagiela JA, &ldquo;Local Anesthetics,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1991, 38(4-5):128-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/23/31093/abstract-text/1819966/pubmed\" id=\"1819966\" target=\"_blank\">",
"        1819966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yagiela JA, &ldquo;Vasoconstrictor Agents for Local Anesthesia,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1995, 42(3-4):116-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/23/31093/abstract-text/8934977/pubmed\" id=\"8934977\" target=\"_blank\">",
"        8934977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10229 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-7484D81656-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31093=[""].join("\n");
var outline_f30_23_31093=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213770\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213771\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213778\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213772\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213774\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213773\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213760\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213749\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162770\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213776\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213763\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213753\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299943\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213757\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213758\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287327\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287328\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213765\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14634279\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213766\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213752\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213762\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10229|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_23_31094="Infective endocarditis: Historical and Duke criteria";
var content_f30_23_31094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infective endocarditis: Historical and Duke criteria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31094/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31094/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31094/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31094/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31094/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31094/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/23/31094/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical definitions of infective endocarditis (IE) are important since underdiagnosis can lead to clinical catastrophe and death, while overdiagnosis can result in weeks of unnecessary antimicrobial therapy with excessive costs and potentially avoidable drug-related side effects. It can, for example, be extraordinarily difficult to distinguish between IE and an alternate source of infection in a bacteremic patient with underlying heart disease.",
"   </p>",
"   <p>",
"    The specific criteria required for the diagnosis of IE will be reviewed here. The general diagnostic approach to this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelletier and Petersdorf proposed the first case definitions for IE in 1977; they relied on pathologic examination of tissues removed at surgery or autopsy. Although this diagnostic modality was highly specific, it lacked sensitivity, and an explicit definition of a pathologic diagnosis was never created. Furthermore, reliance on histopathologic specimens for diagnosis is not usually practical clinically. The modifications of the case definition by von Reyn and coworkers improved the specificity although no prospective validation was undertaken.",
"   </p>",
"   <p>",
"    The most important advancement in the tools for diagnosis of endocarditis was the development of echocardiography and its inclusion in the Duke criteria. Studies taking echocardiography into account have improved the diagnostic accuracy and permit a rational approach to the patient with suspected IE. In addition, new advances in pathology and autoimmunohistochemical diagnostic methods should be incorporated into future studies of IE, particularly in patients with prosthetic valves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pelletier and Petersdorf criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification scheme of Pelletier and Petersdorf consisted of three case categories: definite, probable, and possible.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definite IE required histologic evidence of infected endocardial vegetation(s) from examination of tissue obtained from cardiac surgery, embolectomy, or autopsy.",
"     </li>",
"     <li>",
"      Probable IE required either uniformly positive blood cultures with known underlying valvular heart disease and evidence of emboli to the skin or viscera; or negative blood cultures in individuals with fever (&gt;38&ordm;C), new regurgitant valvular heart murmurs, and embolic phenomena.",
"     </li>",
"     <li>",
"      Possible IE required either uniformly positive blood cultures with known underlying heart disease or embolic phenomena; or negative blood cultures with fever, known underlying valvular heart disease, and embolic episodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria were reasonably specific but lacked sensitivity. In practice, many patients with clinical features presumed to be due to IE did not meet the above criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     von Reyn criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1981, von Reyn and colleagues modified the case definitions of Pelletier and Petersdorf with the intent of improving specificity and clinical utility. These authors divided cases into four categories: definite, probable, possible, and rejected (",
"    <a class=\"graphic graphic_table graphicRef52313 \" href=\"mobipreview.htm?35/5/35932\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As with the previous classification system, pathological confirmation of vegetations or an abscess was required to define a case as definite. Other criteria for diagnosis included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent bacteremia",
"     </li>",
"     <li>",
"      Evidence of active endocardial pathology (eg, the presence of a new regurgitant murmur)",
"     </li>",
"     <li>",
"      Predisposing valvular heart disease",
"     </li>",
"     <li>",
"      The presence of vascular phenomena such as emboli or splinter hemorrhages",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The von Reyn criteria lacked prospective validation, although they improved the specificity of the classification system of Pelletier and Petersdorf. Furthermore, application of the von Reyn criteria results in a large proportion of cases being classified as probable or possible, because most patients with IE do not require valve surgery during the acute phase of their illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DUKE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1994, investigators from Duke University modified the von Reyn criteria to include the role of echocardiography in diagnosis. They also expanded the category of predisposing heart conditions to include injection drug use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/5\">",
"     5",
"    </a>",
"    ]. Later, Fournier et al proposed further expansion of the Duke criteria to include serologic criteria for a diagnosis of Q fever endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/6\">",
"     6",
"    </a>",
"    ]. In 2000, Li et al modified the original Duke criteria to include Q fever serology as a major criterion and refined the criteria to define a case as probable IE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Duke classification relies upon major and minor criteria in a manner analogous to the Jones criteria for acute rheumatic fever. It uses both clinical and pathologic criteria to classify cases as definite IE (",
"    <a class=\"graphic graphic_table graphicRef73023 \" href=\"mobipreview.htm?9/26/9644\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53004 \" href=\"mobipreview.htm?6/31/6653\">",
"     table 3",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/35/4656?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The pathologic criteria are virtually the same as those proposed by Pelletier and Petersdorf, and von Reyn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases can be classified as definite, possible, or rejected using the Duke criteria. Two of these criteria are pathological, and three are clinical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Definite endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Duke criteria, endocarditis is considered definitely present if any one of the following pathological findings or combinations of clinical findings are present (",
"    <a class=\"graphic graphic_table graphicRef73023 \" href=\"mobipreview.htm?9/26/9644\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct evidence of endocarditis based upon histological findings (a pathological criterion)",
"     </li>",
"     <li>",
"      Positive Gram stain results or cultures of specimens obtained from surgery or autopsy (a pathological criterion)",
"     </li>",
"     <li>",
"      Two major clinical criteria",
"     </li>",
"     <li>",
"      One major and any three minor clinical criteria, or",
"     </li>",
"     <li>",
"      Five minor clinical criteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Possible endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible endocarditis is defined as the presence of one major and one or two minor clinical criteria or the presence of three minor clinical criteria (",
"    <a class=\"graphic graphic_table graphicRef73023 \" href=\"mobipreview.htm?9/26/9644\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rejected endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of endocarditis is considered rejected if any of the following are present (",
"    <a class=\"graphic graphic_table graphicRef73023 \" href=\"mobipreview.htm?9/26/9644\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A firm alternate diagnosis is made",
"     </li>",
"     <li>",
"      Resolution of clinical manifestations occurs after four days of antibiotic therapy or less",
"     </li>",
"     <li>",
"      No pathological evidence of infective endocarditis is found at surgery or autopsy after antibiotic therapy for four days or less",
"     </li>",
"     <li>",
"      Clinical criteria for possible or definite infective endocarditis not met",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The negative predictive value of the Duke criteria for rejected endocarditis was at least 92 percent in one report of 49 cases of rejected IE cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/10\">",
"     10",
"    </a>",
"    ]. There were no proven cases of IE; one patient had \"possible\" IE at autopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Major clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major clinical criteria for the diagnosis of endocarditis include the following (",
"    <a class=\"graphic graphic_table graphicRef53004 \" href=\"mobipreview.htm?6/31/6653\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistently positive blood cultures for organisms that are typical causes of endocarditis",
"     </li>",
"     <li>",
"      Vegetations or other typical findings of endocarditis present on echocardiography; these other typical findings include new or partial dehiscence of a prosthetic valve or an abscess in the tissues surrounding a heart valve",
"     </li>",
"     <li>",
"      Evidence of endocardial damage such as a new regurgitant murmur",
"     </li>",
"     <li>",
"      Serological or culture evidence of infection with Coxiella burnetii [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Minor clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor clinical criteria include the following (",
"    <a class=\"graphic graphic_table graphicRef53004 \" href=\"mobipreview.htm?6/31/6653\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      The presence of a predisposing valvular condition or intravenous drug abuse; a predisposing valvular condition is defined as a prosthetic heart valve or a valve lesion that leads to significant regurgitation or turbulence of blood flow",
"     </li>",
"     <li>",
"      \"Vascular phenomenon\" such as emboli to organs or the brain, hemorrhages in the mucous membranes around the eyes. Cerebral microhemorrhages detected by magnetic resonance imaging (MRI) are NOT considered vascular phenomena by the modified Duke criteria, even though they are more common in patients with IE than in age matched controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Immunologic phenomenon\" such as glomerulonephritis, or lesions such as Roth's spots (in the retina of the eyes) or \"Osler's nodes (nodules on the fingers or toes)",
"     </li>",
"     <li>",
"      Positive blood cultures that do not meet the strict definitions of a major criterion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other minor criteria (including hematuria and splenomegaly) have been proposed by the St. Thomas group, but important considerations and validations of these and other criteria have not been undertaken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Q fever endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original Duke criteria were amended for the diagnosis of endocarditis due to Q fever (Coxiella burnetii). The rationale for this change came in part from a study of 20 proven cases of Q fever endocarditis by pathologic examination of the valve, four of which were misclassified as \"possible\" IE using the standard criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/6\">",
"     6",
"    </a>",
"    ]. All were correctly classified if a single positive blood culture for Coxiella burnetii and an antiphase I IgG antibody titer to C. burnetii greater than 1:800 were changed from minor to major criteria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=see_link\">",
"     \"Q fever endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADDITIONAL DIAGNOSTIC TOOLS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transesophageal echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transesophageal echocardiography (TEE) is more sensitive than transthoracic echocardiography (TTE), particularly for detecting smaller vegetations, extension of infection into myocardial tissue, and for assessing prosthetic heart valves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although widely used, TEE had not been formally evaluated for its contributions to the Duke criteria until a study compared the two echocardiographic techniques in 114 cases of suspected IE over a six year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/14\">",
"     14",
"    </a>",
"    ]. TTE and TEE produced concordant results in 55 percent of cases. A change in diagnostic category occurred in nearly 25 percent of cases when the results of TEE were added, 11 percent for patients with native valves, and 34 percent for those with prosthetic valves. Twenty-two patients were reclassified as definite endocarditis from possible based upon TEE findings. Nineteen of these patients had an intermediate probability of endocarditis, positive blood cultures and a negative or only suggestive TTE; TEE demonstrated valvular vegetations, abscesses, or prosthetic valve instability in all of these cases (",
"    <a class=\"graphic graphic_movie graphicRef64233 \" href=\"mobipreview.htm?24/13/24798\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef74493 \" href=\"mobipreview.htm?23/61/24542\">",
"     movie 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    TEE had a positive predictive value of 90 percent for both native and prosthetic valve endocarditis in this study. The negative predictive value of TEE is nearly 100 percent for patients with native valves, but patients with prosthetic valves may have a negative TEE and still have IE. In the latter patients, clinical assessment is especially important. TEE improved the sensitivity of the Duke criteria when clinical evidence of IE was present, especially in patients with prosthetic valves. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cerebral imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine magnetic resonance imaging (MRI) may be useful in patients with definite or suspected IE. In one study including 53 patients, early use of cerebral MRI led to the reclassification from possible to definite IE in one-third of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Molecular techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular techniques such as polymerase chain reaction (PCR) are not part of the Duke criteria. However, they can be useful in the setting of culture-negative endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34646?source=see_link&amp;anchor=H10#H10\">",
"     \"Culture-negative endocarditis\", section on 'Molecular techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DUKE CRITERIA VALIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have validated the Duke criteria and compared their utility with the von Reyn criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/5,16-19\">",
"     5,16-19",
"    </a>",
"    ]. Each of these reports evaluated patients in whom the diagnosis of IE was established pathologically. Investigators from Duke, for example, studied 405 consecutive cases of suspected IE in 353 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/5\">",
"     5",
"    </a>",
"    ]. The following findings were obtained (",
"    <a class=\"graphic graphic_table graphicRef63720 \" href=\"mobipreview.htm?33/52/34635\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      69 cases of IE were confirmed pathologically. Fifty-five (80 percent) were clinically classified as definite using the Duke criteria, versus only 35 (51 percent) being classified as probable by the von Reyn criteria.",
"     </li>",
"     <li>",
"      12 of the pathologically confirmed cases were \"rejected\" by the von Reyn criteria whereas none were by the Duke criteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another study of 63 patients with suspected IE the presence of IE was pathologically confirmed in 10 patients who underwent open heart surgery; all cases were classified preoperatively as clinically definite using the Duke criteria, whereas five were \"rejected\" by the von Reyn criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third series consisted of 115 consecutive patients with suspected IE who were hospitalized in a referral center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/17\">",
"     17",
"    </a>",
"    ]. The diagnosis of IE was confirmed at surgery in 27 patients; 22 were classified as definite by the Duke criteria versus 12 as probable by the von Reyn criteria. In addition, none of these 27 cases was \"rejected\" by the Duke criteria versus five by the von Reyn criteria.",
"   </p>",
"   <p>",
"    Similar results were found in a fourth study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/18\">",
"     18",
"    </a>",
"    ]. Fifteen percent of 54 surgical and autopsy proven cases were rejected by the von Reyn criteria versus none by the Duke criteria. The Duke criteria are also applicable to patients with prosthetic valve endocarditis. In one series of 25 patients, the Duke criteria correctly classified 19 as definite and rejected none; in contrast, the von Reyn criteria rejected five cases (20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Caveats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duke criteria for diagnosis of endocarditis must be interpreted in view of the pretest probability that IE is present. In some circumstances it may be justified to treat for IE even when criteria to diagnose \"definite or probable IE\" are not present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolonged staphylococcal bacteremia in patients with long-term central vascular catheters is usually an indication for long-term antistaphylococcal therapy even if Duke criteria for endocarditis are not met [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31094/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37159?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECOMMENDED APPROACH TO THE DIAGNOSIS OF IE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of patients with suspected endocarditis is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190974102\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical definitions of infective endocarditis (IE) are important since underdiagnosis can lead to clinical catastrophe and death, while overdiagnosis can result in weeks of unnecessary antimicrobial therapy with excessive costs and potentially avoidable drug-related side effects. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pelletier and Petersdorf proposed the first case definitions for IE; they relied on pathologic examination of tissues removed at surgery or autopsy. Although this diagnostic modality was highly specific, it lacked sensitivity, and an explicit definition of a pathologic diagnosis was never created. Furthermore, reliance on histopathologic specimens for diagnosis is not usually practical clinically. The modifications of the case definition by von Reyn and coworkers improved the specificity, although no prospective validation was undertaken (",
"      <a class=\"graphic graphic_table graphicRef52313 \" href=\"mobipreview.htm?35/5/35932\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Case definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subsequently, investigators from Duke University modified the von Reyn criteria to include the role of echocardiography in diagnosis. They also expanded the category of predisposing heart conditions to include injection drug use. They later added Q fever serology as a major criterion and refined the criteria to define a case as probable IE. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Duke criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Using the original Duke criteria, cases can be classified as definite, possible, or rejected. Two of these criteria are pathological, and three are clinical. The major and minor criteria are summarized in the following Table (",
"      <a class=\"graphic graphic_table graphicRef53004 \" href=\"mobipreview.htm?6/31/6653\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Duke criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Major clinical criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Minor clinical criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      According to the Duke criteria, endocarditis is considered definitely present if any one of the following pathological findings or combinations of clinical findings are present (",
"      <a class=\"graphic graphic_table graphicRef73023 \" href=\"mobipreview.htm?9/26/9644\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Direct evidence of endocarditis based upon histological findings (a pathological criterion)",
"     </li>",
"     <li>",
"      Positive Gram stain results or cultures of specimens obtained from surgery or autopsy (a pathological criterion)",
"     </li>",
"     <li>",
"      Two major clinical criteria",
"     </li>",
"     <li>",
"      One major and any three minor clinical criteria, or",
"     </li>",
"     <li>",
"      Five minor clinical criteria (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Definite endocarditis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Possible endocarditis is defined as the presence of one major and one or two minor clinical criteria or the presence of three minor clinical criteria (",
"      <a class=\"graphic graphic_table graphicRef73023 \" href=\"mobipreview.htm?9/26/9644\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Possible endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of endocarditis is considered rejected if any of the following are present (",
"      <a class=\"graphic graphic_table graphicRef73023 \" href=\"mobipreview.htm?9/26/9644\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A firm alternate diagnosis is made",
"     </li>",
"     <li>",
"      Resolution of clinical manifestations occurs after four days of antibiotic therapy or less",
"     </li>",
"     <li>",
"      No pathological evidence of infective endocarditis is found at surgery or autopsy after antibiotic therapy for four days or less",
"     </li>",
"     <li>",
"      Clinical criteria for possible or definite infective endocarditis not met (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Rejected endocarditis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic evaluation of patients with suspected endocarditis is presented in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377264303\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate would like to recognize Dr. G. Ralph Corey for his contributions to previous versions of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/1\">",
"      Lepidi H, Coulibaly B, Casalta JP, Raoult D. Autoimmunohistochemistry: a new method for the histologic diagnosis of infective endocarditis. J Infect Dis 2006; 193:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/2\">",
"      Lepidi H, Durack DT, Raoult D. Diagnostic methods current best practices and guidelines for histologic evaluation in infective endocarditis. Infect Dis Clin North Am 2002; 16:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/3\">",
"      Greub G, Lepidi H, Rovery C, et al. Diagnosis of infectious endocarditis in patients undergoing valve surgery. Am J Med 2005; 118:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/4\">",
"      Bayer AS. Infective endocarditis. Clin Infect Dis 1993; 17:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/5\">",
"      Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/6\">",
"      Fournier PE, Casalta JP, Habib G, et al. Modification of the diagnostic criteria proposed by the Duke Endocarditis Service to permit improved diagnosis of Q fever endocarditis. Am J Med 1996; 100:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/7\">",
"      Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/8\">",
"      Pelletier LL Jr, Petersdorf RG. Infective endocarditis: a review of 125 cases from the University of Washington Hospitals, 1963-72. Medicine (Baltimore) 1977; 56:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/9\">",
"      Von Reyn CF, Levy BS, Arbeit RD, et al. Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med 1981; 94:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/10\">",
"      Dodds GA, Sexton DJ, Durack DT, et al. Negative predictive value of the Duke criteria for infective endocarditis. Am J Cardiol 1996; 77:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/11\">",
"      Klein I, Iung B, Labreuche J, et al. Cerebral microbleeds are frequent in infective endocarditis: a case-control study. Stroke 2009; 40:3461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/12\">",
"      Lamas CC, Eykyn SJ. Suggested modifications to the Duke criteria for the clinical diagnosis of native valve and prosthetic valve endocarditis: analysis of 118 pathologically proven cases. Clin Infect Dis 1997; 25:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/13\">",
"      Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/14\">",
"      Roe MT, Abramson MA, Li J, et al. Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the duke criteria. Am Heart J 2000; 139:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/15\">",
"      Duval X, Iung B, Klein I, et al. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. Ann Intern Med 2010; 152:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/16\">",
"      Bayer AS, Ward JI, Ginzton LE, Shapiro SM. Evaluation of new clinical criteria for the diagnosis of infective endocarditis. Am J Med 1994; 96:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/17\">",
"      Hoen B, Selton-Suty C, Danchin N, et al. Evaluation of the Duke criteria versus the Beth Israel criteria for the diagnosis of infective endocarditis. Clin Infect Dis 1995; 21:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/18\">",
"      Sandre RM, Shafran SD. Infective endocarditis: review of 135 cases over 9 years. Clin Infect Dis 1996; 22:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/19\">",
"      Nettles RE, McCarty DE, Corey GR, et al. An evaluation of the Duke criteria in 25 pathologically confirmed cases of prosthetic valve endocarditis. Clin Infect Dis 1997; 25:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31094/abstract/20\">",
"      Bendig EA, Singh J, Butler TJ, Arrieta AC. The impact of the central venous catheter on the diagnosis of infectious endocarditis using Duke criteria in children with Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2008; 27:636.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2150 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31094=[""].join("\n");
var outline_f30_23_31094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H190974102\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pelletier and Petersdorf criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      von Reyn criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DUKE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Definite endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Possible endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rejected endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Major clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Minor clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Q fever endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADDITIONAL DIAGNOSTIC TOOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transesophageal echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cerebral imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Molecular techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DUKE CRITERIA VALIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Caveats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECOMMENDED APPROACH TO THE DIAGNOSIS OF IE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190974102\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H377264303\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2150\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2150|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?24/13/24798\" title=\"movie 1\">",
"      Mitral valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?23/61/24542\" title=\"movie 2\">",
"      TEE pacerwire vegetation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2150|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/5/35932\" title=\"table 1\">",
"      von Reyn criteria for IE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/26/9644\" title=\"table 2\">",
"      Duke criteria for IE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/31/6653\" title=\"table 3\">",
"      Duke criteria for IE II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/52/34635\" title=\"table 4\">",
"      Validity of Duke criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/35/4656?source=related_link\" title=\"calculator 1\">",
"      Calculator: Diagnosis of endocarditis - Duke criteria for definite endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34646?source=related_link\">",
"      Culture-negative endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=related_link\">",
"      Q fever endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37159?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_23_31095="Lymphomatoid gran CT I";
var content_f30_23_31095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52068%7EPULM%2F60848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52068%7EPULM%2F60848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    35-year-old man who presented with cerebral symptoms with enhancing brain mass on CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 451px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHDAb0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UqX7PN9n8/ypPJzt8zadufTPSmIxR1ZcZU5GRmtU+ItVPhtdAN239krMZxb7RgP65xn9aAK66PqTXT2y6deG5SPzWiEDbwmM7iMZxg9aokYOD1ron8Z64+kjTjdJ5Ozyy4hQSlfQyY3frUPhjQZNYuNz5S1Q/O3r7CgDLtrG7ulZrW1nmVTgmOMsB+VTDRtTY4GnXpPoIG/wr1+xtI7eJILWNUReAFH6mur8KeGtQ1rUEs9Oj3SMfnkByqehzQB8+23hrXbqZYbXRdTmlbhUjtZGY/QAVpt8OvGyjLeDvEgHvpc//wATX314F8E2XhSzQhftF+335sDg+3pXSyuzyrGflPcD5vzoA/OAfDnxueng7xIe/wDyC5//AIml/wCFc+N+f+KN8Sf+Cuf/AOJr9HclPmVsBTtB7H2IJ4xzTo494+bcrHO7jaTn+dAH5vj4deNiSB4O8SEjrjS5+P8Ax2l/4Vz43zj/AIQ3xJn/ALBc/wD8TX6RxBlYjBOSSSeMelCRhV3RjO85z0wKAPzcPw58bjr4N8Sf+Cuf/wCJo/4Vz435/wCKN8Sf+Cuf/wCJr9J0BGc455wO1OAA6cUAfmt/wrjxx/0JviT/AMFc/wD8TR/wrjxx/wBCb4k/8Fc//wATX6U0UAfmt/wrjxx/0JviT/wVz/8AxNH/AArjxx/0JviT/wAFc/8A8TX6U0UAfmt/wrjxx/0JviT/AMFc/wD8TR/wrjxx/wBCb4k/8Fc//wATX6U0UAfmt/wrjxx/0JviT/wVz/8AxNH/AArjxx/0JviT/wAFc/8A8TX6U1C93bxnDzxKfQuBQB+bn/CuPHH/AEJviT/wVz//ABNH/CuPHH/Qm+JP/BXP/wDE1+jT6xp0ZIe9t1IGSC4zVJfFugvceQmqWzS5xtDc0Afnl/wrjxx/0JviT/wVz/8AxNH/AArjxx/0JviT/wAFc/8A8TX6PRajZzSiOK5iaQ8BQwzVugD81v8AhXHjj/oTfEn/AIK5/wD4mj/hXHjj/oTfEn/grn/+Jr9KaKAPzW/4Vx44/wChN8Sf+Cuf/wCJo/4Vx44/6E3xJ/4K5/8A4mv0pooA/Nb/AIVx44/6E3xJ/wCCuf8A+Jo/4Vx44/6E3xJ/4K5//ia/SmigD81v+FceOP8AoTfEn/grn/8AiaP+FceOP+hN8Sf+Cuf/AOJr9KaKAPzWPw58bgZPg3xJj/sFz/8AxNA+HPjcjI8G+JMf9guf/wCJr9JZf4eH69V7U9GDKGGcH1oA/Nf/AIVx44/6E3xJ/wCCuf8A+Jo/4Vx44/6E3xJ/4K5//ia/SmigD81v+FceOP8AoTfEn/grn/8AiaP+FceOP+hN8Sf+Cuf/AOJr9KaKAPzW/wCFceOP+hN8Sf8Agrn/APiaP+FceOP+hN8Sf+Cuf/4mv0pooA/Nb/hXHjj/AKE3xJ/4K5//AImj/hXHjj/oTfEn/grn/wDia/SmigD81v8AhXHjj/oTfEn/AIK5/wD4mj/hXHjj/oTfEn/grn/+Jr9KaKAPzUk+HnjWKNnk8IeI0RRlmbTJwAPUnbXPrY3b209wtrO1vAwWWURkrGT0DHGAfrX6l14v8Z/hJb6r4R1w+DNNii1jUJI5ZolcIkxUkkgHgNz7CgD4Xmhlh2+dE8e5dy71IyPUe1PtLS4vZxDZ28txMeiRIXY/gK1PFujQ6DqYsI71bqeONftAVcCKX+JM5IOD3FW/hvbNceN9GZZbeFYLqOd5LiZYkVVcEkliB+FAGGmnXr3klolncNdR5DwiJi6465XGRimXlpc2Nw0F7bzW84AJjlQowyMjg816dqmuaNouteILPV9Le8kvr1p1vNP1FF3QluEJCsMd+MVW+IFrZ+MvizFY+G5reJL1YYUlnug0e/YOrgcen1oA8zqa1tp7uYQ2kEs8p6JEhZj+AqfWdOm0nVbvT7koZraQxuUOQSPQ1oeCLSS88WaWkTxIUuEkZpZVjUKrAk5YgdKAM86VqIa7U2F2Gsxm5BhbMAzj5+Pl/GqVeneLpb3TvGfjBbW7057XUYZSyGcOs8eCQVKn7wxuAJGcd+leY0AFFFaOhaZJq2oJbx5Vervj7ooAseGtDl1m6I5S2T/WSY/Qe9erafZxwQx21qipGgwAO1R6ZYR2drHa2iYRB+fua9L+HHgOfxHch3V47NDh5sYyPQUAV/AXgi68R3CpCPLhXmSUjtX0b4d0DT/Denpa6dCqcYLYwXPuf6VNpWm2ujWcdnpkKqqY3Dufc+9WJJBJIi8MgBJ5xnigB7TNiPgISTndxwO1ReZsLtIpLNxtJIIFIweTOzLKQMZ7+/NTZLSAtGThsD0HuKAHmMSFWzkAcZ5zmnoioAFGAOlIQzPySFXnjvT8frQAzYS5LtuHZccCngYGB0oooAKKKKACiiigAorE8S+KNL8Owb9RuFEhGVhXl2/DsPevJfEPxe1C5eRNHgW1hHHmEb2P49BQB7jPcQwKTNKkYAz8zAVwviP4o6JpMjQ25N7MMgiM/KD7mvBdS1jU7+b7Rf3lzK0nJJkPP+eKpRwu0oDqSDyee1AHo3iX4s6nqNuYdNjjs424LDlzXnz6lezOWuL26kc/xlz/ACqvI4ZsfwgYUKeBSeaWtzGuAp7jrQBN9sn8xmMhYnPUk1PZ3OLgMqqvOeM5PHqKo7nZAHO7b0wMYFPAl+WT5sdd3WgDcsr4QXqXbNIgi5UBiPwp+o+LNUursyQ3lyM9AJGx+VQG1uPs5l8shCMqx6GseLEEjM24uDjb2FAHR2Hj3xLa4EepTMeBhmLZ/Ouu0v4vatCdmoQW04T7zD5SfwrzK0UG4VSzFV+bK/hUzObmfbbwDPcOM4oA950n4r6LdkLciSBsc8Zwa3rfxz4fnUlL9OOxGDXzBMrW+6I7g5+96H6VCjFM7SQT3zQB9bW/iHSbjPlX9uw7HeBn6VpRyxyjMTq49VOa+P4boq2XZ89ipxj8K3dE8U6to0gfT7x3J/hPT8RQB9TUV88f8LM8TTEZkjQAcnbt/SqGpfELxDdvsN1wn90YFAH0tnnHegV8wW3jzXlYZvpAoI4A4P1rodP+KuuwFI5I4ZmI4DDrz60Ae/UV4nf/ABR19FAWztIGPdgWP5Zp9l8SNQlsWDOpvH4TB4+tAHtNGf0r5kv/ABDrVzdb7y9uCSxyMkAfgK1/BF7rDa9GLK4mlRmwWbO3tyfSgD6EoqC0hMMAUk7yOcnIzU/rQAUUUUAFFFFABRRRQB86/tIfBSLXrS58TeF7dItViUyXVui4+0KOrDH8X86+N2UqxVgQwOCDwQa/VKvmH9pb4KWstne+L/DKLbzx/vL61HCOM8yL6H1FAHyTVvTdQuNNnaa0ZVlKFA5UErnuM9D71UooAczFmLMSWJySeSTTaKKANHStF1HVob2XTbSW4jsoWuLlkHEUY5LH2rOrrvBd5eW2g+K47awS7tp7IJcOZvLMI3fK4H8XPauRoAltoWuLiKGP78jhF+pOK9c0DRodLtVgtxukbl3PVjXl/hzH/CQ6XuXcPtUWR6/OK+mfAPg268RaitvGuyFeZpSv3RQBc+G/ga48Q3iM6lLFDmSQj73sK+kNMsrTSLGK0tUEcUY2jC9fc4p9haW+nWMVlaIEihjCqqjsBipVRV+Us3QLyeD9M0AR4j2ZfOWGdzL602QkbY0DAOTk5zu981O8Cn7pKj0HT8qY0aiYEKFPbBxk/T0oAUARKVRtzY4Xrg+vtUiphVBJyOTg9TTYkXqFZSCevU/j3FS0AFFFFABRRRQAUVmazrmn6PD5l/cJGP7uck/hXlviX4vncYdEhVVHBmfk/gKAPW9R1C106BpryZY0AzyeT9BXknjH4pzSRywaAjW6jKm4lHzH3A7V5quvXV9rQudSnnuMnJBNT+KNTtr+4ZrIIqBcYHA/D1oAw7y9ub64ee8nlmmY8u7ZJqRIGEByyiNgCTjkUKUmEcUEa+YRgkj61JqD20FuLeFne4J2uw6L7UAQ6daNe6hDbQgs0jhRgdea2vFemSaDeNZTOBKoG45zt471laLdSWGq2l1Dt3xuGHfFafim/bV7x7yVwC3JQDJ+tAHO5BAIpqFcYQqVzxt7Us6ZUBNrA9Q3b2oTO/aQAnGCO34UASFXC7znDd/WtzStKea0EkseIw/zHI496m0mw/tC0KKSyL6dCelaOv3NtYabDpVoUKxANNIO7Y6UAaWtatYT6ZFZWVs3lIAnmDgZPeuOvtNEUzAMS33iPSmx63PDAtvGqCHfuO4ZJpdVmKzrLavhCoJbPOaAKflS7t/l7VXoF/lnrRJcMk+5AUI9D1+taFnJNfPGjNEOeSWA/wA9Koa15MF4yQsrIP4wQAT1oArXMjXDl5CCT1yMipJYkFukm5BjOQTz/nmq/myRSAoeufm7KMd6fFw67tuc5JxxQBdhsSbCS6kB28heDUFnJsdVIXnqcc1M+oTmHykO2H+EEe9SXD2K6ZDHAXN0x3Pk/wBKAK8jTMGily0UZyCOWAPrUEVwImZQm9mHrwPrSQMCCZkIyOADnBpIvKJXd+7LYPA5P1oAnOSruFKRtxgDIpLOZ4bmOZUBZG3Y6jitHVJraS3jS03Ii/eQ/wAXuDWKDv3AOynGCB2oA9H1TUoPEmixToqQXkPylAP9YK1ND8GvNpUc946RlzlVYY/HNZPwq8NST6pBfXcbG1jOQW6sfTmvfPIiuI1LW6BF4UADI/pQB4xp/wAMtTm1EyXMy+UzcBuhHtXq3hvw3baNCqx4dgMFsZz9a3IYxEpUHPOafQAUUUUAFFFFABRRRQAUUUUAFQ3cMc9vJHOqtG6lWV/usDxgj0qaigD4b/aN+E6eDdQ/tvRAf7GvJDmHBPkOe2em30rw+v1D1zRbDXNNn0/U7dJ7OdNkkTDgjn9ea/Pj4x+AL34f+LrixniIsZWMlpKDkOh9Pp0oA4OiiigCa2up7VpGt5WjMkbRMVP3lYYIPsRUNFFAG94BszqHjrw5ZKQDc6lbQgnp80qj+tfo/wCHtJtfD2lQafZpwo3Njqx7nmvzs+FBx8UvBx9NZs//AEelfo9I7tsb5UDdGzn/APVQA5JiTuO0gAgsPvD3xU0Tsx2sMMo+b61DCCqhmUnHRupH+I+lK2Uk3vJhRzsBzz6UATlsNjIPsOvXrTFjAkJy3oBzgUxIzlCwDZOc56f/AK6n2jdu4z0B9qAFooooAKKKKAEYhQSegrzzxn8Q4NGhljtjvuv4e4+n/wBeoPiv40fSY107TmJupOHK9VrwnUnmklaWaUyIe+c8/wCNAFvXvEF7rly0l3IxXPTPB5rFt3zIc/Og6npk+3tTgcxFGQDOMgdvarUVt/orShePuqo9e5xQBVnmjQnI2bumBwKjePedwUNnrk9vat5IbW7tOgguVOD2GO1N0rw+r3UavOgiY4LH6+tADlhGnaWkzqfPn4TPZfXNY5+9wPl9zzXc/EjRp7GS0aPDWQiwhU5Hb9a4dtuSxAXAoAVJXQHYe/bvVu2mLyIkr7QTyzcACoWRUtlZnKF+gPRqLi4MyoNiqFGPlHWgBLxka4cRurY7rUOOc9KcD+7yG69sdq7bRdK0HV/D001zfC01GPIAc8GgDE0y8a1014VUB5Tw3cD296qyWhkUsolJPUjJzWrFp9nHBHA0pkuFfJIxtAr2a18K6FH4SWWfoY9zzg85oA+dZ1KMQg28cbhmopHf5cIGA9MA1veLbiwbUHh0hWNshx5h6ufX6VhSQn5TypccEen40AN2nIG8nucimpKkjFVyRjrjipoAzRuGxu+90zx9aRoXQbmVs4z1OP8A61ADY2R8xznAAyWYZ/lVuzjt5bSUtMEcfcAGcgdahCNOpKR8KoyAM1Ao8sZZgFHbAAFACPL5YJdW69hn8aA+N4cMqqc7ietPUAruXo3OfWtGGeyktxDLAVcHO5WyAfegDIZcMzgbXz3G7Pv6ipIFLqMttzhs5/GpJoQNxOGXGC46Y+tWbKJ3VFtk3uemBkKPrQBrXNvZXWnweTdRLLgZQjHIrd8D+A7vUbhbi8x9nJ429SPT/PrV7wd4Ha7WJ7xN2CD5X9Sa9t0Sxjs7URRxqoAxwB8pFADNG02CyhjtxEAY0G0ZzgVrimiNAc7RnOefWnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcJ8Yfh9YfEDwrcWc9vGdSiQtZzk7Sj9hn0Nd3RQB+XWuaTe6Hq11pupwPBd27mORHHIIqhX13+158OheafH4v0qCJJrcbb7aDukXgK34dK+RKACiiigDqfhZx8TvCH/AGGLP/0elfpC6FmG91G3GVH3R6V+b3wrBb4n+EAOp1iz/wDR6V+kEYCAbm+bOWKn9DzQArTBXKRqSwOF54+lESHlVB3A/NID3/rUIQneo3DJCgY4P1q0FEakR4zngNnj/OKAH7hk7ck5wfr6H86I1OSzMST27D/PrQikM2cEHv3P1p9ABRRRQAVleKNUGj6HdXn8aKQg9WPStWs/W9Kt9YsmtbsHYTkY7GgD5V1fUJ9S1Ce6u5SXZm9zzUWm2T31wsIbCf3ieBW3480yHTNZktItq7TgN6D3rCaVbeJVR8sOdwPSgDtNb8E2+naKt4l9FKzLuMY6iuNWXymCBeM4wGzj+tQS393JCIpJXcEcjPFV4ZgArnBx1bouaAOivNLSPT1vYyRuPTOG/CsJZWj2+WzA9ePWr/8AbMskAgbayKeQDzTIr+E7Y7i3yp545OaAN6w8UXV5Zrp1+FnUjakjjO3/AArl7yFoLplYExg8N0yfStO102O+k/4l0xVgPmD5GOa9BtfAQ1Tw/ukvIv7QVfkjDZ47CgDyeeZ5Zi0j85AAC4GMdBSnbsAAO/uT0q/qGk3lnM9vPAVeMkHjB/OqphCJvYhxjjb60AV1bJIwRj1HWpI13PtBXvyelNGdp44+lbmk6Wt1Yz3LTRJIBwpIGR7CgDNtpQsg55J5Ykkn0xXeavqmoWfw+toPMdYpnwOeCK4S3hEcylwWxyeDj869f+JtsJPhxoxtoRGowdvpxQB4htZzksyjsBx+dTieTyFgldXAOVyMEfSleExg7j0454zRHGJR/ANgJyetAF3QITPqG3aCAv8AF0NT6lbzJKyO7AHgfLwR7e1db8NINHluAdVfJAwBnjFezyeGtFvLIhIImiYbgykfzoA+YLea50/zTEcCUYbjIx6VWVEmlAyIt2Msq5r2PxH8PNNa7C2l0qSAcRg5GfeuJ8SeG30qZRhXSPqyZABoAx5dH2mOJJldiA3PBOe2Kzbm0aCcq6MJOi8ZyK2Y7K7kVZSN7E/LtOSB7GvTPAXgY31o8+twkEjEbYwRQB5RpujzagyrHE4jP35HHCivcPCfgXT47W3ZRJ5eAzMRjefb2rq9N8L6bp+zyYslOma1/LyNpGEHG0dCKAILS2S2TyrNUjjU8nHJNXKAMDA6UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBDeW0V5aTW1yiyQTIUdWGQQRg1+e3x18BnwD44uLKEyNYT/AL62dyCSp7cenSv0Pryb9pLwMvjD4fXMttEp1PT/AN/C4XLMo+8nTPTnHtQB8CUU5lKsVYEMDgg8EGm0AdV8KePij4O6/wDIZs+nX/XpX6PxjdLt3EnHzEjBx6f/AF6/OD4UZPxS8HYOD/bNng/9t0r9JTlpGBDbB6jINADUwu7YTI3p0/P3p6R4Ic53kc9PypyfdBwRnsetOoAKKKKACiiigCvf3kNhaS3N0+yGMbmPtXmfiP4lGNg+nLiHGQx/irb+Mt19m8EXADhWldUHqRXz1BdlIFhctsA5J5oA1fEupnWNR+2zBd7DhB3rnnjfO4hgATnA4p+55JFKouR/CBx/nmrEq+XJG+WPYhRj6AUAU3gLRuzgqqjBJ4xmqc2MeSnHP3PUfXtXsVh4a0i98AT3sspWdcn5iBk/SvKLqHygVi+XnouM4oArsZC45RUTqS2RmlM7N9xQoxnLnH6UMrRqpDRjH97gD6VJnbgMB0zgDqevFAF5b7y7NIbdGRmOXk6GrWga/eafdLdW81wJE7dsD1rFeVpDnyn5PU8YNPi3L0IUg87f8aAPdzY2fxB8OfaLORYr5Qdy7vmY4rhIPA2sRzSRTRTL5fBJTK+2Kz/BWrXFhqsNxblg6H5scBhX0T4f1u01i3zEy+cQN6HgmgD5t1Tw5d2CCWSAqgOMsDg1kyXDRnaCpI4IA4H619IfE3Sje+G5XgiVnhBbFfOjxpJMylSrjklgaAG2txN56vt3KMHGOOvvX0tYWVl4o8FWUNwo8mSJT8v8JHpXzcltGI5cswOOw5P+FfQPwq1W3n8LWtt5iiSIYxnrQB5F8RPCDeHtQjjjlEiOPlJz0rkBF5TK0iE54AznB+neu5+MOtnUfErRx7hFB8qHPBx7VythNHOxSQAHBIx2+poA3fCOizarM3lI5RAA2B0/+vXpmjDTNKt1t9b1SQOpx5OSD7ZArzjRfFL6KZVtVXHT936+pxWNdak15fy3E8jvOTuIGenpmgD6J0hdFvVcabLGQg5APP19a878f6Zc6lexxafO1w2QoVOF69K83sfEV1ZXPmWYCuRtzkjP4V7f8J7cy6Mbm7iYTM2RnBGKAJvA/gxNOtEk1FN1wP4Tyv4V3EaLGgVBhR0FOooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACgjIwelFFAHwh+1B4Ifwt4/mvrWErpupfvo2A4D/wAQz9a8ar9Av2kvC8PiP4VaxKyr9p0yF76JscjYpLD8gfyr8/aAOp+FQz8UPB4AyTrFnx6/v0r9J0jw7sWJLH6V+bPwoOPil4OOCcazZ8D/AK7pX6VUAFFFFABRRRQAUUVBfXUdnayTzHCqM47n2FAHnPxznj/sWztWILPIWKn0FeC3GMgIwKjgLnp/nmvRPG19da7fzXVxsCIdsSZ+6K4W9sxvfzCT6gDOfpQBBpzulwqbyA52nj8q7/xZ4Ml0zSra9MvyyKCcDaR6VxVosdtKsr8qGB5HavRvHniiLVtGt7ZI9u2NdmDz0oA84utUung+y7yIFyoUVnzxyRquVxnkbh2pXILErux7nJNWr6zu1gt7i4LbGA2DJ6e9AGbuMkwwuUTH5/8A1qN0krbhHtwTjccfp/nrVi2mNuZnjVZWb5fm7e3tVVpM5Qs27uVwAD6ZoAdF5oK71z1GSeQP61KARnBGO3FMG/bwFB44Of504ttXLjH05oA0NG1E2t1FM6ttDgtnrjvXc3utTWl5BqOjlRC4B2Ke+O4rziNgWUsDg8kd8V0Wk6p5NvKihtjcAehoA9x0zxWl3o8Ul8w/eDDr/Oue1LwHbazO1/psgEEmScA9a4i1vFksY4ppdu85BVsn6V7F4P1SxtPB0UqudkGQ4Y85z/hQB54fCC6clxCzNJJJG3XsB71h6PqkOjeFb778d0sgVMEAD1/GvWvEfizRrXT0ljdGuJUIj2gcV4Dqdyt7cyQyxZwxZueM/wCTQBSu5zqMEl4wJbdyT0LcVWt5ZU2rkEk8gDrVuaULZrawhNofITGOa3fDng691m2muLaPckfUn7uc0AZSwyv5jeWwix/rBn0qOOWOwIYlmfncB/F7113iS4eLRoNOCKvl/fkXAZjXCvE6Op2FsevOaALdgsuo6rbx2sLNLJIAqxj5q+qfD9idP0q3gYYkCDd9a8g+BWgPLqNxqt1G4SFQsRJ4Lf8A6q9woAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4sf8ks8Zf9gW9/8ARD1+atfpV8WP+SWeMv8AsC3v/oh6/NWgDq/hP/yVPwb/ANhqy/8AR6V+lNfmt8J/+Sp+Df8AsNWX/o9K/SmgAooooAKKKO9ABXnvjrWpZpfsESFIlyS553Gu8uZlhMYY4DNjrjNVtR0+11GArIq72B2OOoPrQB4hp2i6hrjslrbsVDHDk8cetP1H4e6tYotxIqyjHzADPNd34K1ZLDV7jRbk7Sp+Qkdee9dvPdwx4BdGz1G4UAfM93YSWMTSTQsM8DeOKh8SxNJa28sK4jC4YDoCK9L+M/mrcWHlwL9nxvJUck59q5qe60jUPD1ppsZAuS3z46gn3oA80wpI3KGA5waluL2S4jRGJZY+ijtn611Wv+AtY0uD7UkBmtG+YMnJA9649k3OySJ0bgN/n+dACQxh2KqhzuJ57n1FDqwIzsYqTyB29qXB3DBwoHQd6huCOASWbqEHegCSRBIgDD3we1PiAmkwuMg4yexphfMOZI1UYzyc5+tNhBWQSeWAQMj5s/hjtQBK6bJiNgz0LDFSxtvxHI5CfTP/AOqpLudbmRWWERnoQp+8afdeUqxxgDI6tjkUAar2EsNhDPDIZI24VkOcV1tvcxwfDu6iLGG6kO1M8bv88Vx9nqke23t1QRxpjJbnPv8A/Wru/FWgX174LhvrTEiQ/eVRg7e/FAHmsst/Jp2yTdtjb7yjsfeqUbvG7N5mcjrjmuh8LarDbXgt76FmspQFlUclffn0qHxNFp1rqUn9mBpIWJZS5z1//XQBT02BdQuRBK0YdyAC3GfavfPhvazaRpk9k8Csw5DAY3Z7V87xtJ5w8vmUngjk5r6q8EJcJ4XsDeD/AEhowW9fagDzvXNEN3bXrpbATxEs+7jHPbPWvJruEwTtuX587Th8ZNfTviNY76yltU5MoKFlOOfQmvn3XtAvLO9NvcEJGvAXsfxoA9i+DULReFdzkne+R7Cu9rA8C2KWHhiyiQDlNxIOc1v0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8WP8AklnjL/sC3v8A6IevzVr9Kvix/wAks8Zf9gW9/wDRD1+atAHV/Cf/AJKn4N/7DVl/6PSv0pr81vhP/wAlT8G/9hqy/wDR6V+lNABRRRQAVHcSeTbyyf3FLfkKkrE8a3BtfC2oyqcN5RAPuaAPFdd8aahqGsSsZSkUbkRr0GRxzWhpHjfURKUfMqZx8vVj9K82kMiSjLH94w6nOPXFejeANIEgS6lZQh+6T0oAu6m8es6lHNblrbUuwzjLfSp9Di1HRNTeXVCdjJt+duCe3WqHjmeOw19Z9NkzKEydnY/0qo1/qN3Y/aNWDOkPzlsdaAPR9dWPX/ChaaP99F+HT/Ir5+1F5LW4ZUBVw2dw7fj612Go+NLiXTzaou2JSTkE9K4S+u5rgKrqBhs4PYUAekeCPiZLaQSWWtKZrYDG8jOM1z/i+DSL2U3ujzYWRslO4JrkXdvJVVAwOeeMn/8AVVjQntrbVoTdh/srt+8VRxj1HvQBUlhGWi3k9t3SmvEd2DKxAPY4z+ldFqENtJqEh0xC1s5IUleTntVG40l7d9t4mAclVOD+NAGa8Sjax2knnjt9aWOPczeW25hyVySR+FSoVtnKKEeI8nBz3rQ0jQ76aU3NtGskBPYdfrQBnQOYiXG0kcAGo3dnfLDJPUjgCtbUtOmhuPLZfLdz8y4wKuWnhv7QgH2uGN2H8Z/z6UAc2uyOKRifLf7wIORmvpH4Q39vq3giKLKyFMxyqa8Q1Lw5/Zn/AB+XcWDjBQ5zVjwt4huvDOobrSUG2k5IY8Nj+VAGv8RfBM+i61JLb5NhPl12Dpz0NZGm6bHqltIsEQM8SElSf5V1vjH4gxatpP2eWNd3J2qcmub8DeKbXQZLo/ZPMedCqkr0oAzfBmlfbfFmnWk8bKpnXKjjoelfVR2xReiIPyAr5SbXWs9e/tC3jWBkfeMHA6+1egal8Tbi90HajqjlcMy8bqANOz1177WrqGNmTbI2V3H1PYVtReEotSuke4kDQk7lzzn/ADzXlPgXXZtM8QxXhjDQsSHVj1B7gV7/ABwSXaxXFmI4YXAfBHUH6UAalpDHb20UMIAjRQFxUtAGBgdKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV+LH/ACSzxl/2Bb3/ANEPX5q1+lXxY/5JZ4y/7At7/wCiHr81aAOr+E//ACVPwb/2GrL/ANHpX6U1+a3wn/5Kn4N/7DVl/wCj0r9KaACiiigArH8W2i3+gXVu38YAH1zWwOnpXPePbuWx8M3NxBnzEIIxQB5fY+CIRBcSTybhGue3NYur61JY7bC0OEiGCynBzXQJ4yhi0RRcIDNP1A64/wD1157ql6lxeyShSiMcDPT1oALfVXS9LSbpMHLE8gfjW94m1ltW0ayt7B/lBzIq8859Pwrj/ssj58ss6Hnj19TW54dL6dfRSiMv5fVT/FQBjzW5PmMySROnJ3cfSs8kk8/UnPNeleNbqz1U2wsrcRXLkJ0AOTWRrXw+1fTdNa+nj+QHLUAcXkAgdzzQHcgKybdv6+/+fSp5ofKUZcFj2xTUCMWaclh6ZzmgDufDVrbHwuGnbe5kyAowVHpWPr0txJM4kizEq4XHcVR02/jtkVcDY+QyE9KnvtTe5gf7O+2Mfw7cUAVI7NrmLbHEy47DHX+tenfCSzuLS9eK/tHeCReC/Y+teX2lzOiFkLI+OCRwfStK81zVpbWOJLuVcDDBGwDQB9Ear4U0XVmVri3XIPBjOOlcD8WvDWm6fpcVzaYhcfKRkfn/ADrzTSPFur6VIwivZHXPILkjHtT/ABT4vuNbtyssbMw/vNnPHNAGTPPDdWC20jSGVc7ZGOBj0qq9vJFaoRGSi8B92cjPam6VGlzcQxTSiNGwpc/wn3r0QeAbbyYvt+sxtbodwaLlevSgDzxYyoDEME28k89qW1l2ThCyqHHVuldN4ptrayMNvprrMqDhuhA9/eucEEXls8i5uFO7kZ4oAluja+U5ZXZlOcxgEGm6WqG9QuG2bsYAyeanjU+W2AwD+o6egx+FQ2DvBcbo+XU856D6+9AHt/gfwFYvEL68kFzC3MUYP3fqa9Hk2WVjiIbUiXAHXAFeRfDTxh9l1VNKu5VNnKu5ZWGNrema7Tx/4lttN097ZZUE8q5U7uooA6TSNSg1GAtC4LodrrkEg1erwr4a+IhY+KzHNMgt7v5XLHADdq91ByMjpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvxY/5JZ4y/7At7/6IevzVr9Kvix/ySzxl/2Bb3/0Q9fmrQB1fwn/AOSp+Df+w1Zf+j0r9Ka/Nb4T/wDJU/Bv/Yasv/R6V+lNABRRRQAVzfxDKDwlfGRtqhetdJXE/GG6Ft4Juc4JkdVA/WgD5wlkKz7lcvt6E9Kj83Kyertk4/GniHdC0gIwDjAHA/E1L9lSOwFx5ybmYr5YGT9aALnh/UDaThSoZQSRntXr3gHQbPV3l1CbbwCgjA6kd/pXidv5tjKkzxBh1Af3rpI/Gus27lbOZY4ypA28D6/WgDr/AB3ottptysySLDIp3KP4mNdFF4v0/VPCU0F/MsMqpsxJ1J7YrzLW9XXVrKzma4ea8BPmls8VRkttlnJISXkB+72oAp3OkyM0k8WBbZY7ycDA9M1k+UcttLEKecHI/wD1VJc+d5m2Sd2HXbnIHtTYJzCmFIK4zljQAwHOevHtV60D+XuXby3OR29qpxAeYnBPPT15rf0DRrzUr5YpAVjcgF26Ke1AGZdIwIcM2ByfQHtxUMtzuiC8huhOa2PFFo9hOlo5QqnVl5xXPb03bQyls9jQAZIHzc+pAqzbwJPHIocibGVT+961ViKMwjd8dRkcn8av2ukl3WSKaMkdy/P4igCgqGNtjb93fdz/APWrUn1Kb+z4rMSMyoSxO4nr2rr5/h/f3Wg/2wNqgrkr3b3rgZo2icqw5oAGd+V37gTk9eamti7gxoXJxkKuB+tJKjxxxMw3Iy/KSOB/9ep9Dkkg1OGTYgMbAlSc557/AKUAd98PvA9/q6vc3SKtgUIQk4y3oPUVzXiHTfsGoyQsoAjbGF4GfWu70rxhqF5qtrHC8cVohIMaEAYI71x/jW9l+33AmbzG8z+DgY/woA57bI7xrbEvIrfcU5Y1a1SSdikl+7GRVwFkPzL6cVTguLixukvYSsUgbgAdKiv7xryZ5ZSzSMxYsaAA3snmK6Eqy4PY9OlfTXw41wa94WtZy4aeMeXL6givmDa0WHCiLJ7dT+FeofA/V5LTxFPpkzx+VcoWRF42sP8AGgD3aiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV+LH/JLPGX/AGBb3/0Q9fmrX6VfFj/klnjL/sC3v/oh6/NWgDq/hP8A8lT8G/8AYasv/R6V+lNfmt8J/wDkqfg3/sNWX/o9K/SmgAooooAK8k+Pt8BZ2Fhv27iZSPX0/lXrdfPvxsv47nxY0JO5bdFXGehI5oA4K0uolmMLoPIIySTznFVVTzJcJkKT+lTSRRsA0LKFJwSxxinN5a2rR9WBzu6gn2oAW+uvtEcS5z5eQOO1QLFIAW2cD1H+NLBF/pMaScAkE/SptQnWSV1jUrGDwM/zoAqxybZN2W3df8mtMaiFhxgYPGOp/nxWSgCtgsTk555oO7cCpXHuM0ASTyeY5bGPanRG3ELfaFZmPp90CiGCec/JGXOM/KuBSxW7tMEZWHODjmgBJApdDAQQ2CAD0ro9IlmjELb3KwkZA4Gc5/H8ah0HRWnvo96SGPdknHbvXU+MrCxtfKXSJpAsqBmDcHNAHHeJrxLqZmjGZGJ+YgEgVjSsAqmNCWxgjPf1q3e2ckHLtv8AfHWqdAEagK20bEJHQdc0/ZuYZJJ7AVE0oacbOAx5Kr19s+lTlSoLFwcnAUdqAPU9L+INxpnhdNNljSWYR7FPTg9BXll7JJd3DySscMeQPr0+lOmcyMhyRtGD3zQI1EO/zOSfukUARMXaNDOQ3l9Bk4UfStPSJ4FGJEL7gWHp0qrFHFljI+QvcdKk3RxTRtb/AD85BJwQaAN21me1h89IiuTjODg/jVO4nlmctM2WPPI9a19X1032iWttFHGJ4j8xRfun1JPWshY5DCSZSA/GW5JPagCndDyTGhZVjcZO0cgVbuLvT7SNItNRnZlDSTSKDg+gBqldwyx7yzgDOSoJqnaRCZsBXU84ycAH3oAvveocMQJSchuOPSn6Bqj6VrlpfwERmKQEgHtnmksrWMSOl08eCOPm6Gqk0MgJJTC4JBHA69cUAfXthcpe2UFzEQ0cqBwR7ip686+B+uDVPCYtHYmWycx5Pde1ei0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvxY/5JZ4y/7At7/6IevzVr9Kvix/ySzxl/2Bb3/0Q9fmrQB1fwn/AOSp+Df+w1Zf+j0r9Ka/Nb4T/wDJU/Bv/Yasv/R6V+lNABRRRQBS1rUYtK02a7n+7GM49T6V8w+JNVbVNZubpoy3nPkbuAe/Wvf/AIon/iir/aR0FfOEcbko0jEsOw6UALeL5sKrGuWByf8AP5VSAMuxI0Ax1P8AXNTy7IS/OXYZwRweagaU+aZFAUn9KAL02mS2kUc0rKAw45x+tVtkMS/vCHboQD0p80098oDNkRgDBNUzQBp2lpBcunOGbgEj/CvUtP8Ag+rWMc010GmZA2zkDpXA+BLMahrNrC6KU8wA/X1r6iiTy4kQHIUAZ+lAHzrNEdJkmgRY0CnZtx8zY65NQ6XqtpbXaCa0ilG7ORxiur+I9vZDXJPKdZJGyTEmTye1c1P4Z1SPT1uYbFxBwdzjocdaAN7V/iBY2Nl5Gk6XGk7cbmAOPoK4i/8AEN1eZZowsjE9Byf8B2qSLT/NLJ8zzD86F0Q+cYgH+0OT8vcD3NAB4fja7vIoL4Zhc4ytdlrfwreO1+0WbIVC7sZrjtIsZItZhs5ZH27gucjAr0Txhrl3Y6S2kQ3XmMygBk44x0oA81uPD8dsrAneynkRnj86y10wszFpUjXdjnnFdL4Y8Sy6XcGSZI5h92SOQbsj0rb8XXeh3ugC40yKOK5LZkiU4Cn1zQBwK6aks3lRuWJ6HIGac1lEkhiZ1JGAW7ZHpVANJv37gec8tgHtmtjwubX7ekmqNIYM5I6flQBTjtVkbZHFuY8kDJOKgkgQKSCFUnBJGcV6fD4p8P2Woxw6dpCRmcFGdupzjmvN9Vt5oNSuUcu0fmHhT2PNADrRIkhwX3Y/u9zV23ne3DIwBQ8E9cVmWTMqgxqQMk5bn8q7zwZoLa5a3d3JIqQwDJJ6fQUAcTql20lztCZUZ3Koxx/SsYkiQ/Pk/wB3HH0+tdHqUMcV7IqKpIJ+Yck1lzWgb7hIwe3b6ZoAo+YGBdHPytktk/jUrTNKBli2RkD29aVLKYsCEldjyPlz7dMVMNJlimjabMZHDCRiOO+c0AevfAjS7mC4uL0gi2lj4JGM817LXnPw08S6Bb6Nb6dHeQxyjn5jgMfavRFkRgCrqQeAQetADqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlfix/wAks8Zf9gW9/wDRD1+atfpV8WP+SWeMv+wLe/8Aoh6/NWgDq/hP/wAlT8G/9hqy/wDR6V+lNfmt8J/+Sp+Df+w1Zf8Ao9K/SmgAooooA5b4m20t14M1BLdS0gTIAr5sJe3g/enMnYN1r65nIEMhK7gFPGM54r5V8XYn1y7lAVEViBGox35oAwpJC7AucnoKekrJGyhRhuCcUqqfMLR8KMkH2FSW969urBERw2QSy5P1oAZZyrFMPMB8s9a2U0V9UgefTtrleSuecViRgfM77NuMkk9PwFdp4fntdP0xbmzJa5DZK5wP/r0AXfB2j31hcQzGKRWjcOSBjAz3rtfFHxCns4Dbw2/ls6Y83OSeO1UdD8ZWs5u7eaMGWRSQU6E4ri7eBb7WJ11B+pOA2eB7UAU49YuW1KK5dt8okBLtyTzXpl18QLa8sFtTE8e5NrEgYBxWdF8N47q28+xny+Nyqf8AP6Vz2teEvEFrL5csBkU5YMnPGf0oA6nQrLT5rvdbbhKqblY9M98CsHxPGbB5HPF0SfmB7ema6zwhodtP4baW7uBbSHgOGAZayvGnhrV76SKOyC3kIXiXOSR70Acz4IsP7a11EmuSu47jzkiut8e+El03R5rwSyzOMAHPQ15jb3tzoWo7TKqXETclOOh9RXR6z491LVbFbW6RSjcN3/WgDjYopZbxI4juZiQEHAz2yaS/DW7izfJdfl65Apl0J7V1kjfakg42/rn3q1ci4u7QTShY2i43dM0AZkyJFIFBLY+8DxU8kvnSpHE529yD+lVgWmLZ3FlHUnsBQirgM5wuenc/SgDoJIpLj7LtBXdhQwXGORW3F4eur2/dXhZiq/MUHBPrXL/2pPJHAhDC3jOCB29elepfDTX4hqRhV1WMjhnbluPfoKAKeheDraKQtfxYtwpcqeB9TUOq3UujWc9ppjqlnLkgDv7n2r0nxnbRRWhuDu8vBJwRj/8AVXIeA7zStXuLixvYYXmb7jHpjOc0AeNXLyhjh3OT/dx+td/8L/C8esyvPrK7LNFyC7bd/NWPHOj2+lXsvl22CSf4M5561jXOu2tppCIjtLcFdoXnCZ70Ad94o1/w54ftPJ0e1gmu8AK4HA+prx3VbqTUbiS4uztEhJYAg5PoKS4vVlt4pCivIh5J6iqVxctPt3gDaeAOBigCKGMtco0e/cDgEdR717J4N8Z3FlaW8N7EZIE43Endn1PrXHfC7Rm1m/uAqoJI13bC3Ueldh4i8OX9nE0qMsig42gcp7mgD1vTL+DULVJreVJAwz8p6fhVuvnbSdcvPD2rRXMLOYEwZY9xAk9q948P6vba3pcN7aMCrjJXup9DQBo0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8WP+SWeMv+wLe/+iHr81a/Sr4sf8ks8Zf9gW9/9EPX5q0AdX8J/wDkqfg3/sNWX/o9K/SmvzW+E/8AyVPwb/2GrL/0elfpTQAUUUnc9aABgGBB6GvmPxpCB4kvlEIRFlK8j+VfTteaeO/CEN9q0t55vll1DbSOCe9AHlWh6daXbTW0rJHIYwUdvX0rB1Oz+yz+SEIbOOeM11sug5R/sxcSoxG3uazUtGvRIk2TcxHj5TnigDF01ra3lkOoQs6MpCjOOau2qnMnkRgr3UnIFT29mJNqSoxJOMN3+o7VpJaRacVnmZmj6Ff7woAu6OkU8ivCuyfb84Az04/GqeqW7ANco+2UHnPb61vaLcQhReWSxqsEgMiZBO09frxU/imDTkuri7iYxWciBiSOd30oApaR8QdT0iKNEhWb+8rKASBXRXfxNtb20QSIYJmGCmcj35rz9L61APkgOMHDMcZ/pXN3csj3EoLDBHQ9OlAHR65rs0iSQxTMInO4/NgfpT/DnjbU9JtpYEuZJFZSEBz+lc7HECiskiyR5wVbkioSIknjwDHjruH+fzoAsXM32yaW4mVVmkyTu6Z70umfaN5eAhwuAQw4PtUbWbJKXf5lPzL/ALQp+nXD290qBcq5wAR0BPpQBb1G6+0GNEs44wvB2t8tdBo9jBrMKWN1LFZucKrHgN9a5m8uha3sqwuHJ7/wjNRQTXD8sCd3JYsB+lAFjX9JGj3s1p5yySIcb1PDewpdC8O3ut3SwWaNI/fHQe2aVY5r24yyNuYAB8ckV12i+I18KmP7HArTY+dSOMfWgDG13wjq+gRrLfxrHE33QpBArEh1IWrDykYSbuWJ6V3niTxifEWyDUcQW3JBQ9Bx1rzrUmhkuSLUsygkLx1FAHrnhW+uPEmhy2d3c8OdgLngD1zXI29lc+F/GEVvEwkcSYRwcjBrD02/uB5NtaTFGHI2nAJre8NyG+8QwQarLtjDcueuf/19/wD61AHRfE7V7lpGs1ESgKPMdVy3I7GvJyrM2WRmY9MjGfrzXZ+N9PvbPXboXMzyIOUbs69vyFc5bRLNIUDYC5y3Xb+JoAoRR5WXe+3bwQW/p3poyfMgcYDnBz9eoxVu5s2kC/Zo3YdBx2qO7tXtlAlQK55Oe35dBQB1/gO6Oj6lazwbkRTh2xwRnp9K9w1jV7ZtCluIFWVJFwfb6180WGpzW8HlIBtH3mPaty28TXS2TW3nlYjz8vQZ9RQA6+1OKW7w6uEDfMFYYP5V3djrtt4f8MRS6UVjunOWVuc/h6V5JPN57mOPEcrNgZzzSBbhXEUrjan8Wd1AHtnh34r2dy4h1qD7K3A82M7lz7jqK9JtLmC8gSe1lSWFxlXQ5Br5HmIBaFHVCvVugP0ruvhv4hvdInKIXMDctC7ZDe4PtQB9B0Vn6LqsOq2wkiBVgAWU9s1dWRGYqGG4cYoAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFBoAKKAMDA6UUANlcRpubpTRkH5jkt90EdPbNVNQYq6lnUL2yaWyuYmiIR2Z/7o6/gKAML4r5/4VX4yzgH+xr3p/wBcHr81q/SD4mNt+EvjMu2T/ZF4MnuTA1fm/QB1fwn/AOSp+Df+w1Zf+j0r9Ka/Nb4T/wDJU/Bv/Yasv/R6V+lNABRRRQAV5p8Y7uezjsnt3Kbsgkema9Lrz3402jT+HraVdv7ubBJHqKAPNrfVJIUFymWY/eyeCPU1FZ61Hp+vf2nNamU4PyD7uf61esdIuLKzjW9jH2K4wN2eR7+1U/Genrplz5MTeZCVBR16H1oAqeLtTtdSkiutJi8hyMnB5zWNFe3EbMSm/HJJ5ycdgaozLulcLJhgQQuepx/On28sjIIowTKMnJ6j3oA09BuLwazbCH7s0ihlI657H9a6L4lhI7gWkAJkGC7g8cjoaXw1ZWNhYm/vZC+oE/ulz0PYmuuv/AN9qdsLvzEaWUAlT6YoA8aEM0UO4Nxnpzj6CmMssjIzg7c9O4Ga67X9Bn066a2eBklHOSePwxR4T0q1vdXSC7nVGI6etAGElmQgCRA71yGHGBVCZmiCAKrHPy55x7V9D2vg/Rrm3ljidS6DaeenHevI/H3h4aDqEcULCVT8w2sB+FAHKSyzuRLJk45AJxiqqu/mEh8M/BJP+cVf8l53YMj7R02nitDwx4ZfW9VFpJcx2aHJEktAGHKBG2AQc/eC9vbNXNMDTkQ8GRiAnP6YqTXNKOlaxJZxXCTtEcB0A2ketVIt0cscgDDDDa3AO7Pf9aANaW8vILpXupAphbmNPlXj+tenaP4ZsfF+hJfWrAXAOxiw6cV4491Ib15WBOWwQx4rt/CXjSXw6yeXAvlE/vQW4I9qAOe8X6XPpmrSWs8b+Ypxx0PvWLuVHKx5Cjq45JFe7eMtMsfHXhX+2dPnEEsSktuxzjqDXhO3cVVCMA445zj+I0ASQSpavutVfOM59ferbXNwRFcwyK1xGwLgc8f5z+dQRW7byC7HcenTJrp7zwnfWelx30kapGwGSWAGO2PzoA9i0JtE8W+GIYp1idggEiF/nQ14x4106x0TWLiws5HManJZ2+Y10/wn8IajcXr6lcvJBaqCEbP3z7e1cv44t/L1+6QjdLC4y2RycdKAG+GNQ23aWo+ZZXUdOgOOldF8YNAGiQadcRhRbyHYy9CW68+tcVply0N/DIm3MfztkbsY7Vr+J/GNz4o08xagVUxNuTAxj/PNAHKwp5jZBwOuG5zVySxlikaLbgSAMpwCKopDnD4zHjJyfzroNO1C0i0yezdN0rcxyBslfpQBiXds/mtGVbzcDcScdqZOWtIwJAyDkLvI49/c9a9E8BSaVcWFxBqibmP3ZSefbmneK9Q8NXcKRW9qXlhwpZR7etAHmYcyOpYll4wB/SvS/AFo902yW2XZn5d56e5PrXE3E1sjjyohGjNzjH+eK09E8R3Fk7+Qcxn+HptB7UAeg+IL6/0C8DwTIs6DCgYAI/wrqPCnjvT9bVIr8LaX4wArdG9xXkOt+IrjVY1DuFkT7rlcmsNI7mcu88+GUKdwOCB6igD6wicSRh1+6elOrx/wN8S7dbeLSdSWXen7uObux7Zr1qyuFurWOZCCrjII+tAE1FFFABRRRQAUUUUAFNdgiFicAd8ZodwiFm6CqXnmRvnUmMn7ooAspKsoYqzAAYOeMe9TAYGB0qC0KlWwQTnJwuKkZirDO0L6k0APoqhrOq22k2ZuLp8IeBgZzXA+IPidYabbSKuDK/IBPP5flQB1utXRmkSOJlAXJ5PB7c+lcjqut2ukuQ10qNHjhW6+przPVvGuo6lESkkkYPX2HqRXF6zqct5Ngys8Y/M/jQB678VPEV9N8HPEbyW0sKTRtFGzgYljaJssMV8OV9Lznb8D/FQUMQJxjJz1iavmigDq/hP/AMlT8G/9hqy/9HpX6U1+a3wn/wCSp+Df+w1Zf+j0r9KaACiiigArm/iHAJvCl2dm8xYkA9wa6SsfxepfwzqKjr5RoA8ssvE6eILKPR7kCMMQGk9AO9dR4j8MaXc+GoDFPGZIVwrk/e9vrXiUazRSs0bFQBjJ+Xv15rr/AAelxd38dvNMWRnB25yPpigDOXwaZbtmaeKNFBJB6/8A1+1YN/PDFdOlvnbGcZA5+prvtbtlt/EMkcW4EqQTzx7V5xqlvJHdygxfNyDkdfcUAXLCfF1E4kYpuBzk19OaBdQXWl2zWzhhsGRnkV8r2QBQvAjYTlm9K6bw74svNMfFtcsqr2ByCcd6APoHW9Gs9YtjDdxg/wC0ByPxriNT8AafpFvJqFm0rPD8+1iPX1pNB8eX15CXuYYii9WT/P8AKuH8X+O9R1KWS1MRiiPy7kPb3oAy49R1K5vr9rOaRPMzlVPbPXNY5u3CXH9ovLO4+627POevtW94d1BNNtblGtgWlHGTXLXySm4lw2ELEqoGf8igCE3roiCFPKTOcjjdWhrOpS6gkKrGVMahAV7++ay4ojMcnOV4YHsPapppfLiWALlc54J3N/8AWoAbGiqUkkkbB98/N/hxTpFUbnDfu3+8Qf8AP+TV62spHsfM+zh1ztGATg/TvUHkERuph4PzYbPy/wCFACro8jafFeD/AFEhIABy2fSq7wL8ykMkann0z+Namk6i9gViLK8R/gcZ/ECqOpXrSzAShfLPJVR0oAbpV/PbQXMUczLFIuGQnKkfSqCbw+UyG68cf5FPSURnCHaTweMge+fWiWMgkBSD94L2A/yKAOz8A6ylleFry3S5iUHhsEL7mr/jHxNLrG2AzCOzU/6lOcVxcdzMbaNAfLhH3lHf0pqwiSYncYgRy/r7YoA9f8PeL5ovC0sFoVNxbrtUAdBjg15JrV29xfSTTSsXdyXw3zE12vw5vNPjg1G1uYwguI2VGkPzZ9q4K+j8q/eLzVdC2S54yM+tAECl7ZmU8A98Z/KmQlkDMrYOcAY61JcD98okAC4x8o6VYMSKqqqB2/hUnk0Adh8HEsrjxKbbUDHh0IWORchz0x9a3/if4Ks9JlTUrAeVBIx3pj7p9q5W+8O3mgeH7XWp8QzOwa3RWwy9Dn2raPxCnvfDSxa1Al3k7SGXB+uaAOcXS5oPJeIMsTjOe2P85rqtP8HSXOiPf2gjZ0BwSM4+tXtB06616yL2hwgXMeBxgn1rtfDllcQwGwcrGUJUjGOnfj1oA+etYtWgunjnPl7OOnf6VQkCxqnlM+McnkZxXtPi7wdLrWsxWskkcM5GY3X0+lc7f/C/VbS5jSedJ4WYBWRf5igDg4G3IuJA3fGAOPTFWLq58u3GEBGAuT1J611Wp+A7zSo5ZfJkKYyJCMD/AOtXNwad5lxuluUAXJwozj2+tAFbRbG91nU7e2tg+534ZRwvvX1XpVoLDTba1BJ8qMKSe5xyfzrlvhp4b03S9Dtrq1jZ55l3GSUfMPYe1dpQAUUUUAFFFFABRkdMjPSszWNd03SY2a+u44iBu25yx/CvONe+LelWDg2FvK5B4yOWoA9H1a7FuyK5AjI555zXPX3iO1t4A4y7H5fLBwc15NrfxavrpFthpsW2T5vMckuuelcRqeranfXBBuWWPqAvAHtkUAe23nxGkRHSJre0UDhmO5s/Sudu/HK3Mpj+0yXErHgB9qivJEtmlmAjcSSk4JZu/b/Jrb0jQbtr7ew2PjnaPun3oA6jxZ4gv9f0k2NsWRkGeOi1wBsp7RRLdM0krcYbJOT79hXYz6nZWEbQQoDcAfNN1ya5W8nlu5GaRxsPATbwP8aAG20wmDW0hdTwqktzms+bT7pJlE6sh5wc8Ee9W4EjWRJQfnxuB9T64q9dztLb7y2QB8xIzt/+tQBJcqf+FH+LAoyq3Ctkf9c2zXzTX1tqmlPp/wAEPEnnT2XmXURmWOCdXbaImPIHSvkmgDq/hP8A8lT8G/8AYasv/R6V+lNfmt8J/wDkqfg3/sNWX/o9K/SmgAoJA68UU1wxA2nGCCfcUAOqhr3Gi3v/AFxbtntV+quqoZdNuUALFkIwO9AHzz4figvL51vCFXLBFHG49q6DRba40zU2u8lPLGYxjt61zNmW07VpJJAqxrI3UdPpXQar4ztdRtntlh8p9u1JOwFAFBtY8/xFJLJEHDEswb+dZHiq5W6vdyjY+Ow/WrfhmBBrEcl0kjwq3LdgKbr8sA1maaFMW44XPBbmgDl4pRbiXa4DMuGUcA+wqv8AOwLKTGBwVXrn6VZnWG4dtqhW6jH+eaFObcyHOVPbgMR7/lQBuaJcyHbDGzRnOSo/irY1Zc6Yjh1M7/eOOgrkbCeWOeCVcA9cjt6Vszz3EzAsMKT8x7Z9KAOj0HwqdZtFkgvIxJ0YEcCrkfw1upJpbY3MRlA3K+c7v8KxfB+otpV01xJ8iLwoz19PxqDUPG+orrL3FpNtJ4BboR6UAZPiDw9d+H9Qa0uwqljuRt2QafokFhJdKLwnceOP5VHf6tdardpPfFp5FyMHofwqrKybFMMZQZ6nqD9aAPf/AA1Y6TdRQPaRRhVHKkDmugk0fTpE2PY2xXoR5Y5rwLwjr+oabqMREzNFIfuE9fpXaz/FW4tLlo7jSflU4zuKk0AaviL4baPNDJPZxNFKuWwp4ryLW9HGnadcyYM2WEe7H3TXb6n8VLycBbe0SOJuoPJIzXHeL9Tn1GyRoIGhhJ3ShRwfSgDjVUgZxkDqcfzqaNx525l3PnAA4Ap9qAxIUDn7wIyK17kWUUISCIeaQP3gP5igCozsASy/OByoA4qM3JhG2MZlbBxjmtfSdIfULe5mtmBaEbmB6DH1/lWTMqySByFQ7h2x0oAbDJM7NK2A5+7jjHFDmOfMZJyvtipb99twruoVHUEED7vH0qXSAiM3ng7nUjrnJ7ZoAs6Fbwy3Y/tIE26/xKOh7VWu5rK21IsEZ8PlVwOFBpDePBbtHzsbg4HSn2WntfyIqR8vxnaCRQB2esa6PHqWFkkAtkhCqSeeenAzXdaT8MNOt9KmtL6RpjIBggY2HHasfwT4AltzHcXEqhhtZAc/MvrXrIAUADoKAMvw/o9t4e0mGxtP9THwpbAOPrWX4v1yw0Z4pJmJnzkKh+Y1b8U/bYoY57LLDOx1AyRzwa8t8c213JeRrMrszjIYDj88+9ABqvi6K/1qLUY/OVY8FSWxxnmu0074maPc26sRIpxyCQTXiF6hjc24YHAIKfSoobN1gUxLuV26jrn0oA9e8VeKV13SmWyR0tcnfuOOAOpxXll1cwQkxWwDFepAxyfWtzTrSW0sJy2yOSRflQtu2+5rnmsJTPt2jzWyW/8A10AfQHwzvWvvCVtI7FmUlOeuB0rqq5T4Y2Ulh4PtIZvvZY59ea6ugAooooAKzPEmoNpei3V3GMyoh2D37Vp1ieI9KkvtNuIYGJLo2FbpnFAHzPf3F3eXFxPdzNNPK2TvPTmsKeNRI5lVSU6Ae3Wt7VYLm3umt7qJlO/EinsR/Sse9T53LY+b5Aw59qAKl/skeIoQMjbkng4qzawSrECqKU+42STz2IqoAUljVgqHpkDII9Prmt6RDDpgs1+eabDsVHPtQBnxtb6dG1xAVnm5AGfufUV6B4SvJr/TJLqeNnCrwEUDJArz+18PXc0vzr5cI5MjcV6h4R8ZaNpNrLok8J/erxOQBhvQ0AebWbC31S6fWkKxu2VQ84z0q/eanYxyN5KBcnB9x0yP5UnibULW5vpGidXk5XezZrn44fMdWlO5sDAA4/8Ar0AWZI4WZ8eZ5bNnaT0H1rY062WSYyuMWuME+4HFZVuUEioDkZAZe3tW5MkkVkshJaHIyAO57UALrFzbSeDPFNuIpMHTrho5CMBSI24/Gvlavq7W4bm48AeIZZEEcUWnXGCBgf6tjg+9fKNAHV/Cf/kqfg3/ALDVl/6PSv0pr81vhP8A8lT8G/8AYasv/R6V+lNABSPux8mM+9LUUjMs0eOVbIxQA+MlkBbGT1xTiMjB6UyIYUnIOSTx0p5IHXigD5y+Iy+R4pu4Y18tR1A4zn1rl2PBIHPYV798QPDGm3lvJqc4KTx/fYfxDGMV4dqV9ZC4KWdoQoBwT3/OgD034Z21vqui3luPLW7xnkda4DxSxtr6eycKViJBNJpniG8hkj+zbY5MANt4OMVjavO81zJLKrOSxOQ3Q0AVJHYyhBtO7v6qatsR/Z62qADnJcjn6VSSLdA5PJzhS3HHrTHR1XKkKhJXGcA+/NAGjGjO2FGff0rodLspJmEDEhSQFXGN1c9o88UEbho3YEDnpzWxo2ry22pCVnOCepHb0oA1Nf0d9OgVmVgHH+rP9f1rjb9WiKx4BduQc12XirWvtVvmLb5eeGweMfyrjrm4ZLdQqoecZxzjrQAzSiReOSxbGeMcng16Z4U+HN1qtqLq6la0tpB8qNyzA+3auS8AadHearHcXQEioeEY4/n1r6Osr2za0HkTRMsa8qpGRgelAHDHwDp2jqL2WQyCAbl3dARXC6wsOr3EkuGJRiCo6fhiu48ZfEGGC3ntdNgWaUZBeToPfFeQx+MNdl1EbPLAY4Cxx/dH0oA2nsNNnijjtUlSRfvM/wDE3pXe+HPBcd3pQm1K4RDMuGQEfd/x61wOqXUCEeeHjuWXdheik1l3mr3jQLALuTyABgBiMD0oA6jxb4O0/QbiIWtyGR8kBsEGuCvnMMjqq/NycDsOxqX+1prtBBfSvLs4iJbIH51UlBlbA3IVPy5U4PvQBb0m7nt45Y7SZtjr8ykDj8ai37mOMtzgn0NaXhKxm1W7lsoLWSeVl2564Pue1eh6P8JLh036rerExP8Aq4huwPrQB5jcMJI4kdR8o654NXvD5h+0u86h4ApLY5P4V7DF8LNIUDzJZWx7CvOvHljZeH9UWHRmLOn3iSM59M0Acs/kTXrzsmIWJCgj37itW01ZtPI8kLuI+YbQce1Sa5rdtqumWyCzWC6h+VnRcB8d65szskW+RQAD8oxyfrQB9CfCu7uNR0eW7uW3ZfYn0HWu2ryn4QeL7W5iOlXIS3n6xjoG9q9TnkWKF3dgqqM5PagDirzxZLJq72Qt1Fr9wk/eJrqYdPgewjhljVwB1Iyea830SynuvETM4womLBj02nkH+tdtovijTNS1i4021k/0mMbtgHBA6mgDxf4l6O2j+InVQDDN80eeMDNZOmQXJXEcu1QQdn1/z0r2Xx34UfVmjlik2KgwSTz0ryS9gk02+Ow73Q4Hp1oApXl7NFPJHnnOJP8AaqGK6JmX+EcY46GrGqQtcL9rjO84IkAI4I68VFZWEt7JBbQKGmlYBACe9AHvHwtvn1DwhbySEko7xjPXANdbWV4Y01NI0SzsodvlxRgMe5fufzrVoAKKKKACiiigDxv4v+H1t9SXVIgFinXa3GAr+v8An1ryK6tX+dyMxhsqeuSfSvpX4oxJL4Nu/NICoVbn614Db6zNaOY4obd9x/1brkY9aAKWgaXEbtZrzcIk4VTzk1b1K8jNyRCqoikjcGOeO3/1qjmnQXcLsoiLkAADaDn29KbPYSi6kkVAd5JXjjPrmgCjq+qSRwCMTM7t0BJIxV7RvDc95pU99OMuDlSRms6No7eTNyx8w5wxUbc9c1p6b4kvyHEUu23QY5HX8KAOb1PT5oZ/O2krKSSAOAe9BWQxjy8sScjJ5BrYl1dbzfGUVlJ5PSmramN1lJXyycr3B/GgCbSNPEkombKN1IboSO35V2GoG1s7KCebBjUHbF13EdSa5uLMMRLMI2fhc9ePamPcZtDFISTuyDjOPxoATxvrr33hTW0CrDA1jNtVeh+Q18t17/4pHl+HtVTlnNpL8w4wNh/OvAKAOr+E/wDyVPwb/wBhqy/9HpX6U1+a3wn/AOSp+Df+w1Zf+j0r9KaACmvtX52HTvTqCAevNADImDJlAAueMU8jIwelQSZDuTyMANn0yc9KmXgAZJwOpoA5v4gTR2vhK/dwNgX6AV89KRPdFGAOflXB9+K+kvGFiuo+GtQt3XduiJA9xzXznp8QkvFgjjVXR9oJ4xz1oA0h4SujHEUaPzZM5GRnA9q5+5ga2uJYmA3q2G+tereLfDkNhpcOoLfsbhk5568dB6V5lJPbtbTOUbz8g7m5GKAJrLQ726KJbxbs8L1rN1DTp9Nv2gvYxHIR8sZPGPyr0HSPGDJplrEIE8+LChlGD9TXHeJ7uTU9TeedH2txtbt+NAFG3aKFJncnbjG0/wBKprK03mAEoAOD/jTtrpIuChjVhtV+9O1AwoYhHC0eRliDjI9qAL2lBry2uIGIPlLu3Absis6OJJnaNSPKzyW6fQVo+FZ4La+bzgzRuhRsHqCOKcwjg3EorndgAnkCgC7Bd/Z7X7NYuFJHJJ/ka0fBupm01Z4DcTASqYXdzxkjg1QttKmvbc3dmqiND87d1/Cqt3DNFOJFBOCCMDuP50ASX87abeXVu6iSRHPLjOBUmn6ozW7FIre0nzkyBecVS1uUzXb3cgVZWj59CapWUiXJaKQ7HYfKRQBa1V0WSOUGVgwBZ25yfeqfzszKcbc9Rg49iKfNDepbrE8UpVSSGJwAc00O0FzvQN8w5PJH0xQBV8mR32MQAOenH4V7F4J8NeHtb0mzN555vkUrIqOPm9+K8oZ280h0Kn0AyK7n4XJPY6h/adzIYdNQ9W/jPbmgD27RdF0/RbfydNtkhTuRyT9TWjWPZ+ItPu3Ailyrfdb1rG8d+LP7IsXTTVE9wRhmRh+7Hr7mgBfHXi230ezkgt3WW7bKlUb5l/8Ar14PqEtxeXkjysWZvn5/wrr9Fsme3m13WCwtFJJM3Vq0tH8VeC7q6+z/AGPFzNwruOc0AeXNcJEcOpbOcDOMH1p9+q2sMLqwZpBkjPIq54h2R6teBP3YWTHIrP8AMWZQM7yp+X2/+tQBTjne3ulmhZ0dWznODnNej+HfEHiPxCBp5lleLbhhjt7muGgt0lWTz1beq7gSu3dXWeGvEZ0bTp4LJQs0oAZiPurg5we1AHR+GvGItb99FeMMqME85Bznp19K9KsdE0nSbuXVo40S6mTDy56j2H5V82zs8VzvthuZm3EhupP0966aS91WTT/tF9NK0QOAedpXuKAPbtW1S0axyGWQn+EdvrXguu6vJcanM4EIjVyBEowuPX3NT6d4hkginDuzAkcjsCf8KzdQsYmImsplaN/mw/BH4UAGmXKpI7KhEbD50ODknqfr1r1D4WaNYy3c1/EqsEUDDEllc9fpXkA/d5AciTOOOh7Y+te+/CrRJNH8Mq1wAJ7pvNYDsMcUAdgfk2bQSBx9BT6KTcN23POM4oAWiiigAoooJwMnpQB558a9TS18NR2e8rJcyDoMnArx7w7o95qV6qxkkBd2OAa6n4xalLd+KEtTu8qFfkC9OfWsHSNYXQrnfvL3LYIAP8zQBj6zCbHUDBdxsGiOQM9vSrcusR38SxM/kyD7uBwfYmneINSt/EGoi6WHyZOQ4Y8ZrkjbvHdusikspOME5PPQUATXUc1zc+QYyWbAB7D3zXe2Pgbz/DkkkV6qzpHuZSP0rjPtD2tvlU2HGA/XB9cUQ3+oWz+a17Ll8BVzjj6elAFcWrWsnkHAcHggYBPrXW6PYg2832kZjjTKbugI9ai8C6Ld+JdffaoYRjdk+/c/nXpGs+AryDS5vIbzJNpxtHbHTFAHihuLi61GWP5t2f4eRitG1tn2kuXbke2R7UvhYwWGsMupq5VXKEHggd/rX0VoXhnQGtIrq1tEdZFByTnNAHyl4yklj0PVkbgC2lHHAOVIrwCv0L+LvhHQ3+HHiu7XT4o7mHSrqVJE4O5YWI/UV+elAHV/Cf8A5Kn4N/7DVl/6PSv0pr81vhP/AMlT8G/9hqy/9HpX6U0AFFFFAEMuPmYggfdPPBB7n86W3KkYVixXipHzjggcjr9ahQmO4MZ4jIyox/n3oAmZQylWGQRgivnTxppEmgeKJQUaO3di8bY4I/8A119GVwvxb0RtT0JbqEEzWp3cenc0AeRahd3F3bIj3BkONyjd0xWIq/Pt3lc8NuGAK73wR4Oj162uZ3PllD8o9fpXM+JLH+zdU+zx8OhwT3JoAoQRmC5iaT7u7HFejaf4GXxBpj3EM4SUfdVhz7c15dLdbJQckSEdu/8AnFeu+BPFIsPD7Rz4JAyAD831oA86l8PXEb3azlIzbH5lfqfp71hXFwjohcMjKNo45xW/4puZLnU5bgyl1lJPHv61zU0UzOPmDDP0A/CgCSFF2xspCuOQR/WlcTPJkrk5yWU44z3FWDaq9ovQyAZz02gdxWhpViJLG6nZztiTnuaAKVpfXMSALKVwcFV4B+ordWe41YxCOJSxwuBxz61zUgWWZZAAoUYAHX8a6Pwdei11SIyIsibgSD1oAXVfDd3HABKgZgeF/wDrnvUthpcOhWsd9qiKHLAxW+OSexr0jxbr2n2WjNceSGnONi4rx3XL2bU2MzzOWHRc4x1x+FAGpd6m2rXOZwkcTk7UXt681Qv4X05vLRhslQE8ZzWbBbTybU8qYMeMZzn8a9s8E+CdNvtFtbnWYTPcrnaGYjaO2RQB5Ho9jJfXqBY2kQNukx6d6reP/Et1f3iWcAFpYW3yRwxcDI7n3r6ctNB0yyjdLSzih3rtJQc4+teL/EjwpouhXQuLu6OJTnylGWb2x2oA5TwXfajYob+5kP2MgoN3GTjjFbHheC/13xGkEcDTQFt0qOPurnqTWHeX39pzQPFbvFZ2/wDq1z6dz71638E5EuLfUZyqibcFYgYOO2aANn4n+H31LwNPZadHjyMOsa9wOtfNGjaXdT6zBB5TqyyDdx93mvs2si50HTN8lwltDBOQSZkQAj3oA8D8bwpfeJRHpG4IyKp46v3qjN4fu7C9S0eP96FDlRzn2rtLi1tYdRnTS0L3AJZS/O7n9Kz4tC1jVdQ82NJVmQbmViSfwoAzzpSskSS3CxSSHBVqXWfCt3Y20zQqrWcQy7R84PpUms2GpaPFHcanCwmzlAwxj60/UNZmm0FUEgjSZizKDj8SO9AHM6UFF0sgUNJkEDGN3tjrXpmpatZap4PvbQRLbajAuDER/Ce/t1rzizilgjguYFKOGO07c5JP/wBervm3U17vCFnYjcc8A+lAGRbI6sp2My5HTNXLyByVH3WAJwe9afiDTzaxQpEylsZf1z6Vl2lrc6peQ29oHllbCxgnkn2oA674WeHU1bVPNuot1vb/ADsGHBbPA/rXusYKoAQoI4wvQVh+DPD8Xh3Ro7ZSXnf55pCclm/wFb1ABTWViwIbAHbHenUUANTcFAfBbuR0p1FNkXfGy+ooAGdVOCRnIGPeqc0olbdyYgcDHc0zynjcNIxABHzcHHtS3CrtVEbeCTkACgDwj4oFofF93LGnYMAAfSua0/TJJ4rm/aJ3jQ4HB5OP0r1T4oeHf9ITUpHGxwqkemO30rhX8SDToZbK0jiMDcbzyCf85oA88lkuL2clleOND8uew9a0HLIisXbzGHr0FT380ktwzJlR1YIMAVElsd8OATu6gjpQA21WNrpFuZBGpwxP3uM11es6XZ216ksiziGSIGCQD5XOOPyrV+EfhC21nWLm61lS4TlYu3416L8SPC6zeHGeyfYtqMrEVBGPQenNAGD8A0WNdUQqvmjaWYfyr14jIweleL/Bi7is9WmtnPlm4TA3H7zA9P517RQB8yfEnSBYePrqKOMgTNvUDrg8ivTvht4khtYo9J1B1hc/6sseM+melcz8ZCLfxhDdbN5SIfLnrwO1clqGqy6iu8xRRCPBGByPoaAPdfi0wX4V+MixwP7GvB+cL1+a1fQHxZ+JOuW/hNvDjXnmQXqlH3csIx2z2r5/oA6v4T/8lT8G/wDYasv/AEelfpTX5rfCf/kqfg3/ALDVl/6PSv0poAKKKKACmONpL4JIGMAdafjnPeigBsTb41Y4yRnikmjWaJ45AGRwVIPcUKQJGUBhnnpxT6APN7W6g8HaxcwXLbbZ5Mx8fwmuU+JENpqd39ttWQK4BwMfX1rsfi7ov2vTI9RjTdJbHnnHFeOW88k7wwSOyrnoPX1oAtafpkUqyTSxMDCNwcdwP5Vmy3Z+1NOAwHQKPTpjitKTU5BehUK+Q3yMo5z25qhe28kLlNjeUCSp9qAKr3DCLy3UuScqR1H1pmG2YyAx746UHAbLbQegPrUkVnPcbZIgzY6qp/n/AJ7UAWYSiWTNdozjbtRlHO7/AAqvZ3jpZzpJtG4ZIxyKvXbOljHCrK0ajLDGMGs2BVW4UHJL4BJHWgCK5kZGURgKG43Nzip9Nu3gkV9pYqMfMcjHsau6nZwpGhjKSbWGQDwPr+dVjGjyBbZAoxyP60ATX2oT3kYSZy20/Lk5xWeqGMgl2MbjALHqfY1JdxvGw8p1kUgggHBHvUkMZkjiUgrjjk5A+nvQB6N4HhitDBc3wWSPbjAOevf61Jq3i3VNJ1sQ6VEwa4fCpKnBz3rkrLWJtPe2QHz0RgxTPPFeqeGNYtPE+upcC1QSQDADAHHv9aAO6tTL9iia6IE2wGTHY45rwP4mFdV16URsZDDncGOCPavbfFWqx6LoV1ey/wAC4UY6k9K+bTdSy6nNcOWkabIdx2z0zQBW0+4a3kjMYKgHG1hx+P8AjXongXxbF4e1H7LdwiO0usMzLyFPr+tee3enzwXOxRvkKg/Kc/Ke4HrWl4YaN9WhS8TMOfmWRuAB9KAPpT7faC3Sc3ESwuMqzNjIqwCrrkEMp7jkGvDvE2qW100cdjOzwRZ2Ren0NekfD8TTeGbd3ldH3HAByMenNAHJ/EDS30O9/tHT0PlzdfRDXP6b46u9OmQyfvFXkjofz+vava9UFpJZSLfFPII53Efp714l4v0zS/s0r6ZPuXzDjK4yfQ0AZnivxdceIpI1ukCQr02EgVV0a+iYC2ntxLH/AAqDkj3FYduskEgTDNk52MeDXVeEdStrLX7e4uYFMW8bgOiHPPFAHpNh4FtbrR7fziyOcOoPVPTms+bQLHwlbgzkTzTE4dgcKPTNelwypNEskTB0YZDDoRWd4hsIdQsvJlHzZypx0oA8H1y7FxdHZkL/ADrv/g94dFvBJrE6YkkBjhBOcL3IrhNa0S5sZ2DxyYZyEI7+9e5+FrEad4fsLYdViBb6nk/zoA1aKKKACiiigAooooAR1DqVPQ1HFAkbbhkn3qWo7mUQW8krdEUmgDzL4ua1JvTS4I96qN8h+v8AhXkF9bNCFPDo2D8pB/A5+lbPi3V/7Uv55SXVt7K3zHkZNYMCKC/nSMUHKqB0oAhjWN5RvGxyOR7Z7+tdBIdLEFpc/vluYV+5jO6sKZkkcGDcSDl9xwT7UcKAzs3THJoA6m08fX9lIi6ZbJFKD8pde3uO9dB4i8Yazf8AhRJLyKNFY7XMfAPvXAWlszuJDuVCw+f0rqb+9t30sacWCMRwW9fr/SgDmdK1CSy1CC8hYh1bcCOCTXuej/ECwv8ATFkaWNLjHzDPGa+db6TBZcMHTIIx1qjbyXct8kFm772YYCg5H4UAep/ELUl1i6jvY41cRgxsT2rgRqVraSTfbJljgEZLuQflA61sraalJbTWkAaSXIUjHPTk14x8UtVa1ZtITKyn/XD0APSgDjPFuqjWNeu7uMsYGciLdx8o6cVj0UUAdX8J/wDkqfg3/sNWX/o9K/SdnVc7jjAzX5sfCf8A5Kn4N/7DVl/6PSv0oRQqhRnA9aAFHvRRRQAUUUUAMmUvGQCQevFPpGGQRkjPcUkeQoDHJHGfWgBl1AlzbyQygFJFKkGvnvxRpE+ia3dWzBTEhzHnqwPIr6JrgfitpHm6eNUhjDvBxIuOq+tAHi1tAxuA0yYVjnJI45rofF/kDT7VIGGQoLHOc1z93PuIZiCCv3O2O2KNQ3+TAxD+Uwyu4/lQBRcFd2MNt9ORUtrqFxb2hjjLrk4IBycZ/wA80yJHO8jIQDkippXjOn+TG5EhbJbbyR6UAPtoybOTdkRk569607HSo54lnIPl7Tk49Ky9KhkdnjjUtHtzjGQMe9dXoHiay07SLiznh3suQM+vb+lAHG6jBLA7qA7KT1zjPvmqrykA7FyWUZAPPWtTUNS3q21sB2xgrkD0xUU+nMoilfaqyEEFlK4PYn2oAzmuPKyiJkJgH0I9D6U2J3bcA3lIBuCkZ696dNE4ujnayBtpMZzke/r2rSexkjkIaJySuVIX71ADbLy7x4xPIsKAYDEdvWur8P6xD4fZpLS6SY9Bj5T+VcktnM5QOjxknPPX8qjntmE4iKbnHUjHymgDv9e1u+8QeHJp5mbyFYkK3auEsFH2yLcTtyc81oWF60NnJayS7lfliWx+GayosRO6wDB+7jv/AProA7JtImv5kl00NIqjBbGSpq//AMIHeQ26PK3ktJyZHGAK6P4aaJfyaFM0sgiSX7hB5pfiNfanpujQWsJ8xeVbaMse1AHBzWGm6ejq18JJA2CAPlz6Z/Cu9+HE14J7dLe4jmtGypVT9xRXkLtLdOVA5HO3vmuw0TU5NKNrFboySP8ANvBxjnpQB7N4jsbW602VrlTiIGQFfX39a8itV0i7M0V/O8fJYDb97Pcdq6jxN4yeOBbSQIRKmSy9Tz39K87lCXN2ZZF3R8hSp5B9z6UAb2oaTax6DcXFhbTTAYVp2H3R/SuKvrb7FGs0bgliBtU54+n4V2+g+LFstIudN1LDQPlcrwV47/nXEXciI7xY/dO5ZO5X3oA774f+MnsQ9vduHiA/djOAQOv0r1Dw/rtrrsJltkZdvHzjn8K+cLaxujF58IVo+hYcj6V0XgzX7jRdXjaX/UZ+YLnBFAHqHiPRL+bWrNrWRTamQMQx+7yCR/Wu1AwAOPwqlpOp2urWa3NlKskZ4OD0Poau0AFFFFABRRRQAUUUUAFV9QiE9hcRH+ONh+lWKCMjB6UAfJ2qMI7mYHEZDleBnnJ7VRjPnSBUKM2QRkY3H/IrofHunfYvE1/C7ttMx24wAcmsjTYrWBlurmRgithVxyT9PSgBkYW3uP3mSzt0PTipTEdhcgcHac9adbxxXd86WYZwcuzYx35o1IqTIsQzgEcDGTQAqaw8KfZ7fYsR+8x5OeaypppGJDnkNuzjBqE9cL8xxnA60ciFmdzLL27Z+tAD5ZjLtEjLu7HucVteBAf7dXZGJJdjKpYc59q5m5kkkyXjVi3APXb2xXuHw58BTWNnZ6rdShWdPNLuQNo/oMUAcPoHi6PwXc6vrniAExRIyRwhMl5f4f618ueKNauPEOv3uq3hHnXMhcgDAA7Cu/8A2g/FFlrfjS5s9FMTabaOVEsTllmfoWryugAooooA6v4T/wDJU/Bv/Yasv/R6V+lNfmZ8PL6HTPH/AIZv7k4gtdTtp5DnGFWVWP6Cv0whljnhSWF1kicBldTkMD0INAD6KKKACiiigAooooAKhvLeO7tZbeYZjlUow9jU1FAHzxq9inhzxE9rewM8YJ2ZUHcDWHqN7LMxTaBbx5ATqAD0r274leG31ixS6s4995AMYHVlrgvCng2a/wBX8vUEaOBFOd4xkdgaAONivvK0qS0MAHmHO/HNZyxv5JIJ4GN3vXe+IvC08F88EUJx/BwP85rmL15dOnWF4YvlHPGQ3+FAC6JqNxpFvLIu1hKNpDjG4e3+e1Z97Gso8wEKJOcDsfarwgmv7Ka5RWAjOCpxgDPam2WmXdzZSXMe028XLZOQPwoA6b4baBbXQutW1Tm0tjwGHGeawfHOpW2qal5dphLaM4Rc4zz0q9Drc48MSWduGgCtubHRxXLXEYkBZ1UknI/GgCG2JVV8tWQqQTvHWtr+17rySwCqfubx/hWVPFDEkf2cyNg5cA4qzbxzT2pSJQytyR0YUAW7G4V2JkbLqMjPdqo3ErxzGSdijt3Hetnw/bpa6vDJc2/2mFB80ZOGPHWtG50Bp4ri9t4WEZc4VlzsHb/IoA40GVGG8KwPQrzj6ita3so57Ka4j8wupA45bPWqHklpm4HHBK84/CvR/hXpM98rloSbTdh3YcEc9M0AbPwchuxHdCSSb7Pj5dxI59hVH4rSTRa3bx2xZ1VeYwOx9Pzr0e81HTtDtScbVHG1Rg8V5V4g8QWeoXc1xHvSVzuGfmGPSgDib6yMUu9N0eTkhuCuRk1cS2upbIXCyeZhuqgnA/z6VuJpya8zPYKTKo+ZMkEAd8mpP7QtILF9NtAI7qJvnbbwT6CgDmbiSWbLEs8nQVHbSyJeKxO0L9+MnOefSptRM0Zyy7hgkEccVd8LWt1rd3JbxKjtGnmeY4wQB2z0oA07HQItRY38NwBbN/rIyNrA+oqt4x0bR7S0+0aPqCyu4G6OT7y/Sue1DVru1v5oVDLEpxlTwMfSrul6ZcaraTXyMCIx1zz9ADQBWt5bmz0kwxOwjuW3Ag9CPrVzw1pV1r2qx20cm2Q9e2Pcg1RW/fyzayqqqp+Xj7pr0/4M6OPMu9WkjXH+rib1J+8R/KgD0Hw7o8Gh6ZHZ2/OOWfGCx9a06KKACiiigAooooAKKKKACiiigDxz4zaSLe+h1JUGJeCTyCfTH615JKEnHzthMkA5wfwPpX1N4s0aPXdEuLOQDeVzG2OjV8z6hpqWl88LBQyNg556eooA6X4f/YFt7mKS0e4e4/dq5ONv0qDxNpUFpbzRFHi3EFMH9OKn8I742gSEcod2FHY/zrtNb0C41eOJrdBu4OMfN1oA8ctYYLd3e4l2RY29CT0/nWc8QQgxymROgc/xD6V2fjnw/caOiDyBtYYBI6n1rkLZIlx9qLqe6oOnGaAH2kUccsbTqojX5wOP5VtfGb43iDwRB4c0eNf7Qu7fy7qXd/qU6YA9SK4vxj4itdE07zYVDSP8iRYB+bHUmvDrqeS6uJJ5jukkYsx96AIycnJ60lFFABRRRQAV9K/st/F25sNTt/CHiG6RtMlBWzmlODC/ZM9we2elfNVOVirBlJDA5BHBBoA/VIHIyOlFfNn7OHxwXWFtfC/iycJqKLstbyR+LjHRWz0bH519JIwdQynINAC0UUUAFFFFABRRRQAVgX8F5H4itZouLNxhyuOD71v1FdQLc27xSZAYYyDgj3FAHE+LNaS01Ly8xs/RcDJFeU+IJlk1FQVJTJI/lg11Wq6XLp/iGWG9Erx9Uk7kdj70lxaaTbRfaZ42kYfNnuaAMezt4DpQigkEb3DhACeM9qPI/wCETuxb6mFuYJRhoweCD71m+I7uO6uR9mDIrdNuP1rIvZJiEWeVpF+uDQB6xb6HpWu+T/Z8nkwbcbe6/wCNVbj4aWi28scNx5l0ORzgEV574c1S4sL+MRsSjHDDP8vSu1XWrw2Vw0k5jdBwc/NjtQAyy8K6Z4dl+0eKFeSNs+UiZIPp0rUudAttXtTc6OnlqrZzjBx71zOha6Li63a1HJe2gGNznBX6V65pTaSLNJdOlzFjBG7DAH2oA4fQdNggvA08e4KcORzgZ6fSuxjS2Ony2UEqbZScYHIzVw22nW0ImSGNhLwGx0+tYXiS5stOsybdz9rPKeUeV/CgCjZeB9PfWE+3K3nKd5weG9hXoVtbw2sIit41jjHRVGBXlEPiG60xkv5i7DIVmY43Zxxiu3i8W2kmmC68tlY9FbgH8aAOf+I8ZYSvCGGBtY+h9ff6V5LjfINxUJ1PHevVPEVxc3ngy/1F2kAZiDtAGBXjds5AMpjDKOTu60Adnqe+zsYLvTVl+zBMSSLkZb047VgWM0Ud+nnSjaxBYn5sCu207W7WX4dTWSxrHcAnO7keuRXn0VqC5MhPXPyDpQBs6s9ldXSxRXPlZ4B2ZB/D0ruNEtdN8OeG7n/SEF/dxkq64yRj0rz7SLcQ3iXFyymJMFSxyf8AOah1W/e/1Z55XVSBjDcce1AFnSPDtzqXnzIN6gk55OfU1SvN1i/2e2nZHB3MM4Gf8an07xNfabcgwDr8hCjHHoRVu60ltaSS+0vE7ZzMFOWU/SgDnYlmvrmOND5kjsEXPBJzz0r6c8Mad/ZWg2dmwQPGg37RgFjyf1NeffCfwU9nINW1OHZIOIImGCv+1XqtABRRRQAUUUUAFFFFABRRRQAUUUUAFfPfxQsFtvG14AEUTbXDd+RmvoSvIPjTYCLUbS/OdkqGNm7qR6UAef6JPJY3ayfMpVg2Ox/HvXvul67ap4aGp3K+UiL8wC8n6V8/afMZZVUW4dieTnk17dp1hDd+E4redcMFywU8ZxQB5b4t8Uxa7qUoaRoYznY7k446V514gvF0u1ubycK0Ua9VHX6e9dT4ysbHRmnnnuwLSLLsxGRXzp4z8Uz+ILrYhaOwjP7uL19zQBl67q9zrN89xctwT8iDog7AVm0UUAFFFFABRRRQAUUUUAPikeGVJImZJEIZWU4II6EV9lfs7fGWPxJZQaF4hu9uvQqRG8pwLtR0/wCBAfnXxlUttPLa3Ec9tI8U0bB0dDgqR0INAH6lwyrKCV7HBBqSvmX4AfHFtcuV0XxbLCmqqu20ucbRcDH3G7bvfvX0pbXCzrkAq390igCaiiigAooooAKKKKAM3XNJg1W22yovnJzG+OVP+FeKatFeW+oS22oxGLbnlvun8K99rE8U+HbXxBZGKb93OOUlA5B9D6igDyrTfD01/apMsB8kHqOQfwrk/EdsLXUZYiCFUnaq9x617X4fs7vQ7eKwu0Vk3YEvb868x+IVuP8AhJb3cMoD1XoO1AHKQqkEaSEBm6gFsH8KnSee4lWa7mYByBmQdvrVSOMyyoqOCoOcHsP5UX9y8swV+VX5V2jgUAdfquu2kPhOPTrO3UTs/wA8vf1qn4V15LOVIrliY3OCcEFT/hWJFFu053j5PRlzz9abHZM4AUsGI5HWgD1a+12W4EMcO7YvGY1yJPw9ea2NO0lJLmOW/iOZRgnGPL9M5qn8OU0uy8P+ZcPHNLCdzPjOz6V3FtqlheWwmhuYXhPcsB/OgDnfG1hBFpUEaRqx8wBVfmsnV7aCLwwWBVZY1yBHwPpzXQeJb6yF1YRSyxbcseTx0HeotSvdFuNKkiW5h8zGAA3JNAD/AAlp0c/g6KGb5luk3PnnrXC+JvBotmuJ4Nphi6og7e4rd1vxHc6VY2cUDIsZXnH92sTV/FNjLpPlW87SPIuCUOSD7+1AHnrzRo0kdvNsjByUPIP4VVE7xSABw6Hrnnj+lLMJACZEVlDdfb0q/b2kdrEt5JsYscRwuPvfnQBYvbQJpUUNs2ZJMOY93bt1696zL6zmtdjynLEcggnH50/VZpWnGJ2jcDIjYbhj0qxPdS3OmwKFWVg+0jrj0zQBnR77qNo2I8wL8rDIOO5r1P4MaBqFvM+p3cbQWzIViVhzJ7/So/h/8PHklh1PXIxHGMNHbf3vQt7e1euqoVQqgBQMADgAUALRRTPMGVxgqc/pQAvmJnBYD6/XFOpiAsSzAjngE5z7+1PoAKKKKACiiigApCRkAkZPQUtHOfagAooooAKyPFejxa5olxaSrliCyY6hscVr0UAfMxvV0uQxxxYlQlTgjII+vSpP+FnXmnWhE0qRWiA7pG7Ctv49eGodGSXxLG4jtHP+kjP3W9R9fSvkjxV4ouNcIhC+VaochR1f3agDQ+I3jW48U6lIInkTTg25Iz1Y+rVxlFFABRRRQAUUUUAFFFFABRRRQAUUUUAORmR1dGKupyCDgg19H/AD43jTEXQvGV3IYE5tb6Rmcqc/cf19j+dfN1FAH6i2eoRzIrlwUcbkYEEMPbFXgQwyCCPUV8EfCL41ax4KnSz1OSbUtDICiB3y0HPVD6e3Q19leEPGOl+JNNjvtFvobuzIAJXgo3Uqe4NAHXUd8U2ORJFyjBh7U48igAopjN5YyQSo7jt9aVpFVSxPA70AOopFYMMg+9LQAjqrqVcAqeCDXm/i/wAC3d/qZuNOZRCy4YFvTpxXpNFAHzVrOnmwnltWK/al+V8dPrT7bQpLdoJZpYjDMD8ynla9g8WeAdN112uIx9nvDzvHRvqK83vvDGseGw/mwyyWROCyHeAP6UAY1wtvYzMYHMsjcY6ZH0rPlvHdHEhKB+AxHPHsPrVvVkWZw4YgKMDIw35VVeKUJtc5Oc4ZcZHpQBNpckqabOIp5FBYZjB4PvUulJLNdIiTyRu2MopwD+FWY760g0qQQQKt3gqXLcD2x+XWqFsbgJvjCl+oZRkD8aAOw8SaY0+jjyiIzGN6Fjgt61wzzIrQguzKBhuxB+lbmkteajGbOSR2AbdlSTtq3rfh3+xCkziOZZBkoc5+vsaAI3ddft7bequY12c5WsyLS57O8aNUKyg5HB5/nmtOKe8sreOSPCwPjggAj8TXpPh670e6SG4uFiN7GPuofmz9O9AGQ/he11Owtry6gWIqn75FbBPHcfhXnHiZBa3yq6gRgfu03EFR9a9w1KG/vpT9jiCRsOCVGCPrWQPhtZXWoC61O4klUHIiTgH2J9PpQB5Zp2g3eutbnTbKVi5AkYn5frntXsngfwTaeG7YtKRcXknLuwyF9lz/ADrptPsbbTrVLaxgjggToiDAFWKACiig+1AEb5fAQjGfmPX8DTYUkEjtIcjnA/z0p+1SS4Xc3Tj605eB0I70ALRSAhhkEEeopaACiiigAopNwABJxnpmgMpYgMCR1GaAFooooAKZIWX5sjHTG0mn0ybPlNgMTjopwaAEhlEhYYIZTgj/AOvWB448Z6J4K0iXUNdvYoFVSY4iw8yY+ir1JrzD4r/G3SvBSyW1i632sFGEUUbBlhboPMOf0r4+8beMdc8a6u2peI75rq4xtUYCpGPRVHAFAG98WPihrfxD1aSS+neLS43JtrJThIx6kdzx1NcBRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFb/AIN8W6x4P1aPUNDujFKnWNvmjcHsy9DWBRQB9s/CX446T4sZbW/dNM1jCqYppQEuHI/5ZnHqPumvb7W/SUESKY3HUHn6V+XKMyOroxV1OQQcEGvavhh8e9b8PSW1j4jkfVNIQ43t808Q/wBlj159aAPugHIyOlI2f4Tg+4rxjTv2hPh95KNNr0kTHkxvZTkj2yEI/KtFP2hPhkw+bxIVP/Xhcn/2nQB6mQzHouA3Qj+tAmU9GBB59OOn868u/wCGg/hh/wBDN/5IXX/xumH9oH4ZKCV8TBjnp/Z9z07/APLOgD1iivJl/aD+GijB8SA46bbC5Ax/37qT/hoP4Yf9DN/5IXX/AMboA9VpGUMpVgCD1Bryv/hoP4Yf9DN/5IXX/wAbo/4aD+GH/Qzf+SF1/wDG6AO7v/DGlXsole1RJAc7kAGfrWdq3g+zl0uSKyt4Rc5JV2GDn61yv/DQfww/6Gb/AMkLr/43R/w0H8MP+hm/8kLr/wCN0AUo/hxqdzu+0GKM9cjv+dVp/BmpaekpjtXZFUYZeR+X41rf8NB/DD/oZv8AyQuv/jdH/DQfww/6Gb/yQuv/AI3QByGmaDr321fJtJrdi2d6nA+nPtXf6x4R1e+hgZZomm2/N5gBANZ//DQfww/6Gb/yQuv/AI3R/wANB/DD/oZv/JC6/wDjdAGpceA7nU9ItrTUb9Y/LbLeUmcj0rovDfhTTtBG61QvNjBkb+g7VxP/AA0H8MP+hm/8kLr/AON0f8NB/DD/AKGb/wAkLr/43QB6rRXlX/DQfww/6Gb/AMkLr/43R/w0H8MP+hm/8kLr/wCN0Aeq0V5V/wANB/DD/oZv/JC6/wDjdH/DQfww/wChm/8AJC6/+N0Aeq0V5V/w0H8MP+hm/wDJC6/+N0f8NB/DD/oZv/JC6/8AjdAHqtFeVf8ADQfww/6Gb/yQuv8A43R/w0F8Me/ib/yn3X/xugD1WivKv+Gg/hh/0M3/AJIXX/xuj/hoP4Yf9DN/5IXX/wAboA9Voryr/hoP4Yf9DN/5IXX/AMbo/wCGg/hh/wBDN/5IXX/xugD1Qg5BDcdxilx+teVf8NB/DD/oZv8AyQuv/jdH/DQfww/6Gb/yQuv/AI3QB6rRXlX/AA0H8MP+hm/8kLr/AON1z3jf9pbwfpmjPJ4VuG1rUzxHCYJYY192Z1H5CgD2jWtWsdF06a+1S6itbWJSzPIwA4GcD1PtXyf8Xv2k7nVEn0vwKslpaNw2oNlZW9Qo/hHvXjvxD+JXibx9cBvEF8XtkbdFaxLsijPTgevua4ugCSeaS4nkmndpJZGLM7HJYnqTUdFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image shows well-defined and poorly defined nodules throughout lung. Most nodules are smaller than 1 cm. Nodules are located along bronchovascular structures or interlobular septa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lee JS, Tuder R, Lynch DA. Lymphomatoid granulomatosis: Radiologic features and pathologic correlations. Am J Roentgenol 2000; 175:1335. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    48-year-old woman who presented with hypercalcemia and multiple pulmonary nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: CT image reveals multiple large conglomerated masses with air bronchogram. Numerous small nodules have aggregated to form well-defined irregularly marginated nodules of variable size. B: CT image at same level as A, obtained after patient underwent treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone for six months, reveals nodules and masses are smaller and have almost disappeared. However, coarse linear opacities along bronchovascular bundle have become more abundant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lee JS, Tuder R, Lynch DA. Lymphomatoid granulomatosis: Radiologic features and pathologic correlations. Am J Roentgenol 2000; 175:1335. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31095=[""].join("\n");
var outline_f30_23_31095=null;
var title_f30_23_31096="Complications of intravesical BCG immunotherapy";
var content_f30_23_31096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of intravesical BCG immunotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31096/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31096/contributors\">",
"     Michael A O'Donnell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31096/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31096/contributors\">",
"     Derek Raghavan, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31096/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/23/31096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravesical administration of Bacillus Calmette-Guerin (BCG), a live attenuated strain of Mycobacterium bovis, has become a mainstay of adjunctive therapy for superficial bladder cancer. While generally well tolerated, both local and systemic infectious complications can arise. When disseminated BCG infection occurs, antituberculous therapy with or without glucocorticoids should be administered.",
"   </p>",
"   <p>",
"    The infectious complications of BCG immunotherapy will be reviewed here. The clinical use of this agent for the treatment of superficial bladder cancer is discussed separately. Disseminated infection has also been rarely reported in patients receiving BCG vaccination for the prevention of tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link\">",
"     \"Treatment of non-muscle-invasive bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40136?source=see_link\">",
"     \"BCG vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which BCG leads to the development of infectious complications is not fully understood. Its mechanism of action as an immunotherapeutic agent in cancer is not fully known but recent evidence suggests that elaboration of a particular helper T cell cytokine profile known as the \"Th1 response\" is an integral part of its mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Intravesical BCG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Considerable debate exists in the literature about whether infectious complications due to BCG represent a hypersensitivity reaction or ongoing active infection. The hypersensitivity hypothesis gained early credence based upon the presence of granulomas and the absence of recoverable organisms. In a number of case reports, acid-fast bacilli have not been demonstrated and organisms have not grown despite a high clinical suspicion of BCG infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A response to glucocorticoids, administered along with antituberculous drugs, has also supported the notion of a hypersensitivity response.",
"   </p>",
"   <p>",
"    In contrast, other case reports have demonstrated viable organisms in a variety of tissues, including lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/5\">",
"     5",
"    </a>",
"    ], liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], pancreas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/8\">",
"     8",
"    </a>",
"    ], psoas abscess contents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/9\">",
"     9",
"    </a>",
"    ], mycotic aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/10\">",
"     10",
"    </a>",
"    ], bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/11\">",
"     11",
"    </a>",
"    ], and vitreous fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The fastidious growth nature of BCG in culture and a doubling time of 24 to 48 hours contribute to the difficulty in its isolation. M. bovis has also been demonstrated by PCR in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/14\">",
"     14",
"    </a>",
"    ], although in other reports these studies have been negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both viewpoints about the pathogenesis of complications due to BCG have merit and both probably play a role in the manifestations of disseminated infection. Organisms are most likely to gain access to lymphatics and blood through disruption of uroepithelial cells and, as with other mycobacterial infections, disseminate to a variety of sites. Manifestations at these distant sites may reflect initial dissemination or even reactivation of infection following alteration in the immune status of the host, hypersensitivity responses, or a combination of both. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22378?source=see_link\">",
"     \"Microbiology and pathogenesis of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe adverse events due to local instillation of BCG are uncommon. In a retrospective analysis of 2602 patients reported in 1989, the overall rate of serious complications was less than five percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/15\">",
"     15",
"    </a>",
"    ]. The most common complication was fever &gt;103&ordm;F in 2.9 percent followed in decreasing frequency by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant hematuria (1 percent)",
"     </li>",
"     <li>",
"      Granulomatous prostatitis (0.9 percent)",
"     </li>",
"     <li>",
"      Pneumonitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatitis (0.7 percent)",
"     </li>",
"     <li>",
"      Arthralgia (0.5 percent)",
"     </li>",
"     <li>",
"      Epididymitis (0.4 percent)",
"     </li>",
"     <li>",
"      Sepsis (0.4 percent)",
"     </li>",
"     <li>",
"      Rash (0.3 percent)",
"     </li>",
"     <li>",
"      Ureteral obstruction (0.3 percent)",
"     </li>",
"     <li>",
"      Contracted bladder (0.2 percent)",
"     </li>",
"     <li>",
"      Renal abscess (0.1 percent)",
"     </li>",
"     <li>",
"      Cytopenia (0.1 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No differences in the incidence of complications were observed comparing different BCG preparations or doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/15\">",
"     15",
"    </a>",
"    ]. A Cochrane review identified six randomized trials of intravesical BCG including 585 patients; local complications included urinary frequency, cystitis, fever, and hematuria in 71, 67, 25, and 23 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/16\">",
"     16",
"    </a>",
"    ]. No cases of BCG sepsis or deaths occurred in this review.",
"   </p>",
"   <p>",
"    There are conflicting data on the safety of steroids in patients treated with BCG. In one series of 24 patients who had concomitant treatment with steroids or were immunocompromised the incidence of side effects was comparable to that of patients without evidence of immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, a fatal case of BCG reactivation and sepsis three years after uneventful BCG treatment for bladder cancer was documented following several months of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/18\">",
"     18",
"    </a>",
"    ]. Advanced age is also considered a risk factor. In one series of 58 patients, approximately one-half of those &ge;70 years of age developed complications from BCG treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic sepsis and even death can also develop early following local instillation of BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/11\">",
"     11",
"    </a>",
"    ]. During the initial clinical experience with BCG as an intravesical agent, most cases of sepsis could be traced back to recognized errors in BCG administration such as traumatic catheterization, administration too early after transurethral surgery, or instillation during a concomitant UTI. All these conditions result in physical disruptions in the urothelial blood barrier. Nowadays, sepsis has been estimated to occur in approximately one in every 15,000 patients treated with intravesical BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Localized disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     BCG cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of bladder irritation, such as dysuria and frequency, develop in the majority of patients within two to four hours of BCG instillation; a low grade fever and malaise may accompany these symptoms, especially in patients who have received prior intravesical instillations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/3\">",
"     3",
"    </a>",
"    ]. Such manifestations generally resolve within 48 hours.",
"   </p>",
"   <p>",
"    Infection can also spread locally to involve structures within the genitourinary tract. Such infections include granulomatous ulceration of the glans penis, prostatitis, epididymitis, ureteral obstruction, bladder contracture and renal abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Granulomatous prostatitis may be quite common although symptomatic disease is not. In one series of 12 patients undergoing cystoprostatectomy following BCG instillation, nine had evidence of granulomatous prostatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/23\">",
"     23",
"    </a>",
"    ]. Prostate specific antigen (PSA) levels rose following treatment in 27 of 36 patients (75 percent) in another study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/24\">",
"     24",
"    </a>",
"    ]. In 15 cases (42 percent), the increase was clinically significant; PSA returned to normal levels within three months.",
"   </p>",
"   <p>",
"    Symptoms from BCG infection of any of these structures cannot be distinguished from infection due to other organisms. This is particularly problematic as up to 20 percent of patients receiving intravesical BCG develop a conventional bacterial UTI at some point during treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/25\">",
"     25",
"    </a>",
"    ]. Occurrence in proximity to local instillation of BCG can be helpful, but cases of epididymoorchitis arising years after the BCG therapy have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, a level of clinical suspicion must be maintained once this treatment has been administered. In one report of eight cases with a review of the literature, the authors describe both early and late (&gt;1 year) presentations of BCG infection; the late disease involved local granulomatous infection in the genitourinary tract usually with positive cultures for M. bovis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious complications of BCG intravesical instillation relate to disseminated infection. Sepsis is the most fulminant manifestation, but infection of a number of organs can also arise. In the small case series cited above, early disease presenting in the first 8 to 12 weeks after instillation included systemic symptoms; three of the five patients had pneumonitis and hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/27\">",
"     27",
"    </a>",
"    ]. While noncaseating granulomas were found in tissue biopsies, M. bovis was not typically recovered. In another case report, peritoneal tuberculosis was observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/6\">",
"     6",
"    </a>",
"    ]. It is important to note that leukocytosis is not always observed with disseminated BCG infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A classic sepsis syndrome can occur, complete with fever, rigors, hypotension, disseminated intravascular coagulation, and respiratory failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/21\">",
"     21",
"    </a>",
"    ]. These manifestations are probably due to high levels of cytokines released directly into the bloodstream as part of the hypersensitivity response (so called cytokine storm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/28\">",
"     28",
"    </a>",
"    ]. This rare event typically develops soon after the BCG instillation. Delayed cases have been reported years after an apparently uncomplicated treatment; the administration of systemic glucocorticoids may have caused reactivation of a dormant focus in one of these latter cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatous hepatitis rarely arises as either an early or late complication of BCG intravesical instillations. The typical presentation was illustrated by a case report in which a patient presented with fever and jaundice five days after a particularly difficult catheterization, which had been associated with gross hematuria; this individual had undergone 13 previous instillations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/3\">",
"     3",
"    </a>",
"    ]. Although most cases develop days to months after multiple instillations, M. bovis was recovered from blood cultures within hours of the first instillation in one case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with granulomatous hepatitis present with symptoms and signs of hepatitis, including fever, anorexia, and jaundice. Noncaseating granulomas are found on liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/7\">",
"     7",
"    </a>",
"    ]; eosinophils can also be seen in these specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/3\">",
"     3",
"    </a>",
"    ]. Three cases have been reported in which renal insufficiency accompanied granulomatous hepatitis; epithelioid granulomas were found on renal biopsy in two of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/30\">",
"     30",
"    </a>",
"    ]. A progressive mycotic abdominal aneurysm was also noted in one case of granulomatous hepatitis, which occurred one year after the last BCG instillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40406?source=see_link\">",
"     \"Hepatic granulomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A miliary nodular or interstitial pattern on routine chest radiography and CT scanning develops in some patients with disseminated BCG infection, most often in association with sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. Dyspnea, accompanied by fever and malaise, has been described. Progression to respiratory compromise can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis is another rare complication of disseminated BCG infection. The majority of the handful of reported cases involves the spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/33-35\">",
"     33-35",
"    </a>",
"    ], presumably due to spread from the urinary tract through Batson's plexus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with vertebral involvement present with back pain and, depending upon the duration of symptoms and vertebral bodies involved, may have motor weakness. When a psoas abscess accompanies the vertebral infection, pain in the hip and inability to straighten the leg can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bony involvement outside of the spine has also been described. In one case, BCG infection involved a total hip arthroplasty and adjacent bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/36\">",
"     36",
"    </a>",
"    ]. The patient presented with six months of hip pain, associated with rigors and sweats but not fever, six years after the joint replacement surgery and 17 months after completing BCG bladder instillations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of osteoarticular side effects after intravesical BCG therapy ranges from 0.5 to 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/20\">",
"     20",
"    </a>",
"    ]. Arthralgia is the most common symptom; the differential diagnosis includes reactive arthritis and septic arthritis.",
"   </p>",
"   <p>",
"    Patients with reactive arthritis may demonstrate polyarthritis or oligoarthritis, predominantly of the lower extremities, usually within two weeks after instillation of BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. In a review of 43 case reports, 53 percent of patients were positive for HLA-B27, and at least 19 percent complained of axial pain, compatible with spondyloarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with reactive arthritis, associated genitourinary symptoms include frequency, cystitis, and hematuria. One-third of patients have had conjunctivitis, and several have had uveitis.",
"   </p>",
"   <p>",
"    Septic arthritis may be due to bacterial infection, or less commonly, due to M. bovis infection. Suspicion for infection should be increased in the setting of monoarthritis following intravesical BCG installation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with joint inflammation should undergo arthrocentesis for synovial fluid examination; studies should include cell count and differential WBC count, evaluation for crystals, gram stain, bacterial culture, and AFB smear with mycobacterial culture. In addition, fluid should be reserved for M bovis PCR testing pending the initial findings and clinical course. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of positive bacterial cultures, therapy should be tailored accordingly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of evidence for infection, treatment with nonsteroidal antiinflammatory drugs (NSAIDs) should be initiated. If joint symptoms persist after two weeks of NSAID treatment, glucocorticoid therapy, empiric antituberculous therapy, or both may be appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1049945536\">",
"    <span class=\"h3\">",
"     Prosthetic devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with prosthetic devices (pacemakers, artificial heart valves, orthopedic hardware) do not appear to be at increased of complications from intravesical BCG. In a series of 1045 patients treated in a multicenter study of intravesical BCG plus interferon, there were no unexpected complications in the 143 patients with a prosthetic device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/41\">",
"     41",
"    </a>",
"    ]. Three of these patients (2 percent) developed fever, all of whom defervesced without complications within 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other manifestations of infection that may be caused by BCG include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A fever of unknown origin accompanied by night sweats, anorexia, fatigue, weight loss, and pancytopenia occurred in two patients who had granulomas in bone marrow. M. bovis was recovered in bone marrow cultures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several patients with mycotic aneurysms due to BCG have been described, including one with subsequent involvement of an aortic graft [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/10,14\">",
"       10,14",
"      </a>",
"      ] and another with multiple sites including a carotid aneurysm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One patient with a known abdominal aneurysm had a psoas abscess which was initially confused with a walled off aneurysm rupture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An elderly man developed loss of vision in association with endophthalmitis following BCG bladder instillation; M. bovis was recovered from vitreous fluid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/12\">",
"       12",
"      </a>",
"      ]. In three other cases, a common pattern of elderly, debilitated, and immunocompromised patients was found to have a poor response to systemic antituberculous therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specimens should be obtained for staining for acid-fast bacilli, culture, and PCR testing for mycobacterial DNA in any patient with suspected disseminated BCG infection, even though all of these procedures can be negative in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Empiric therapy may be instituted when the clinical suspicion is high. Despite concerns about cases in which M. bovis cannot be demonstrated, organisms have been recovered or demonstrated by PCR in an increasing proportion of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/5,11,12,14,29,36\">",
"     5,11,12,14,29,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop mild symptoms of cystitis following BCG instillation, even if accompanied by low-grade fever, usually do not require specific therapy other than analgesics. As noted above, symptoms usually resolve within 48 hours.",
"   </p>",
"   <p>",
"    Fever higher than 39.0&ordm;C (102.5&ordm;F) may occasionally develop acutely but does not necessarily signify BCG infection. In this setting, it may be impossible to distinguish an infectious from a non-infectious event. Such patients are best seen, evaluated, and sometimes hospitalized for observation. Empiric therapy with a fluoroquinolone antibiotic should be considered until the etiology of the fever is established. A fluoroquinolone will treat the majority of non-BCG bacterial UTIs and has reasonable antimycobacterial activity.",
"   </p>",
"   <p>",
"    The cardinal sign of BCG infection is a relapsing fever with drenching night sweats persisting beyond 48 hours. For either acute severe symptoms or those that persisting beyond 48 hours, antituberculous therapy should be prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients with disseminated infection should also be hospitalized and treated with antituberculous agents with or without glucocorticoids. Patients who develop infectious complications severe enough to require antituberculous therapy should generally not receive further BCG bladder instillations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antituberculous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. bovis is susceptible to most of the antituberculous drugs with the exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    , to which it is typically resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/43\">",
"     43",
"    </a>",
"    ]. M. bovis is also quite sensitive to later generation fluoroquinolone antibiotics. When BCG sepsis is suspected, a formal infectious diseases (ID) consultation is useful, particularly if symptoms do not respond quickly to treatment.",
"   </p>",
"   <p>",
"    The following is a recommended approach to the treatment of patients with BCG infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/21,44\">",
"     21,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with symptoms of moderate to severe cystitis persisting beyond 48 hours following instillation &mdash; a fluoroquinolone (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      500 mg once daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      (INH) (300 mg orally once daily). If symptoms progress or fail to resolve within one to two weeks, INH should be continued (or substituted) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      (600 mg orally once daily) may be added. If symptoms respond quickly, two additional weeks of treatment usually suffice; otherwise therapy should be given for three months. A short two to three week course of tapering oral steroids sandwiched in between antibiotic coverage can be helpful in refractory cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with infection disseminated outside the bladder &mdash; Multidrug antibiotic therapy is recommended for at least three to six months, depending upon the severity of symptoms and organ system involved. For extravesical infection, it may take several days to weeks before the febrile response to BCG infection responds to appropriate antibiotic therapy. The management of patients with disseminated mycobacterial infection is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16614?source=see_link&amp;anchor=H12#H12\">",
"       \"Mycobacterium bovis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several cases have been reported in which treatment was extended beyond six months due to relapse of symptoms, usually when glucocorticoids were tapered rapidly (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative antituberculous regimens (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , fluoroquinolones, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ) have been used in elderly patients when INH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    were avoided because of concerns about liver toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BCG sepsis and other disseminated infection in which hypersensitivity was believed to be a component of the pathogenesis have been empirically treated with systemic steroids with improvement in the clinical symptomatology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Murine models support a role for early glucocorticoids as a potentially life saving maneuver particularly during the acute phase of BCG sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/15,47\">",
"     15,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, caution should be exercised in the use of glucocorticoids in patients, and it is recommended that an infectious disease consultant be involved in this decision.",
"   </p>",
"   <p>",
"    Glucocorticoid doses are usually gradually tapered once symptoms have resolved. Both the recurrence of symptoms and granuloma formation have been noted in some cases when glucocorticoids were tapered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No measures have been demonstrated to be effective in preventing the occurrence of disseminated BCG infection.",
"   </p>",
"   <p>",
"    Concurrent administration of INH with intravesical instillation has largely been unsuccessful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/34,48,49\">",
"     34,48,49",
"    </a>",
"    ]. Case reports have documented the occurrence of disseminated infection. As examples, vertebral osteomyelitis developed in one patient despite INH (300 mg orally once daily) for six weeks during bladder instillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/34\">",
"     34",
"    </a>",
"    ], and another patient had granulomatous hepatitis despite two days of INH (600 mg orally) after each bladder instillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trial randomly assigned 957 patients with superficial bladder cancer to intravesicular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    or BCG, the latter with or without concurrent INH (300 mg orally the day before, day of and day after each instillation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link\">",
"     \"Treatment of non-muscle-invasive bladder cancer\"",
"    </a>",
"    .) INH did not decrease the frequency of cystitis or fever in patients treated with BCG, and one case of BCG-induced lung infection developed in a patient receiving preventive INH. INH therapy also led to treatment discontinuation in significantly more patients (13 versus 7 percent).",
"   </p>",
"   <p>",
"    Fluorquinolones may be more effective than INH. This was illustrated by a trial in which 115 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    or placebo 6 and 18 hours after each BCG administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/50\">",
"     50",
"    </a>",
"    ]. Treatment with ofloxacin reduced the incidence of severe local reactions and the need for antituberculosis therapy. No cases of BCG sepsis occurred in this trial, and the ability of ofloxacin to prevent this more serious complication could not be assessed. A more recent study using prulifloxacin reported very similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A theoretical concern has also been raised that INH or fluoroquinolone prophylaxis might reduce the antitumor activity of BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/36\">",
"     36",
"    </a>",
"    ], due to a reduced host immune response to the organism but no clear animal or clinical evidence of reduced efficacy has been found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/47,49,50\">",
"     47,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of breaks in the urogenital epithelium is known to be a risk factor for the development of disseminated infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, patients with difficult bladder catheterizations, preexisting cystitis, or persistent gross hematuria following transurethral resection of the bladder tumor (TURBT) should have BCG instillation deferred for a minimum interval of several weeks.",
"   </p>",
"   <p>",
"    Reduction of BCG-related local side effects and fever can be achieved by BCG dose reduction to one-half to one-fourth of the typical dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In one study using concomitant intravesical interferon-alpha a one-third lower BCG dose reduced serious inflammatory and infection events by almost 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/54\">",
"     54",
"    </a>",
"    ]. Further dose reduction to one-sixth standard dose, however, resulted in a decrease in efficacy for preventing recurrence with no decrease in toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While many studies have shown that BCG regimens using lower doses have similar efficacy, at least one trial showed a significantly reduced cancer response rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/56\">",
"     56",
"    </a>",
"    ]. For this reason titration of the BCG dose to a level where symptoms are acceptable is becoming a preferred alternative to automatic dose reduction. Other regimen modifications that improve BCG tolerance include reducing the dwell time to 30 minutes or applying treatments on an every other week schedule as needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31096/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacillus Calmette-Guerin (BCG) is a live, attenuated strain of Mycobacterium bovis, which is widely used as an adjuvant treatment in the management of non-muscle invasive urothelial bladder cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of non-muscle-invasive bladder cancer\", section on 'Intravesical BCG'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although serious complications following intravesical BCG are rare, systemic infections and sepsis can occur. This risk may be increased in BCG is instilled too early following surgery or after traumatic catheterization. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A localized BCG cystitis is the most common complication observed, and this can be difficult to differentiate from other urinary tract infections (UTIs), since up to 20 percent of patients may have conventional UTIs following treatment. A short course of a fluoroquinolone or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      is often effective in managing symptoms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'BCG cystitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Antituberculous therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More serious systemic infections (eg, sepsis, pneumonitis, hepatitis, arthritis) have been reported. Multidrug, antibiotic therapy for three to six months is indicated in this setting, sometimes with the addition of corticosteroids to control hypersensitivity-related symptoms. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Systemic disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Antituberculous therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=see_link&amp;anchor=H18#H18\">",
"       \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\", section on 'Therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/1\">",
"      Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Gu&eacute;rin disease after vaccination: case report and review. Clin Infect Dis 1997; 24:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/2\">",
"      Mitropoulos DN. Novel insights into the mechanism of action of intravesical immunomodulators. In Vivo 2005; 19:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/3\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-1998. A 57-year-old man with fever and jaundice after intravesical instillation of bacille Calmette-Gu&eacute;rin for bladder cancer. N Engl J Med 1998; 339:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/4\">",
"      Elkabani M, Greene JN, Vincent AL, et al. Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer. Cancer Control 2000; 7:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/5\">",
"      McParland C, Cotton DJ, Gowda KS, et al. Miliary Mycobacterium bovis induced by intravesical bacille Calmette-Gu&eacute;rin immunotherapy. Am Rev Respir Dis 1992; 146:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/6\">",
"      Soylu A, Ince AT, Polat H, et al. Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Gu&eacute;rin. Ann Clin Microbiol Antimicrob 2009; 8:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/7\">",
"      Fradet V, Gaudreau C, Perrotte P, et al. Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer. Can Urol Assoc J 2007; 1:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/8\">",
"      Alvarez-M&uacute;gica M, G&oacute;mez JM, V&aacute;zquez VB, et al. Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder cancer: a case report and review of the literature. J Med Case Rep 2009; 3:7323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/9\">",
"      Hakim S, Heaney JA, Heinz T, Zwolak RW. Psoas abscess following intravesical bacillus Calmette-Guerin for bladder cancer: a case report. J Urol 1993; 150:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/10\">",
"      Hellinger WC, Oldenburg WA, Alvarez S. Vascular and other serious infections with Mycobacterium bovis after bacillus of Calmette-Gu&eacute;rin therapy for bladder cancer. South Med J 1995; 88:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/11\">",
"      Viallard JF, Denis D, Texier-Maugein J, et al. Disseminated infection after bacille Calmette-Gu&eacute;rin instillation for treatment of bladder carcinoma. Clin Infect Dis 1999; 29:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/12\">",
"      Han DP, Simons KB, Tarkanian CN, Moretti ST. Endophthalmitis from Mycobacterium bovis-bacille Calmette-Gu&eacute;rin after intravesicular bacille Calmette-Gu&eacute;rin injections for bladder carcinoma. Am J Ophthalmol 1999; 128:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/13\">",
"      Gerbrandy SJ, Schreuders LC, de Smet MD. Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer. Ocul Immunol Inflamm 2008; 16:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/14\">",
"      Wolf YG, Wolf DG, Higginbottom PA, Dilley RB. Infection of a ruptured aortic aneurysm and an aortic graft with bacille Calmette-Gu&eacute;rin after intravesical administration for bladder cancer. J Vasc Surg 1995; 22:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/15\">",
"      Lamm DL. Efficacy and safety of bacille Calmette-Gu&eacute;rin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31 Suppl 3:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/16\">",
"      Shelley MD, Court JB, Kynaston H, et al. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev 2000; :CD001986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/17\">",
"      Yossepowitch O, Eggener SE, Bochner BH, et al. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol 2006; 176:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/18\">",
"      Izes JK, Bihrle W 3rd, Thomas CB. Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin. J Urol 1993; 150:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/19\">",
"      Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Gu&eacute;rin therapy. Urol Oncol 2008; 26:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/20\">",
"      Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 1986; 135:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/21\">",
"      Lamm DL. Complications of bacillus Calmette-Gu&eacute;rin immunotherapy. Urol Clin North Am 1992; 19:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/22\">",
"      French CG, Hickey L, Bell DG. Caseating granulomas on the glans penis as a complication of bacille calmette-gu&eacute;rin intravesical therapy. Rev Urol 2001; 3:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/23\">",
"      LaFontaine PD, Middleman BR, Graham SD Jr, Sanders WH. Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology 1997; 49:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/24\">",
"      Leibovici D, Zisman A, Chen-Levyi Z, et al. Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin. J Urol 2000; 164:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/25\">",
"      Smith JA Jr, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/26\">",
"      Menke JJ, Heins JR. Epididymo-orchitis following intravesical bacillus Calmette-Gu&eacute;rin therapy. Ann Pharmacother 2000; 34:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/27\">",
"      Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Gu&eacute;rin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003; 36:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/28\">",
"      Rival G, Garot D, Mercier E, et al. [Acute respiratory failure and septic shock induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy]. Presse Med 2006; 35:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/29\">",
"      Proctor DD, Chopra S, Rubenstein SC, et al. Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma. Am J Gastroenterol 1993; 88:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/30\">",
"      Modesto A, Marty L, Suc JM, et al. Renal complications of intravesical bacillus Calmette-Gu&eacute;rin therapy. Am J Nephrol 1991; 11:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/31\">",
"      Kamphuis JT, Buiting AG, Miser&eacute; JF, et al. BCG immunotherapy: be cautious of granulomas. Disseminated BCG infection and mycotic aneurysm as late complications of intravesical BCG instillations. Neth J Med 2001; 58:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/32\">",
"      Mignon F, Chevri&egrave;re A, Mesurolle B, et al. [Miliary induced by intravesical BCG immunotherapy for carcinoma of the bladder: CT Findings]. J Radiol 2002; 83:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/33\">",
"      Katz DS, Wogalter H, D'Esposito RF, Cunha BA. Mycobacterium bovis vertebral osteomyelitis and psoas abscess after intravesical BCG therapy for bladder carcinoma. Urology 1992; 40:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/34\">",
"      Fishman JR, Walton DT, Flynn NM, et al. Tuberculous spondylitis as a complication of intravesical bacillus Calmette-Guerin therapy. J Urol 1993; 149:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/35\">",
"      Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol 1999; 37:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/36\">",
"      Guerra CE, Betts RF, O'Keefe RJ, Shilling JW. Mycobacterium bovis osteomyelitis involving a hip arthroplasty after intravesicular bacille Calmette-Gu&eacute;rin for bladder cancer. Clin Infect Dis 1998; 27:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/37\">",
"      Clavel G, Grados F, Lefauveau P, Fardellone P. Osteoarticular side effects of BCG therapy. Joint Bone Spine 2006; 73:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/38\">",
"      Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 2006; 26:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/39\">",
"      Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/40\">",
"      Miranda S, Verdet M, Vernet M, et al. [Acute reactive arthritis after intravesical instillation of bacillus Calmette-Gu&eacute;rin. Two case reports and literature review]. Rev Med Interne 2010; 31:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/41\">",
"      Rosevear HM, Lightfoot AJ, Nepple KG, O'Donnell MA. Safety and efficacy of intravesical bacillus Calmette-Gu&eacute;rin plus interferon &alpha;-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices. J Urol 2010; 184:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/42\">",
"      Coscas R, Arlet JB, Belhomme D, et al. Multiple mycotic aneurysms due to Mycobacterium bovis after intravesical bacillus Calmette-Gu&eacute;rin therapy. J Vasc Surg 2009; 50:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/43\">",
"      Durek C, R&uuml;sch-Gerdes S, Jocham D, B&ouml;hle A. Sensitivity of BCG to modern antibiotics. Eur Urol 2000; 37 Suppl 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     O'Donnell MA, Burns J. Intravesical BCG in Treatment and Prophylaxis of Urothelial Bladder Cancer. In: Urothelial Cancer: American Cancer Society Atlas of Clinical Oncology, Droller (Ed), BC Decker Inc, Hamilton, Ontario 2004. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/45\">",
"      Wittes R, Klotz L, Kosecka U. Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail. J Urol 1999; 161:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/46\">",
"      Steg A, Leleu C, Debr&eacute; B, et al. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res 1989; 310:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/47\">",
"      Durek C, Jurczok A, Werner H, et al. Optimal treatment of systemic bacillus Calmette-Gu&eacute;rin infection: investigations in an animal model. J Urol 2002; 168:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/48\">",
"      Thompson D, Cumming J. Granulomatous hepatitis following intravesical BCG therapy. Br J Urol 1990; 66:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/49\">",
"      van der Meijden AP, Brausi M, Zambon V, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001; 166:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/50\">",
"      Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006; 176:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/51\">",
"      Damiano R, De Sio M, Quarto G, et al. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu&eacute;rin-induced toxicity? BJU Int 2009; 104:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/52\">",
"      Takashi M, Wakai K, Ohno Y, et al. Evaluation of a low-dose intravesical bacillus Calmette-Gu&eacute;rin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol 1995; 27:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/53\">",
"      Mart&iacute;nez-Pi&ntilde;eiro JA, Solsona E, Flores N, Isorna S. Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO. Eur Urol 1995; 27 Suppl 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/54\">",
"      O'Donnell MA, Lilli K, Leopold C, National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004; 172:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/55\">",
"      Ojea A, Nogueira JL, Solsona E, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007; 52:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/56\">",
"      Morales A, Nickel JC, Wilson JW. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 1992; 147:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/57\">",
"      Andius P, Fehrling M, Holm&auml;ng S. Intravesical bacillus Calmette-Gu&egrave;rin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 2005; 96:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31096/abstract/58\">",
"      Bassi P, Spinadin R, Carando R, et al. Modified induction course: a solution to side-effects? Eur Urol 2000; 37 Suppl 1:31.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2973 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31096=[""].join("\n");
var outline_f30_23_31096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Localized disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - BCG cystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Systemic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1049945536\">",
"      - Prosthetic devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antituberculous therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40136?source=related_link\">",
"      BCG vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40406?source=related_link\">",
"      Hepatic granulomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22378?source=related_link\">",
"      Microbiology and pathogenesis of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16614?source=related_link\">",
"      Mycobacterium bovis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_23_31097="Childhood exposure to intimate partner violence";
var content_f30_23_31097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Childhood exposure to intimate partner violence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31097/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31097/contributors\">",
"     Kathleen M Franchek-Roa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31097/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31097/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31097/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31097/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/23/31097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intimate partner violence is a common form of violence against women in American society. Studies have found that between 25 to 35 percent of women in the United States have suffered violence from an intimate partner at some point in their lives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Intimate partner violence against men also occurs, but less is known about the frequency; a 2010 national survey found that about one in four men had experienced rape, physical violence,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stalking by an intimate partner in their lifetime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women between the ages of 20 and 34 are at the greatest risk for intimate partner violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/3\">",
"     3",
"    </a>",
"    ] and because many of these women are mothers, millions of children are exposed to intimate partner violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Exposure to such violence is a major threat to children&rsquo;s health and well-being [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. It has deleterious effects on a child&rsquo;s developing brain resulting in long-term adverse consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Data from the Adverse Childhood Experiences (ACE) studies indicate that adverse childhood experiences, such as exposure to intimate partner violence, dramatically affect adult mental and physical health and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics encourages health care professionals to use an ecobiodevelopmental framework to understand how exposure to toxic stress (eg, domestic or community violence, maternal depression, parental substance abuse, food scarcity, poor social connectedness) during childhood can lead to permanent changes in learning, behavior, and physiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. Chronic toxic stress in childhood causes physiologic changes that lead to stress-related chronic illness and unhealthy lifestyles in adulthood.",
"   </p>",
"   <p>",
"    Family violence has a significant impact on an individual's health, as well as community health and healthcare resources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Intimate partner violence frequently remains undiagnosed because victims may conceal that they are in abusive relationships, and the clues pointing to abuse may be subtle or absent. Pediatricians are well-placed to identify maternal intimate partner violence because victims of intimate partner violence seek health care for their children, even if they do not for themselves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, effects, and treatment of children who are exposed to intimate partner violence and some aspects of diagnosing, screening, and counseling women for intimate partner violence are reviewed here. A more thorough discussion of diagnosing, screening, and counseling women for intimate partner violence is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/54/14183?source=see_link\">",
"     \"Intimate partner violence: Intervention and patient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/15/6393?source=see_link\">",
"     \"Intimate partner violence: Diagnosis and screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H245691900\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intimate partner violence is a pattern of coercive behaviors that may include repeated sexual and physical violence, psychological abuse, progressive social isolation, deprivation, intimidation, stalking, and reproductive coercion. These behaviors are perpetrated by someone who is or was involved in an intimate relationship with the victim and are used to establish power and control over the victim [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Abusive relationships are characterized by episodic, unpredictable outbursts by the abuser that often begin as verbal and emotional abuse but, over time, tend to become physical. As the abusive relationship continues, the victim begins to live in a state of constant fear, terrified about when the next episode of abuse will occur.",
"   </p>",
"   <p>",
"    \"Witnessed violence\" is verbal or physical violence that is heard or seen by a child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the definition of child witness to violence is expanded to include not only the actual observation of the violence or abuse, but also the observation of the effects of the violence suffered by the victim, such as visible injuries, bruises, intimidation, and fear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/27\">",
"     27",
"    </a>",
"    ]. The abusive behavior that may be witnessed by children in the home ranges from loud arguments to hitting, shoving, slapping, punching, and potentially lethal assaults (eg, strangulation or the use of a weapon) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each year in the United States, intimate partner violence is estimated to result in 2 million injuries to women and nearly 600,000 injuries to men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2005, there were 1510 intimate partner violence homicides, of which 78 percent of the victims were women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/28\">",
"     28",
"    </a>",
"    ]. It is estimated that at least 15.5 million children (30 percent of the US population of children) live in homes where intimate partner violence occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/5\">",
"     5",
"    </a>",
"    ]. These estimates probably underrepresent the true incidence because many cases of intimate partner violence go unreported. Children living in such homes become involved in the violence in a variety of ways, eg, they can sustain injuries either intentionally or unintentionally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/29\">",
"     29",
"    </a>",
"    ], try to stop the violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/30\">",
"     30",
"    </a>",
"    ], affect the mother&rsquo;s decision-making process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], and are at high risk to becoming victims of child abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolating the quantitative contribution of repeated exposure to violence, family dysfunction, and social stressors from the effects of witnessing intimate partner violence is difficult because these variables usually occur in combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Nonetheless, exposure to intimate partner violence has short- and long-term effects on a child's emotional, social, and cognitive development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/7-11,35,36\">",
"     7-11,35,36",
"    </a>",
"    ]. The effects for an individual child may be dependent upon several variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The proximity and severity of the violence",
"     </li>",
"     <li>",
"      The number of violent disruptions",
"     </li>",
"     <li>",
"      The age of the child",
"     </li>",
"     <li>",
"      The sex of the child",
"     </li>",
"     <li>",
"      The relationship of the child to the abuser and victim",
"     </li>",
"     <li>",
"      The loss perceived by the child",
"     </li>",
"     <li>",
"      The relationship of the violent act to the child's daily routine",
"     </li>",
"     <li>",
"      The domain of adjustment that is challenged",
"     </li>",
"     <li>",
"      The availability of a support system",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a meta-analysis concluded that &ldquo;mere exposure&rdquo; to intimate partner violence is associated with poor emotional and behavioral outcomes in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/43\">",
"     43",
"    </a>",
"    ]. Positive relationships in the family, better parenting performance, a supportive environment outside the home, fewer social stressors (eg, poverty, low educational level, substance abuse), fewer maternal health problems, and less severe violence exposure are protective factors for children who are exposed to intimate partner violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mental health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many children who are exposed to intimate partner violence exhibit an increase in externalizing behaviors such as aggression, conduct disorders, and impulsivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/8,9,48\">",
"     8,9,48",
"    </a>",
"    ]. They also may suffer from internalizing behaviors such as anxiety, intrusive thoughts of violent events, disrupted sleep pattern, and depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/8,9,49\">",
"     8,9,49",
"    </a>",
"    ]. Internalizing behaviors may improve if the intimate partner violence resolves. In a retrospective study of 320 children with caregiver-reported intimate partner violence, resolution of intimate partner violence after child protective services investigation was associated with improvement in child behavior problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who witness life-threatening acts toward their parents may exhibit symptoms of posttraumatic stress disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. Repeated exposure to violence may cause the child to have a fatalistic world view, which in turn may lead to risky behaviors (eg, drug abuse, noncompliance with medications, sexual promiscuity, careless operation of vehicles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Age-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child's immediate reaction to the violent act is varied and significant. Most reactions can be predicted by the child's age and developmental stage. Typical responses include crying, attempting a physical intervention, trying to protect the parent, creating a distraction, or becoming involved in the conflict [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/57\">",
"     57",
"    </a>",
"    ]. Children who attempt to physically intervene in parental conflict are at risk for incurring physical injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants may have disrupted feeding and sleep routines, excessive crying, and developmental delay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. Children as young as 12 months respond to loud arguments and disruption by crying or becoming more aggressive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Toddlers may display comforting, acting out, or distracting behaviors. Acting out or distracting behaviors may defuse interparental aggression by redirecting the attention of the adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/57-59\">",
"       57-59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preschool children may recreate the violent act during play [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/56,58\">",
"       56,58",
"      </a>",
"      ]. In addition, they may be withdrawn, have regressive behavior (eg, bed-wetting or thumb-sucking), have nightmares, stutter, or exhibit anxiety and clinging behavior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/59,61\">",
"       59,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      School-age children may blame themselves for the violence in their homes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. They may have somatic complaints of headache or stomach ache and varying degrees of anxiety. They also may have increased aggression and depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/49,63,64\">",
"       49,63,64",
"      </a>",
"      ]. School absenteeism increases and school performance decreases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/49,59,65-67\">",
"       49,59,65-67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adolescents may adopt inappropriate behaviors (eg, dressing older or younger than their age). They may become depressed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/68\">",
"       68",
"      </a>",
"      ], abuse substances to escape the pain, or act out in an aggressive manner [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sex-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of family-related violence vary by sex. One study compared problem behaviors and social competence of 126 children (aged 6 to 11 years) from violent and non-violent families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/70\">",
"     70",
"    </a>",
"    ]. Girls from violent families had more internalizing symptoms (depression, low self-esteem, low self-worth, and higher anxiety levels). In contrast, boys displayed more externalizing behaviors (eg, conduct disorders, impulsiveness, and poor control of temper). These behaviors affected their social competence. Boys also were found to suffer from depression, anxiousness, and withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cognitive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who live in homes where intimate partner violence occurs may have problems in school for a variety of reasons. They may have difficulty concentrating because of lack of sleep, depression, or posttraumatic stress; they may be forced to change schools when they move to a safe home or shelter; they may have frequent absences from school [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/71\">",
"     71",
"    </a>",
"    ]. One study that examined the developmental and learning profiles of children whose mothers were intimate partner violence victims, found that approximately 40 percent of the preschool children had developmental delays and were at risk for developing future school problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/71\">",
"     71",
"    </a>",
"    ]. Nearly one-half of the school-aged children had one or more indicators of academic problems (eg, grade repetition, failing grades, need for special services). Other studies have also documented the adverse effect on academic performance in children exposed to intimate partner violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/66,72\">",
"     66,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thirteen children from nine families with intimate partner violence were interviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/57\">",
"     57",
"    </a>",
"    ]. Children expressed fear for themselves and their parents and feelings of powerlessness. The children coped by seeking solitude or talking with their stuffed animals during the explosive arguments or violent acts, becoming hypervigilant, or compartmentalizing their feelings. They fantasized to escape the fighting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Parent-child interaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who live in homes with intimate partner violence may be blamed as the cause of the parental conflict [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/62\">",
"     62",
"    </a>",
"    ]. One in five women in the Spousal Assault Replication Program database reported that the children were the cause of the domestic upheaval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/73\">",
"     73",
"    </a>",
"    ]. The parent-child relationship may be affected if the parent views the child as responsible for the domestic conflict; this, in turn, may affect the way in which the child responds to witnessing a traumatic event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Parenting style",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents who are in violent relationships may suffer from depression, anxiety, and powerlessness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/58,70,74\">",
"     58,70,74",
"    </a>",
"    ]. The stress of intimate partner violence may affect their parenting style, which, in turn, may affect the behavior of the children. In one study of 37 battered women and 37 comparison mothers, the battered mothers reported increased stress and inconsistency in parenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/75\">",
"     75",
"    </a>",
"    ]. Battered mothers may alter their parenting style according to the presence or absence of the abusive partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some mothers reported being more punitive toward the children in the presence of the abuser since the punishment from the father would be worse. They also reported using their children as the target of their anger and frustration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/33\">",
"     33",
"    </a>",
"    ]. Other mothers were more lenient toward their children because they felt the need to compensate for the stress the child experienced and the lack of parental involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Related to separation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children from violent homes may experience effects related to separation if their mothers choose to seek refuge from the abuser. It may be necessary for these children to leave their home, school, friends, and other support systems. The feelings that they have may range from sadness and protectiveness to relief and pleasure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/69\">",
"     69",
"    </a>",
"    ]. Preschool children have the most difficulty in adjustment. They express their feelings through behavior problems, sleep disturbances, enuresis, and regressive behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/44,69\">",
"     44,69",
"    </a>",
"    ]. On the other hand, behavior problems associated with exposure to violence may improve after separation. While 42 percent of the three- to six-year-old children whose mothers left a violent relationship had behavior problems warranting clinical intervention at the time of interview, the mothers reported that the behavior of most of the children improved after the separation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Child abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children are at increased risk for abuse when there is interspousal aggression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/35,36,77\">",
"     35,36,77",
"    </a>",
"    ]. In 30 to 60 percent of homes where child maltreatment or intimate partner violence occurs, the other form of violence is also present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/78\">",
"     78",
"    </a>",
"    ]. One study found that the probability of child abuse in a family was 5 percent when there was one act of intimate partner violence and nearly 100 percent when there were 50 or more acts of intimate partner violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18408?source=see_link\">",
"     \"Child neglect and emotional abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long-term effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term effects of exposure to intimate partner violence are described in retrospective studies and archival records. They include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/36,49,69,80-88\">",
"     36,49,69,80-88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Low self-esteem",
"     </li>",
"     <li>",
"      Trauma-related symptoms",
"     </li>",
"     <li>",
"      Poor social adjustment",
"     </li>",
"     <li>",
"      Conduct disorders",
"     </li>",
"     <li>",
"      Antisocial behavior",
"     </li>",
"     <li>",
"      Self-injurious behavior",
"     </li>",
"     <li>",
"      Perpetrator of child abuse as an adult",
"     </li>",
"     <li>",
"      Potential to become a victim or perpetrator of violence toward others",
"     </li>",
"     <li>",
"      Substance use and high-risk sexual behavior during adolescence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631266552\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a significant overlap between intimate partner violence in the home and child maltreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/35\">",
"     35",
"    </a>",
"    ]. Identifying intimate partner violence may be an important means of preventing child abuse because intimate partner violence is a leading precursor to child maltreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many women will disclose intimate partner violence victimization when asked in a pediatric setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. However, surveys of pediatric practitioners indicate that fewer than 10 percent routinely screen all families for intimate partner violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. The reasons for lack of screening included lack of education, lack of time, lack of support staff, and insufficient or inadequate referral sources.",
"   </p>",
"   <p>",
"    The presentation of children who are exposed to intimate partner violence is variable (",
"    <a class=\"graphic graphic_table graphicRef79356 \" href=\"mobipreview.htm?2/47/2812\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55436 \" href=\"mobipreview.htm?22/3/22588\">",
"     table 2",
"    </a>",
"    ). Children exposed to intimate partner violence present with the same complaints as those who are not exposed to intimate partner violence. That is why clinicians should develop a routine for asking about violence as part of the health maintenance visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/89,91,92\">",
"     89,91,92",
"    </a>",
"    ]. However, they must recognize that the process of disclosing intimate partner violence is frightening to the victim. She or her children may have been threatened with death for revealing the abuse or trying to leave [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/35\">",
"     35",
"    </a>",
"    ]. She may only be willing to reveal the abuse if she believes that she can improve her situation.",
"   </p>",
"   <p>",
"    Another aspect of screening for intimate partner violence is that the answers to the screening questions are less important than the",
"    <strong>",
"     process",
"    </strong>",
"    of asking the questions. Asking about the safety of all family members gives the woman the message that she can obtain help from the clinician if and when she needs it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     RADAR acronym",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Massachusetts Medical Society developed an acronym, \"RADAR,\" to guide healthcare providers with the process of screening (",
"    <a class=\"graphic graphic_table graphicRef54867 \" href=\"mobipreview.htm?1/39/1662\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef86514 \" href=\"mobipreview.htm?33/31/34302\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/95\">",
"     95",
"    </a>",
"    ]. The Institute for Safe Families modified the guide to be specific for pediatric healthcare providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/96\">",
"     96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      R = Routinely screen patients for abuse &ndash; Although many women who are victims of intimate partner violence will not volunteer information, many will acknowledge that they are victims if asked. Intervening on behalf of battered women is an active form of preventing child abuse.",
"     </li>",
"     <li>",
"      A = Ask direct questions &ndash; Screening adults can be prefaced with the following statement: \"Because violence is so common in many people's lives and witnessing violence can have negative effects on children, we have begun to ask all our families about their experiences with violence.\" Sample questions include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Have you ever been harmed by or felt afraid of your partner?",
"     </li>",
"     <li>",
"      Have you ever been hit, kicked, punched, or otherwise hurt by your partner?",
"     </li>",
"     <li>",
"      Do you feel unsafe in your current or previous relationship?",
"     </li>",
"     <li>",
"      Have your children witnessed anything violent or frightening in their home, community, or school?",
"      <br/>",
"      <br/>",
"      Screening adolescents can be prefaced with the following statement:",
"      <br/>",
"      <br/>",
"      \"I don't know if this is a concern for you, but many teens I see are dealing with violence or bullying issues, so I've started asking questions about violence routinely. Sometimes if someone is being hurt in",
"      <span class=\"nowrap\">",
"       her/his",
"      </span>",
"      own relationship, they may have seen it happen in their own family.\"",
"     </li>",
"     <li>",
"      Have you seen anyone get hurt in your home?",
"     </li>",
"     <li>",
"      Do you ever feel afraid of or controlled by someone you're dating or a friend?",
"     </li>",
"     <li>",
"      Has anyone hit you at home in the last year?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      D = Document your findings &ndash; Thoroughly document in the chart the patient's description of the violence and any injuries that are present. When the patient is a child, ask the victim if it is safe to document in the child's chart. If further information about the violence needs to be documented, then place details in a \"restricted access\" document. Check with your hospital or clinic as to how to document sensitive information. Document what information was given to the victim and the referrals made.",
"     </li>",
"     <li>",
"      A = Assess safety of victim and children &ndash; Assess patient safety. Help the victim reduce the danger to herself and her children when they leave the outpatient setting. A safety assessment includes some of the following questions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Are you afraid to go home?",
"     </li>",
"     <li>",
"      Are there guns in the home?",
"     </li>",
"     <li>",
"      Are you planning on leaving?",
"     </li>",
"     <li>",
"      Do you need access to a shelter?",
"     </li>",
"     <li>",
"      Can you stay with family or friends?",
"     </li>",
"     <li>",
"      Has the violence increased?",
"     </li>",
"     <li>",
"      Have there been threats of",
"      <span class=\"nowrap\">",
"       homicide/suicide?",
"      </span>",
"     </li>",
"     <li>",
"      Has there been violence against the children?",
"     </li>",
"     <li>",
"      Have you ever been choked?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      R = Review",
"      <span class=\"nowrap\">",
"       options/referrals/reporting",
"      </span>",
"      requirements &ndash; Refer the patient to specialists trained to help victims cope with all aspects of the abuse. Take time to talk about options available to the victim and her family. Give the victim written information if she feels that it is safe to do so. Call authorities (ie, law enforcement or Child Protective Services) if appropriate. Find safe shelter for family if needed. Refer to the specific state statutes regarding documentation and reporting and child exposure to violence reporting requirements (",
"      <a class=\"external\" href=\"file://www.childwelfare.gov/systemwide/laws_policies/statutes/witnessdv.cfm\">",
"       www.childwelfare.gov/systemwide/laws_policies/statutes/witnessdv.cfm",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Whom to screen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many advocacy groups and medical organizations recommend screening for intimate partner violence victimization in the health care setting, including the American Academy of Family Physicians, American Academy of Neurology, American Academy of Pediatrics, American College of Emergency Physicians, American Congress of Obstetrics and Gynecology, the American Medical Association, and the United States Preventive Services Task Force [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/27,97,98\">",
"     27,97,98",
"    </a>",
"    ]. The Institute of Medicine also recommends that women and adolescents should be screened and counseled for interpersonal and domestic violence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, recommendations for screening women for intimate partner violence victimization have also been included in the Affordable Care Act.",
"    <em>",
"    </em>",
"   </p>",
"   <p>",
"    Mothers should be screened to identify victims of intimate partner abuse. Teenagers should be screened to identify exposure to violence in the home, as well as to identify",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevent their own involvement in violent intimate relationships. Screening should be performed yearly at well-child visits and at new patient visits. In addition, screening should be performed when the mother or teenager is involved in a new intimate relationship, becomes pregnant, or when risk factors for intimate partner violence are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15561?source=see_link\">",
"     \"Date rape: Identification and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     How to screen",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advocates in the field of intimate partner violence suggest that using direct questions, rather than vague statements, will have a greater sensitivity of identifying victims [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The clinician or other healthcare provider should not routinely screen the mother if her partner or other adults are present.",
"     </li>",
"     <li>",
"      The health care provider should ask the screening questions in the mother's primary language and not use children or family members as interpreters.",
"     </li>",
"     <li>",
"      Caution should be used when verbally screening a mother who has children older than two or three years of age in the room. Strategies to employ may include asking these questions when the child is having hearing and vision screening or another time when the parent and child may be separated such as while obtaining a urine sample.",
"     </li>",
"     <li>",
"      Teenagers should be screened without caregivers or partners.",
"     </li>",
"     <li>",
"      Inform the mother about the limits of",
"      <span class=\"nowrap\">",
"       practitioner/patient",
"      </span>",
"      confidentiality related to intimate partner violence before screening. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Mandatory reporting'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Who should ask",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for intimate partner violence should be performed by any member of the healthcare team who is trained in screening for intimate partner violence and is knowledgeable about interventions and referrals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric healthcare providers can intervene in the following ways if they suspect that a patient lives in a household with intimate partner violence (",
"    <a class=\"graphic graphic_algorithm graphicRef86514 \" href=\"mobipreview.htm?33/31/34302\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Send supportive messages by telling the mother that you are concerned about her and her children's safety. Let her know that she is not alone and that there are people who can help her. Tell her that the violence is not her fault. Inform her that intimate partner violence is a crime that she can report to law enforcement agencies. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Mandatory reporting'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Assess safety needs of mother and children by asking her if she feels safe to go home. Assess if she has family or friends she can turn to for help. Ask her if she feels that her children are safe. Offer basic safety skills so that the child can prepare for a future eruption of violence. Be cautious about providing written material. It may jeopardize the safety of the victim if it is found by the abuser.",
"     </li>",
"     <li>",
"      Make referrals by giving the mother numbers to local shelters or the National Domestic Violence Hotline number, 1-800-799-SAFE (1-800-799-7233), which can provide clinicians in every state with information on local resources. Provide information about mental health services for her and her children. Encourage the mother to seek medical care for herself. Additional resources for information about intimate partner violence include [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/99\">",
"       99",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.futureswithoutviolence.org/\">",
"       Futures Without Violence",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.instituteforsafefamilies.org/\">",
"       Institute for Safe Families",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.leapsf.org/html/index.shtml\">",
"       Look to End Abuse Permanently",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Listen to the child's feelings. Explore what it means to the child to feel that he or she is betraying the mother's partner through disclosure. In addition, the child may be confused by conflicting emotions (eg, disapproval of the perpetrator's actions, but affection for the perpetrator or resentment for the mother's helplessness, but sympathizing with her trauma) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Offer reassurance that conflict can be resolved in a nonviolent manner and referral for classes on conflict resolution (eg, at a local school or mental health agency).",
"     </li>",
"     <li>",
"      Refer the child for support and counseling if it can be done without endangering the child or mother. The child who has been separated from the abuser may need grief therapy. He or she will experience the loss of the family unit, the possible loss of contact with the abuser, and the loss of his or her former daily life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mental health services",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are exposed to intimate partner violence have unique emotional needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/39\">",
"     39",
"    </a>",
"    ]. The parents may be unavailable for emotional support, either because they are unsafe (the perpetrator) or addressing their own trauma (the victim). In addition, parental conflict, family dysfunction, maternal depression, decreased support and nurturance, isolation, relocation, economic, and social disadvantage may be ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/42,100\">",
"     42,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The emotional response of children to witnessing intimate partner violence may include terror, fear of death, fear of loss of a parent, rage, guilt, and a sense of responsibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/39\">",
"     39",
"    </a>",
"    ]. They may feel helpless and view the world as unpredictable, hostile, and threatening.",
"   </p>",
"   <p>",
"    The goals of mental health therapy include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Promoting open discussion of the child's experience, a process that may help the child to integrate the experience into a self-understanding, reduce the sense of isolation, and permit the child to begin to heal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/101,102\">",
"       101,102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Helping the child to cope with his or her emotional responses to violence and to acquire positive behavior patterns.",
"     </li>",
"     <li>",
"      Reducing the symptoms the child experiences in response to violence.",
"     </li>",
"     <li>",
"      Helping the family to create a safe, stable, nurturing environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Mandatory reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the statutes specific to intimate partner violence and assault can change frequently for each state, the clinician should refer to his or her local and state laws regarding intimate partner violence reporting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31097/abstract/27\">",
"     27",
"    </a>",
"    ]. The issues of concern for the clinician are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How is intimate partner violence defined in the state's statutes?",
"     </li>",
"     <li>",
"      What types of assaultive injuries need to be reported to law enforcement agencies (eg, all assaultive injuries or only injuries that occurred from the use of weapons, etc)?",
"     </li>",
"     <li>",
"      What are the state's statutes regarding commission of intimate partner violence in the presence of a child (ie, does this equate to child abuse)?",
"     </li>",
"     <li>",
"      What are the legal requirements for healthcare providers for chart documentation?",
"     </li>",
"     <li>",
"      When making a report to law enforcement, what information needs to be included?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This information can be obtained from the local district attorney's office and is usually available online. In cases of suspected child",
"    <span class=\"nowrap\">",
"     abuse/neglect,",
"    </span>",
"    all 50 states mandate reporting to the appropriate agency. However, states differ on whether child witnessing of violence is child abuse. Regardless of the state's statutes, in all cases of intimate partner violence where child exposure is possible, the practitioner must assess the safety of the home situation and determine whether it is safe for the child(ren) to return home. If the home situation is not deemed to be safe, or the child has been abused or neglected, then a report must be made to the appropriate authority in that state. Refer to the specific state statutes in regards to documentation and reporting and child witness to violence reporting requirements (",
"    <a class=\"external\" href=\"file://www.childwelfare.gov/systemwide/laws_policies/statutes/witnessdv.cfm\">",
"     www.childwelfare.gov/systemwide/laws_policies/statutes/witnessdv.cfm",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should discuss communication and discipline with parents during routine well-child exams. Offer the following tips:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Parents should keep children out of angry discussions: this avoids modeling of inappropriate behavior by the child",
"     </li>",
"     <li>",
"      Parents should be consistent with their rules, which should be agreed upon in the child's presence",
"     </li>",
"     <li>",
"      Each parent should maintain good communication with each child, which fosters a healthy relationship",
"     </li>",
"     <li>",
"      Review with parents the negative effects of interspousal conflicts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With increasing awareness and education, the healthcare provider can become an important resource to help families end the cycle of abuse. Intimate partner violence is a pediatric, healthcare, and social issue in our communities, states, and countries. Healthcare providers should unite to become an authoritative voice to proclaim that \"abuse is not OK.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intimate partner violence is a pattern of coercive behaviors that may include repeated sexual and physical violence, psychological abuse, progressive social isolation, deprivation, intimidation, stalking, and reproductive coercion. These behaviors are perpetrated by someone who is or was involved in an intimate relationship with the victim and are used to establish power and control over the victim. (See",
"      <a class=\"local\" href=\"#H245691900\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to intimate partner violence has short- and long-term effects on a child's emotional, social, and cognitive development. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presentation of children who are exposed to intimate partner violence is variable (",
"      <a class=\"graphic graphic_table graphicRef79356 \" href=\"mobipreview.htm?2/47/2812\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef55436 \" href=\"mobipreview.htm?22/3/22588\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The \"RADAR\" acronym was developed to guide healthcare providers in screening for intimate partner violence (",
"      <a class=\"graphic graphic_table graphicRef54867 \" href=\"mobipreview.htm?1/39/1662\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef86514 \" href=\"mobipreview.htm?33/31/34302\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'RADAR acronym'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening mothers and teenage patients for intimate partner violence should be performed when risk factors for intimate partner violence are present, at new patient visits, yearly at well-child visits, and when the mother or teenager is involved in a new intimate relationship or becomes pregnant. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Whom to screen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When intimate partner violence is suspected or disclosed, pediatric healthcare providers can make referrals to local shelters or the National Domestic Violence Hotline number, 1-800-799-SAFE. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who are exposed to intimate partner violence may benefit from mental health services if a referral can be made without endangering the child or victim. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Mental health services'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should refer to his or her local and state laws regarding intimate partner violence reporting. This information can be obtained from the local district attorney's office and is usually available online (",
"      <a class=\"external\" href=\"file://www.childwelfare.gov/systemwide/laws_policies/statutes/witnessdv.cfm\">",
"       www.childwelfare.gov/systemwide/laws_policies/statutes/witnessdv.cfm",
"      </a>",
"      ). If the home situation is not deemed to be safe, or the child has been abused or neglected, then a report must be made to the appropriate authority in that state. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Mandatory reporting'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Adverse health conditions and health risk behaviors associated with intimate partner violence--United States, 2005. MMWR Morb Mortal Wkly Rep 2008; 57:113.",
"     </a>",
"    </li>",
"    <li>",
"     Black MC, Basile KC, Breiding MJ, et al. The National Intimate Partner and Sexual Violence Survey (NISVS): 2010 Summary Report. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention. Available at: www.cdc.gov/ViolencePrevention/pdf/NISVS_Report2010-a.pdf (Accessed on February 16, 2012).",
"    </li>",
"    <li>",
"     Catalano S. Intimate Partner Violence in the United States. Washinton, DC: Department of Justice (US); Bureau of Justice Statistics, 2007. www.ojp.usdoj.gov/bjs (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/4\">",
"      Finkelhor D, Turner H, Ormrod R, Hamby SL. Violence, abuse, and crime exposure in a national sample of children and youth. Pediatrics 2009; 124:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/5\">",
"      McDonald R, Jouriles EN, Ramisetty-Mikler S, et al. Estimating the number of American children living in partner-violent families. J Fam Psychol 2006; 20:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/6\">",
"      Moore CG, Probst JC, Tompkins M, et al. The prevalence of violent disagreements in US families: effects of residence, race/ethnicity, and parental stress. Pediatrics 2007; 119 Suppl 1:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/7\">",
"      Edleson JL. Children's witnessing of adult domestic violence. J Interpers Violence 1999; 14:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/8\">",
"      McFarlane JM, Groff JY, O'Brien JA, Watson K. Behaviors of children who are exposed and not exposed to intimate partner violence: an analysis of 330 black, white, and Hispanic children. Pediatrics 2003; 112:e202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/9\">",
"      Hazen AL, Connelly CD, Kelleher KJ, et al. Female caregivers' experiences with intimate partner violence and behavior problems in children investigated as victims of maltreatment. Pediatrics 2006; 117:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/10\">",
"      Kernic MA, Wolf ME, Holt VL, et al. Behavioral problems among children whose mothers are abused by an intimate partner. Child Abuse Negl 2003; 27:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/11\">",
"      Whitaker RC, Orzol SM, Kahn RS. Maternal mental health, substance use, and domestic violence in the year after delivery and subsequent behavior problems in children at age 3 years. Arch Gen Psychiatry 2006; 63:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/12\">",
"      Shonkoff JP, Garner AS, Committee on Psychosocial Aspects of Child and Family Health, et al. The lifelong effects of early childhood adversity and toxic stress. Pediatrics 2012; 129:e232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/13\">",
"      American Academy of Pediatrics, Stirling J Jr, Committee on Child Abuse and Neglect and Section on Adoption and Foster Care, et al. Understanding the behavioral and emotional consequences of child abuse. Pediatrics 2008; 122:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/14\">",
"      Perry BD, Pollard R. Homeostasis, stress, trauma, and adaptation. A neurodevelopmental view of childhood trauma. Child Adolesc Psychiatr Clin N Am 1998; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/15\">",
"      Anda RF, Felitti VJ, Bremner JD, et al. The enduring effects of abuse and related adverse experiences in childhood. A convergence of evidence from neurobiology and epidemiology. Eur Arch Psychiatry Clin Neurosci 2006; 256:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/16\">",
"      Dube SR, Felitti VJ, Dong M, et al. The impact of adverse childhood experiences on health problems: evidence from four birth cohorts dating back to 1900. Prev Med 2003; 37:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/17\">",
"      Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med 1998; 14:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/18\">",
"      Garner AS, Shonkoff JP, Committee on Psychosocial Aspects of Child and Family Health, et al. Early childhood adversity, toxic stress, and the role of the pediatrician: translating developmental science into lifelong health. Pediatrics 2012; 129:e224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/19\">",
"      Wisner CL, Gilmer TP, Saltzman LE, Zink TM. Intimate partner violence against women: do victims cost health plans more? J Fam Pract 1999; 48:439.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Costs of intimate partner violence against women in the United States. Atlanta, GA: US Department of Health and Human Services, 2003. file://www.cdc.gov/ncipc/pub-res/ipv_cost/ipv.htm (Accessed on September 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/21\">",
"      Bair-Merritt MH, Feudtner C, Localio AR, et al. Health care use of children whose female caregivers have intimate partner violence histories. Arch Pediatr Adolesc Med 2008; 162:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/22\">",
"      Martin SL, Mackie L, Kupper LL, et al. Physical abuse of women before, during, and after pregnancy. JAMA 2001; 285:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/23\">",
"      Rivara FP, Anderson ML, Fishman P, et al. Intimate partner violence and health care costs and utilization for children living in the home. Pediatrics 2007; 120:1270.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Clinical Preventive Services for Women: Closing the Gaps, The National Academies Press, Washington, DC 2011.",
"    </li>",
"    <li>",
"     Black MC, Basile KC, Breiding MJ, et al.. The National Intimate Partner and Sexual Violence Survey (NISVS): 2010 Summary Report, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/26\">",
"      McCloskey LA, Figueredo AJ, Koss MP. The effects of systemic family violence on children's mental health. Child Dev 1995; 66:1239.",
"     </a>",
"    </li>",
"    <li>",
"     Groves BM, Augustyn M, Lee D, Sawires P. Identifying and responding to domestic violence. Consensus recommendations for child and adolescent health. file://www.futureswithoutviolence.org/userfiles/file/HealthCare/pediatric.pdf (Accessed on February 08, 2012).",
"    </li>",
"    <li>",
"     Bureau of Justice Statistics, Office of Justice Programs. Homicide trends in the US. file://bjs.ojp.usdoj.gov/content/homicide/homtrnd.cfm (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/29\">",
"      Christian CW, Scribano P, Seidl T, Pinto-Martin JA. Pediatric injury resulting from family violence. Pediatrics 1997; 99:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/30\">",
"      Edleson JL, Mbilinyi LF, Beeman SK, Hagemeister AK. How children are involved in adult domestic violence - Results from a four-city telephone survey. J Interpers Viol 2003; 18:18.",
"     </a>",
"    </li>",
"    <li>",
"     Schecter S, Edleson JL. In the best interest of women and childre: A call for collaboration between child welfare and domestic violence constituenceies. Prevention Report, 1995. www.mincava.umn.edu/papers/wingsp.htm (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/32\">",
"      Zink T, Elder N, Jacobson J. How children affect the mother/victim's process in intimate partner violence. Arch Pediatr Adolesc Med 2003; 157:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/33\">",
"      Smith J, Berthelsen D, O'Connor I. Child adjustment in high conflict families. Child Care Health Dev 1997; 23:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/34\">",
"      Brooks RM, Mott AM. Domestic violence: what should paediatricians do? Arch Dis Child 2008; 93:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/35\">",
"      Thackeray JD, Hibbard R, Dowd MD, et al. Intimate partner violence: the role of the pediatrician. Pediatrics 2010; 125:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/36\">",
"      Holt S, Buckley H, Whelan S. The impact of exposure to domestic violence on children and young people: a review of the literature. Child Abuse Negl 2008; 32:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/37\">",
"      Kashani JH, Daniel AE, Dandoy AC, Holcomb WR. Family violence: impact on children. J Am Acad Child Adolesc Psychiatry 1992; 31:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/38\">",
"      Martinez P, Richters JE. The NIMH community violence project: II. Children's distress symptoms associated with violence exposure. Psychiatry 1993; 56:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/39\">",
"      Groves BM. Mental health services for children who witness domestic violence. Future Child 1999; 9:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/40\">",
"      Wolfe DA, Zak L, Wilson S, Jaffe P. Child witnesses to violence between parents: critical issues in behavioral and social adjustment. J Abnorm Child Psychol 1986; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/41\">",
"      Prinstein MJ, La Greca AM. Links between mothers' and children's social competence and associations with maternal adjustment. J Clin Child Psychol 1999; 28:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/42\">",
"      Shipman KL, Zeman J. Emotional understanding: a comparison of physically maltreating and nonmaltreating mother-child dyads. J Clin Child Psychol 1999; 28:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/43\">",
"      Evans SE, Davies C, DiLillo D. Exposure to domestic violence: A meta-analysis of child and adolescent outcomes. Aggress Violent Behav 2008; 13:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/44\">",
"      Hughes HM. Psychological and behavioral correlates of family violence in child witnesses and victims. Am J Orthopsychiatry 1988; 58:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/45\">",
"      Muller RT, Goebel-Fabbri AE, Diamond T, Dinklage D. Social support and the relationship between family and community violence exposure and psychopathology among high risk adolescents. Child Abuse Negl 2000; 24:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/46\">",
"      Zolotor AJ, Runyan DK. Social capital, family violence, and neglect. Pediatrics 2006; 117:e1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/47\">",
"      Howell KH, Graham-Bermann SA, Czyz E, Lilly M. Assessing resilience in preschool children exposed to intimate partner violence. Violence Vict 2010; 25:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/48\">",
"      Currie CL. Animal cruelty by children exposed to domestic violence. Child Abuse Negl 2006; 30:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/49\">",
"      Hurt H, Malmud E, Brodsky NL, Giannetta J. Exposure to violence: psychological and academic correlates in child witnesses. Arch Pediatr Adolesc Med 2001; 155:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/50\">",
"      Campbell KA, Thomas AM, Cook LJ, Keenan HT. Resolution of intimate partner violence and child behavior problems after investigation for suspected child maltreatment. JAMA Pediatr 2013; 167:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/51\">",
"      Kilpatrick KL, Williams LM. Post-traumatic stress disorder in child witnesses to domestic violence. Am J Orthopsychiatry 1997; 67:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/52\">",
"      Pynoos RS, Nader K. Children who witness the sexual assaults of their mothers. J Am Acad Child Adolesc Psychiatry 1988; 27:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/53\">",
"      Kilpatrick KL, Williams LM. Potential mediators of post-traumatic stress disorder in child witnesses to domestic violence. Child Abuse Negl 1998; 22:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/54\">",
"      Lehmann P. The development of Posttraumatic Stress Disorder (PTSD) in a sample of child witnesses to mother assault. J Fam Viol 1997; 12:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/55\">",
"      McCloskey LA, Walker M. Posttraumatic stress in children exposed to family violence and single-event trauma. J Am Acad Child Adolesc Psychiatry 2000; 39:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/56\">",
"      Groves BM, Zuckerman B, Marans S, Cohen DJ. Silent victims. Children who witness violence. JAMA 1993; 269:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/57\">",
"      Ericksen JR, Henderson AD. Witnessing family violence: the children's experience. J Adv Nurs 1992; 17:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/58\">",
"      Zuckerman B, Augustyn M, Groves BM, Parker S. Silent victims revisited: the special case of domestic violence. Pediatrics 1995; 96:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/59\">",
"      Knapp JF. The impact of children witnessing violence. Pediatr Clin North Am 1998; 45:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/60\">",
"      Emery RE. Family violence. Am Psychol 1989; 44:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/61\">",
"      Wolfe DA, Korsch B. Witnessing domestic violence during childhood and adolescence: implication for pediatric practice. Pediatrics 1994; 94:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/62\">",
"      Jaffe PG, Hurley DJ, Wolfe D. Children's observations of violence: I. Critical issues in child development and intervention planning. Can J Psychiatry 1990; 35:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/63\">",
"      Hurley DJ, Jaffe P. Children's observations of violence: II. Clinical implications for children's mental health professionals. Can J Psychiatry 1990; 35:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/64\">",
"      Bailey BN, Delaney-Black V, Hannigan JH, et al. Somatic complaints in children and community violence exposure. J Dev Behav Pediatr 2005; 26:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/65\">",
"      Barnett D, Vondra JI, Shonk SM. Self-perceptions, motivation, and school functioning of low-income maltreated and comparison children. Child Abuse Negl 1996; 20:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/66\">",
"      Delaney-Black V, Covington C, Ondersma SJ, et al. Violence exposure, trauma, and IQ and/or reading deficits among urban children. Arch Pediatr Adolesc Med 2002; 156:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/67\">",
"      Silverstein M, Augustyn M, Cabral H, Zuckerman B. Maternal depression and violence exposure: double jeopardy for child school functioning. Pediatrics 2006; 118:e792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/68\">",
"      Lehrer JA, Buka S, Gortmaker S, Shrier LA. Depressive symptomatology as a predictor of exposure to intimate partner violence among US female adolescents and young adults. Arch Pediatr Adolesc Med 2006; 160:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/69\">",
"      Rollins JA. Minimizing the impact of community violence on child witnesses. Crit Care Nurs Clin North Am 1997; 9:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/70\">",
"      Jaffe P, Wolfe D, Wilson SK, Zak L. Family violence and child adjustment: a comparative analysis of girls' and boys' behavioral symptoms. Am J Psychiatry 1986; 143:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/71\">",
"      Wildin SR, Williamson WD, Wilson GS. Children of battered women: developmental and learning profiles. Clin Pediatr (Phila) 1991; 30:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/72\">",
"      Kernic MA, Holt VL, Wolf ME, et al. Academic and school health issues among children exposed to maternal intimate partner abuse. Arch Pediatr Adolesc Med 2002; 156:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/73\">",
"      Fantuzzo J, Boruch R, Beriama A, et al. Domestic violence and children: prevalence and risk in five major U.S. cities. J Am Acad Child Adolesc Psychiatry 1997; 36:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/74\">",
"      Dubowitz H, Black MM, Kerr MA, et al. Type and timing of mothers' victimization: effects on mothers and children. Pediatrics 2001; 107:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/75\">",
"      Wolfe DA, Jaffe P, Wilson SK, Zak L. Children of battered women: the relation of child behavior to family violence and maternal stress. J Consult Clin Psychol 1985; 53:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/76\">",
"      Holden GW, Ritchie KL. Linking extreme marital discord, child rearing, and child behavior problems: evidence from battered women. Child Dev 1991; 62:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/77\">",
"      Jouriles EN, Barling J, O'Leary KD. Predicting child behavior problems in maritally violent families. J Abnorm Child Psychol 1987; 15:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/78\">",
"      Edleson J. The overlap between child maltreatment and women battering. Violence Against Women 1999; 5:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/79\">",
"      Ross SM. Risk of physical abuse to children of spouse abusing parents. Child Abuse Negl 1996; 20:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/80\">",
"      Milner JS, Robertson KR, Rogers DL, et al. Child history of abuse and adult child abuse potential. J Fam Violence 1990; 5:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/81\">",
"      Cappell C, Heiner RN. The intergenerational transmission of family aggression. J Fam Violence 1990; 5:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/82\">",
"      Hotaling GT, Sugarman DB. An analysis of risk markers in husband to wife violence: the current state of knowledge. Violence Vict 1986; 1:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/83\">",
"      Widom CS. Does violence beget violence? A critical examination of the literature. Psychol Bull 1989; 106:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/84\">",
"      Berenson AB, Wiemann CM, McCombs S. Exposure to violence and associated health-risk behaviors among adolescent girls. Arch Pediatr Adolesc Med 2001; 155:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/85\">",
"      Roberts TA, Klein JD, Fisher S. Longitudinal effect of intimate partner abuse on high-risk behavior among adolescents. Arch Pediatr Adolesc Med 2003; 157:875.",
"     </a>",
"    </li>",
"    <li>",
"     Edelson JL. Problems associated with children's witnessing of domestic violence. Applied Research Forum. National Online Resource Center on Violence Against Women (Rev 1999). file://new.vawnet.org/Assoc_Files_VAWnet/AR_witness.pdf (Accessed on February 08, 2012).",
"    </li>",
"    <li>",
"     Edelson JL, Nissley BA. Emerging responses to children exposed to domestic violence. Applied Research Forum. National Online Resource Center on Violence Against Women (October 2006). file://www.vawnet.org/applied-research-papers/summary.php?doc_id=585&amp;find_type=web_desc_AR (Accessed on February 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/88\">",
"      Russell D, Springer KW, Greenfield EA. Witnessing domestic abuse in childhood as an independent risk factor for depressive symptoms in young adulthood. Child Abuse Negl 2010; 34:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/89\">",
"      Siegel RM, Hill TD, Henderson VA, et al. Screening for domestic violence in the community pediatric setting. Pediatrics 1999; 104:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/90\">",
"      Duffy SJ, McGrath ME, Becker BM, Linakis JG. Mothers with histories of domestic violence in a pediatric emergency department. Pediatrics 1999; 103:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/91\">",
"      Holtrop TG, Fischer H, Gray SM, et al. Screening for domestic violence in a general pediatric clinic: be prepared! Pediatrics 2004; 114:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/92\">",
"      Bair-Merritt MH, Jennings JM, Eaker K, et al. Screening for domestic violence and childhood exposure in families seeking care at an urban pediatric clinic. J Pediatr 2008; 152:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/93\">",
"      Erickson MJ, Hill TD, Siegel RM. Barriers to domestic violence screening in the pediatric setting. Pediatrics 2001; 108:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/94\">",
"      Borowsky IW, Ireland M. Parental screening for intimate partner violence by pediatricians and family physicians. Pediatrics 2002; 110:509.",
"     </a>",
"    </li>",
"    <li>",
"     Massachusetts Medical Society. Use your \"RADAR\" to recognize and treat intimate partner violence. file://www.massmed.org/AM/Template.cfm?Section=Home6&amp;TEMPLATE=/CM/ContentDisplay.cfm&amp;CONTENTID=7357 (Accessed on February 08, 2012).",
"    </li>",
"    <li>",
"     Institute for Safe Families. RADAR for Pediatrics. Available at: www.instituteforsafefamilies.org/radar.php (Accessed on September 13, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/97\">",
"      Moyer VA, U.S. Preventive Services Task Force*. Screening for intimate partner violence and abuse of elderly and vulnerable adults: u.s. Preventive services task force recommendation statement. Ann Intern Med 2013; 158:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/98\">",
"      ACOG Committee Opinion No. 518: Intimate partner violence. Obstet Gynecol 2012; 119:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/99\">",
"      Pattishall AE, Cruz M, Spector ND. Intimate partner violence, mental health disorders, and sexually transmitted infections: important screening opportunities for pediatric healthcare providers. Curr Opin Pediatr 2011; 23:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/100\">",
"      Campbell JC, Lewandowski LA. Mental and physical health effects of intimate partner violence on women and children. Psychiatr Clin North Am 1997; 20:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31097/abstract/101\">",
"      Pynoos RS, Eth S. Witness to violence: The child interview. J Am Acad Child Adolesc Psychiatry 1986; 25:306.",
"     </a>",
"    </li>",
"    <li>",
"     Peled E, Davis D. Groupwork With Children of Battered Women: A Practitioner's Manual, Sage Publications, Thousand Oaks, CA 1995.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 591 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31097=[""].join("\n");
var outline_f30_23_31097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H245691900\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mental health",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Age-related",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sex-related",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cognitive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Parent-child interaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Parenting style",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Related to separation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Child abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long-term effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H631266552\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RADAR acronym",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Whom to screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      How to screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Who should ask",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mental health services",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Mandatory reporting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/591\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/591|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?33/31/34302\" title=\"algorithm 1\">",
"      Intimate partner violence screening algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/591|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/47/2812\" title=\"table 1\">",
"      Effects violence exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/3/22588\" title=\"table 2\">",
"      SSx exposure to intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/39/1662\" title=\"table 3\">",
"      RADAR acronym for pediatricians",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15561?source=related_link\">",
"      Date rape: Identification and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/15/6393?source=related_link\">",
"      Intimate partner violence: Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/54/14183?source=related_link\">",
"      Intimate partner violence: Intervention and patient management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_23_31098="Normal B and T lymphocyte development";
var content_f30_23_31098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Normal B and T lymphocyte development",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31098/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31098/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31098/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31098/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31098/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/23/31098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/23/31098/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/23/31098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1229438\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocyte development involves a complex series of tightly choreographed events. Current models are based on studies of genetically engineered mice, in vitro culture systems that support lymphoid development, and rare patients with genetic forms of immunodeficiency. The process is orchestrated by many different genes, which often act at specific stages of B or T cell differentiation. These genes variously encode several different types of factors, including lineage-specific transcription factors, growth factors, and chemokines; DNA recombinases (RAG1 and RAG2) and terminal deoxytransferase (TdT), which direct the rearrangement and diversification of B and T cell antigen receptor genes, respectively; and the DNA modifying enzyme activation-induced cytosine deaminase (AID), which is needed for immunoglobulin class-switching and the production of high affinity antibodies.",
"   </p>",
"   <p>",
"    Of clinical importance, many lymphoid malignancies appear to be the neoplastic counterparts of cells &ldquo;arrested&rdquo; at particular stages of lymphoid differentiation, as judged by cytologic appearance, patterns of growth, immunophenotype, and genetic features. This insight serves as the organizing theme for the current World Health Organization (WHO) Classification of Lymphoid Malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/1\">",
"     1",
"    </a>",
"    ], which sorts lymphoid tumors according to their apparent cell of origin.",
"   </p>",
"   <p>",
"    This topic review will focus on the early events of B and T cell development and provide a description of some of the markers that define both early and later stages of B and T cells. Development of the immune system in fetal and neonatal life is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31242?source=see_link\">",
"     \"The development of immune cells in the fetus and neonate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229463\">",
"    <span class=\"h1\">",
"     NORMAL LYMPHOID TISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoid tissues are subdivided into primary and secondary lymphoid organs. The primary lymphoid tissues responsible for the initial generation of B and T lymphocytes are the bone marrow and thymus, respectively.",
"   </p>",
"   <p>",
"    Secondary lymphoid tissues include lymph nodes, spleen, tonsils, and the aggregations of lymphoid tissue located in the gastrointestinal and respiratory tracts. Within these lymphoid organs, B and T lymphocytes inhabit highly organized tissues containing some areas in which B and T cells are largely segregated. Specifically, B cells mainly localize to follicles, whereas T cells mainly localize to interfollicular areas.",
"   </p>",
"   <p>",
"    In addition to lymphocytes, non-lymphoid cells (eg, dendritic cells,",
"    <span class=\"nowrap\">",
"     monocytes/macrophages,",
"    </span>",
"    histiocytes, endothelial cells, and follicular dendritic cells) contribute to the formation of distinct microenvironments. Within these areas, specific cell-cell interactions occur that are required for the generation of cellular and humoral immune responses.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229488\">",
"    <span class=\"h1\">",
"     ORIGIN OF LYMPHOID CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All white blood cells are derived from hemopoietic stem cells (HSCs). The embryonic origins of human HSCs remain somewhat controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/2\">",
"     2",
"    </a>",
"    ]. Blood forming cells first appear in the yolk sac around day 16 of gestation, but yolk sac hematopoiesis is largely restricted to the production of primitive red cells. It is believed that definitive HSCs arise in the dorsal aorta around the end of the third week of gestation. These HSCs appear to migrate to the liver, which becomes the main site of hematopoiesis after six weeks of gestation, and the placenta, which is the source of the HSCs that are found in cord blood. Progenitor cells from these tissues populate the thymus by seven to eight weeks of gestation. Bone marrow hematopoiesis commences by about five months of gestation and under normal circumstances is the primary source of hematopoietic cells after birth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The earliest committed hematolymphoid progenitors are derived through asymmetric cell divisions, in which undifferentiated HSCs give rise to daughter cells with greater proliferative potential but lacking the property of self-renewal. The events that lead to the appearance of cells that are committed to lymphoid differentiation are not completely understood. It is generally agreed that HSCs first give rise to multipotent progenitors (MPPs). In the bone marrow, some of these MPPs become committed to the B cell lineage, an event that requires certain transcription factors (eg, E2A and Pax5) and the suppression of Notch signaling, which otherwise overrides B cell differentiation programs and directs MPPs towards the T cell lineage. Other early progenitors in marrow (sometimes known as early thymic progenitors, or ETPs) migrate to the thymus, an organ rich in stromal cells expressing ligands that activate Notch signaling, which induces these cells to undergo T cell differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229513\">",
"    <span class=\"h1\">",
"     B CELL DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;New B cells are generated throughout life in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/3\">",
"     3",
"    </a>",
"    ], first in the liver during gestation and thereafter in the bone marrow. Early B cell development constitutes the steps that lead to B cell commitment and the expression of surface immunoglobulin, which is essential for B cell survival and function. These events culminate in the production of mature B cells, which leave the marrow and migrate to secondary lymphoid tissues, such as the lymph nodes, the spleen, and the Peyer's patches of the gut. Subsequent steps occur after B cells interact with exogenous antigen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T helper cells; these constitute the \"antigen-dependent phase\" that results in the generation of humoral immune responses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nomenclature used to describe these steps varies somewhat among authors, and depends in part on how finely one wishes to make distinctions between \"discrete\" developmental stages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/4\">",
"     4",
"    </a>",
"    ]. The earliest recognizable stage is called the B progenitor cell or pre-pro-B cell. Subsequent stages include the pro-B cell; the pre-B cell; the naive or mature B cell; several different types of antigen-activated B cell; the plasma cell; and the memory B cell.",
"   </p>",
"   <p>",
"    Even at the pro-B cell stage of development, lineage commitment is not complete, as these cells can be \"reprogrammed\" along a different pathway by combinations of cytokines and extracellular signals. As an example, progenitor B cells develop into dendritic cells when cultured with IL-1beta, IL-3, and IL-7, tumor necrosis factor, stem cell factor, and Flt-3 ligand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/5\">",
"     5",
"    </a>",
"    ]. The relevance of this finding to in vivo B cell or dendritic cell development is unclear.",
"   </p>",
"   <p>",
"    As a further complication, there is evidence that the program of B cell development that occurs early in life (prenatally and during the first few post-natal years of life) differs from the program of B cell development that predominates in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/6\">",
"     6",
"    </a>",
"    ]. The section that follows will focus on the stepwise events of early B cell development, acknowledging that there is uncertainty about some of the details.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229574\">",
"    <span class=\"h2\">",
"     Role of immunoglobulin gene rearrangements in B cell development",
"    </span>",
"    &nbsp;&mdash;&nbsp;As will be evident from the discussion below, productive rearrangement of the Ig heavy and light chain genes is an essential facet not only of mature B cell function but also of all but the earliest stages of B cell development. The germline DNA contains segments coding for different portions of the immunoglobulin molecule. For the immunoglobulin heavy chain, these consist of a very large number of variable (V) segments, a smaller number of diversity (D) segments, a few joining (J) segments, and a constant region for each subclass of immunoglobulin heavy chains (mu, gamma, alpha, delta, and epsilon). Light chain genes have a similar organization, but lack D segments. During early stages of B cell development functional rearrangement of the heavy chain gene locus (IgH) allows for assembly of the pre-B cell receptor complex. This complex transmits signals that lead to cessation of IgH rearrangements (a process termed allelic exclusion) and initiation of light chain rearrangements, first in the kappa light chain locus and then (if these are non-productive) the lambda light chain locus. Production of a complete immunoglobulin molecule comprised of two heavy chains and two light chains allows for assembly of the mature B cell receptor on the cell surface, which transmits signals that cause the cessation of light chain gene rearrangement and further maturation to the mature B cell stage. A detailed summary of this process is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229599\">",
"    <span class=\"h2\">",
"     Pro-B cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrinsic factors such as interleukins (IL)-3 and IL-7, insulin-like growth factor 1, and stem cell factor (SCF) promote the development of pro-B cells from earlier progenitors. The pro-B cell stage is denoted by the expression of Pax-5, a master transcription factor that is essential for not only the generation of pro-B cells, but also all subsequent stages of B cell development up to the plasma cell stage. Other events associated with this stage are expression of RAG1 and RAG2, which catalyze D-JH rearrangements within the immunoglobulin heavy chain gene loci, and the surface expression of CD19 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/7\">",
"     7",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef54590 \" href=\"mobipreview.htm?39/8/40076\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .) CD19 is a component of a multimolecular surface complex involved in signaling in response to antigen and T cell help [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/8\">",
"     8",
"    </a>",
"    ]. Pro-B cells also express HLA-DR (class II histocompatibility antigen) and CD34, a 115 kD type I transmembrane glycoprotein present on other very early hematopoietic progenitors that is probably involved in cytoadhesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229690\">",
"    <span class=\"h2\">",
"     Pre-B cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;During this stage of B cell development, immunoglobulin (Ig) heavy chain genes complete V-D-J recombination, allowing the surface expression of a complex consisting of an Ig heavy chain and molecules called surrogate light chains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] that show homology to Ig light chain V and C regions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .) Several of these genes have been identified in humans. VpreB is a non-rearranging gene encoding most of an Ig V domain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=see_link\">",
"     \"Structure of immunoglobulins\"",
"    </a>",
"    .) The other genes encoding surrogate light chains belong to a family called lambda 5 or lambda 5-like. The surrogate light chain genes are expressed only in pre-B cells, and the complex containing the Ig heavy chain and the surrogate light chain is called the pre-B cell receptor. Genetic defects that prevent expression of the pre-B cell receptor, or which prohibit the transduction of signals via the receptor, lead to an absence of B cells and agammaglobulinemia. Congenital agammaglobulinemia is associated with loss-of-function mutations in genes that encode components of the pre-B cell receptor or downstream signaling molecules. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      lambda 5 surrogate light chain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      CD79a [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/14\">",
"       14",
"      </a>",
"      ] (see below)",
"     </li>",
"     <li>",
"      CD79b [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bruton tyrosine kinase (BTK) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      B cell linker protein (BLNK) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ZAP-70, a 70-kDa Syk-family protein tyrosine kinase that is also expressed in T cells and natural killer cells, may also be required for pre-B cell receptor signaling, based on defects observed in ZAP-70 deficient mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The assembled pre-B cell receptor transmits pro-growth signals that result in a 32- to 64-fold expansion (five or six cell divisions) in cell numbers. It is not clear whether pre-B cell signaling is autonomous or follows receptor activation by a currently unknown ligand.",
"   </p>",
"   <p>",
"    A number of markers first appear during the pre-B cell stage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD79a and CD79b (Ig-alpha and Ig-beta, respectively), which associate non-covalently with surface Ig and constitute the signal transducing components of the pre-B cell receptor. Ig-alpha and Ig-beta are also components of the Ig receptors on the surface of mature B cells.",
"     </li>",
"     <li>",
"      CD10 (also known as common acute lymphoblastic leukemia antigen [CALLA], neutral endopeptidase 24.11, or enkephalinase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/19-22\">",
"       19-22",
"      </a>",
"      ]) is a zinc metalloprotease capable of inactivating a variety of peptide hormones including glucagon, enkephalin, atrial natriuretic peptide, substance P, oxytocin, bradykinin, neurotensin and angiotensins I and II, as well as f-Met-Leu-Phe.",
"     </li>",
"     <li>",
"      CD20 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/23\">",
"       23",
"      </a>",
"      ] is a tetraspan phosphoprotein that resides in lipid raft domains. CD20 functions as a Ca",
"      <sup>",
"       ++",
"      </sup>",
"      conductive ion channel that may regulate B cell activation and cell cycle progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       CD29/49d,",
"      </span>",
"      a member of the beta-1 integrin family of cell adhesion molecules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/25\">",
"       25",
"      </a>",
"      ]. It is involved in the adhesion of pre-B cells to bone marrow stromal cells via its ligands VCAM-1 and the extracellular matrix protein fibronectin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CD40, a member of the TNF receptor family, is a 50 kD phosphoprotein expressed on a subset of pre-B cells. CD40 is involved in growth regulation of B cells and immunoglobulin class switching [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/27\">",
"       27",
"      </a>",
"      ]. CD154, the ligand for CD40, is expressed on activated CD4+ T cells and is a member of the tumor necrosis alpha family [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/28\">",
"       28",
"      </a>",
"      ]. The CD40-CD154 interaction is central to the generation of humoral responses to T-dependent antigens. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"       \"The humoral immune response\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CD22, a member of the Ig superfamily, which binds to sialic acid-bearing molecules on other hematopoietic and non-hematopoietic cells. CD22 down-regulates antigen receptor signaling by recruiting other signaling molecules, including the SHP-1 tyrosine phosphatase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TdT (terminal deoxytransferase), a specialized DNA polymerase that adds random nucleotides to double-stranded DNA breaks created by RAG1 and RAG2, thereby contributing to the diversification of Ig genes. TdT is a sensitive marker for benign and malignant pre-B cells, but is not specific, as benign and malignant pre-T cells also express TdT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230059\">",
"    <span class=\"h2\">",
"     Mature B cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transition from the pre-B cell stage to the mature B cell stage is marked by successful rearrangement of either a kappa or lambda Ig light chain gene, which permits the expression of a complete IgM antibody molecule on the cell surface. If surface IgM interacts strongly with membrane-bound self-antigen (such as MHC) on other cells, then that B cell either dies by apoptosis or undergoes further Ig gene rearrangement (a process called receptor editing) to create a new Ig with a different specificity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .) Mature resting B cells continue to express HLA-DR, CD19, CD20, and CD40, but no longer express CD10, CD34, RAG1, RAG2, or TdT.",
"   </p>",
"   <p>",
"    Rearrangement of kappa light chain genes generates a by-product called a &ldquo;kappa recombination excision circle&rdquo; (KREC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/30\">",
"     30",
"    </a>",
"    ]. This is an episomal circular DNA fragment consisting of the DNA that was in between the Vkappa and Jkappa gene segments prior to rearrangement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link&amp;anchor=H2#H2\">",
"     \"Immunoglobulin genetics\", section on 'Immunoglobulin gene organization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The KREC does not replicate, but it is carried in the nucleus of one of the daughter cells arising from a round of B cell division. As a result, a larger fraction of B cells exiting the bone marrow have KRECs that are diluted as B cell clones expand by cell division in the periphery. A normal overall proportion of KREC-containing B cells is an indicator of ongoing development in the bone marrow. An abnormally low level of KRECs indicates some process that impedes B cell development. KREC measurement is undergoing development as a potential screening tool for defective B cell development in newborns or older individuals.",
"   </p>",
"   <p>",
"    After exiting the bone marrow, most mature B cells migrate to the secondary lymphoid organs &mdash; principally the lymph nodes, tonsils, spleen, Peyer's patches, and less well organized collections of lymphocytes that are found in the respiratory tract, GI tract, and the skin. These B cells enter tissue by binding to a specialized endothelium within small vessels known as high endothelial venules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/31\">",
"     31",
"    </a>",
"    ]. Two surface molecules, CD44 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/32-35\">",
"     32-35",
"    </a>",
"    ] and CD62-L (L-selectin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/36-39\">",
"     36-39",
"    </a>",
"    ], play important roles in lymphocyte extravasation. Once within organized secondary lymphoid tissues, mature B cells express both surface IgM and IgD, and well as other molecules that mediate cell-cell and cell-extracellular matrix adhesive interactions, including",
"    <span class=\"nowrap\">",
"     CD11a/CD18",
"    </span>",
"    (LFA-1) and",
"    <span class=\"nowrap\">",
"     CD29/49d",
"    </span>",
"    (VLA-4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surface immunoglobulin (sIg) mediates antigen binding and internalization for antigen presentation, and is also linked to signal transduction pathways that are triggered by receptor aggregation. The receptor complex consists of a transmembrane form of a complete Ig molecule and two heterodimers comprised of Ig-alpha (CD79a) and Ig-beta (CD79b) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=see_link\">",
"       \"Structure of immunoglobulins\"",
"      </a>",
"      .) The cytoplasmic portions of Ig-alpha and beta proteins contain short sequences called \"immunoreceptor tyrosine-based activation motifs\" (ITAMs). Similar sequences are found in the cytoplasmic portions of molecules constituting the T cell antigen receptor complex and the high affinity IgE Fc receptor. These motifs participate in protein:protein interactions that link Ig-alpha and Ig-beta to signaling pathways in the cytoplasm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/7\">",
"       7",
"      </a>",
"      ]. As mentioned above, Ig-alpha and Ig-beta are also required for pre-B cell receptor signaling in pre-B cells, and mutations in Ig-alpha or Ig-beta in humans are associated with a lack of B cell development and agammaglobulinemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CD11a (integrin alpha-L) is non-covalently associated with CD18 (integrin beta-2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/37\">",
"       37",
"      </a>",
"      ]. Within secondary lymphoid tissues,",
"      <span class=\"nowrap\">",
"       CD11a/CD18",
"      </span>",
"      mediates B cell binding to B cells, T cells, monocytes, and follicular dendritic cells via its ligand ICAM-1 (CD54). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=see_link\">",
"       \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CD20 is present on more than 95 percent of B cells in both peripheral blood and in secondary lymphoid organs. As mentioned previously, this molecule may function as a membrane ion channel that plays a role in B cell activation. Loss-of-function mutations in CD20 are associated with defects in T cell independent B cell responses to antigen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/42\">",
"       42",
"      </a>",
"      ]. CD19 and CD20 are the markers most often used to enumerate B cells in routine clinical applications of flow cytometry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/43\">",
"       43",
"      </a>",
"      ]. In addition, the anti-CD20 antibody,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , is a widely used therapy for several malignant and autoimmune diseases; this antibody kills B cells, both by fixing complement and initiating antibody-dependent cell-mediated cytotoxicity, and its use leads to a transient reduction in B cell numbers and hypogammaglobulinemia.",
"     </li>",
"     <li>",
"      CD19 and CD21 occur on the B cell membrane in a complex with CD81 (TAPA-1) and interferon induced transmembrane protein 1 (IFITM1, also known as CD225) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/8\">",
"       8",
"      </a>",
"      ]. This complex has an important role in lowering the signaling threshold of the Ig receptor complex. CD21 is also the receptor for the C3d complement fragment and for the Epstein-Barr virus (EBV). CD21 is found on the majority of resident B cells within secondary lymphoid tissues, but is infrequently expressed on B cells in the peripheral blood. Signaling via CD21 is important in B cell activation, in the development of B cell memory, and in regulating the production of autoantibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/44\">",
"       44",
"      </a>",
"      ]. EBV can infect B cells via CD21, and this property has been exploited to transform cultured peripheral blood mononuclear cells into cell lines that will grow indefinitely, providing useful tools to study a variety of aspects of B cell biology. In addition to CD21, B cells also express CD35, which is the C3b complement receptor 1. B cells can utilize these complement receptors to bind immune complexes, an event that can lead to B cell activation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=see_link\">",
"       \"Regulators and receptors of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CD29 (integrin beta-1) associates with CD49d (integrin alpha-4) to form VLA-4 that mediates adhesion of activated B cells to follicular dendritic cells in germinal centers through binding to its ligand VCAM-1 (CD106) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/45\">",
"       45",
"      </a>",
"      ]. Follicular dendritic cells in the germinal centers stimulate B cell growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CD40 is a receptor for CD154 (CD40 ligand), which is expressed on activated T cells. CD40 plays a central role in antigen-dependent B cell development in lymphoid tissues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"       \"The humoral immune response\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mature B cells express many other surface molecules as well, some of which are restricted to the B cell lineage (",
"    <a class=\"graphic graphic_table graphicRef78500 graphicRef57546 \" href=\"mobipreview.htm?27/16/27918\">",
"     table 2A-B",
"    </a>",
"    ). This table also shows the temporal sequence of the expression of some of the markers used to follow B cell development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230519\">",
"    <span class=\"h2\">",
"     B cell subsets",
"    </span>",
"    &nbsp;&mdash;&nbsp;All mature B cells have immunoglobulin receptors and express CD19 and CD20, but can be divided into subgroups based on expression of other surface markers (",
"    <a class=\"graphic graphic_table graphicRef68762 \" href=\"mobipreview.htm?17/0/17420\">",
"     table 3",
"    </a>",
"    ). These subsets are functionally distinct and may have different roles in the immune system. There is some evidence that these subsets diverge prior to immunoglobulin gene rearrangement at very early stages of B cell development.",
"   </p>",
"   <p>",
"    B cells have been classified into two major types:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CD5- (or \"conventional\" B cells, also called B-2 cells)",
"     </li>",
"     <li>",
"      CD5+ (also called B-1 cells, which are further subdivided into B-1a and B-1b)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CD5 is expressed by T cells and some B cells. A ligand for CD5 on human B cells is CD72, a cell surface molecule of unknown function that is also expressed on B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/48\">",
"     48",
"    </a>",
"    ]. The functions of CD5 and CD72 on B cells are not known. There are data from mice suggesting that CD5 acts to suppress signaling via the Ig receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each of these B cell populations is distinct with respect to its immunophenotype, requirements for activation, and responses to ligation of certain receptors. However, B-1b cells have some characteristics in common with both B-1a and B-2 cells (",
"    <a class=\"graphic graphic_table graphicRef68762 \" href=\"mobipreview.htm?17/0/17420\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CD5+ (B-1a) subset is prominent early in ontogeny, as CD5 is expressed on the following cells:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Almost all fetal liver B cells",
"     </li>",
"     <li>",
"      40 to 60 percent of fetal spleen B cells",
"     </li>",
"     <li>",
"      60 to 80 percent of umbilical cord blood B cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adults, 5 to 30 percent of B cells in the peripheral blood are B-1a cells, 4 to 6 percent are B1-b cells, and 65 to 89 percent are B-2 cells. CD5+ B cells are also prominent in the peritoneal cavity (19 to 76 percent), and can be found in the lymph nodes and in the spleen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B-1a cells appear to be a self-renewing population of cells that is primed to produce polyreactive low affinity antibodies (\"natural antibody\") that interact with a wide variety of foreign and self antigens. These include IgG Fc, single-stranded DNA, thyroglobulin, insulin, E. coli beta-galactosidase, and tetanus toxoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/55\">",
"     55",
"    </a>",
"    ]. These self-reactive antibodies are predominantly encoded by Ig genes that carry few, if any, somatic mutations, consistent with the view that B-1a cells do not pass through germinal centers or experience a germinal center reaction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .) Most B-1a cells produce IgM antibodies. Despite having some self-reactivity, these antibodies occur in healthy individuals and are not themselves pathogenic. They may have a beneficial role in host defense through their IgG-binding (rheumatoid factor) activity, which could enhance immune complex formation, complement lysis, or opsonization and phagocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. These antibodies may also assist in homeostasis by binding to aging and apoptotic cells and cellular debris, which if not cleared might be proinflammatory and immunogenic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40792?source=see_link&amp;anchor=H4#H4\">",
"     \"Function and clinical applications of immunoglobulins\", section on 'Antibody specificity and cross-reactivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has also been suggested that CD5+ B cells have a relatively greater role in the primary immune response to antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/59\">",
"     59",
"    </a>",
"    ]. This stems from their capacity to rapidly differentiate into antibody-secreting plasma cells following activation (described below), thus providing some measure of humoral immunity during the week or so lag between initial exposure to antigen and the appearance of specific high-affinity antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B cells circulate as resting cells for some weeks. If they are not activated within that period of time, they die by apoptosis and are replaced by new B cells. The antigen-dependent phase of B cell development is synonymous with the generation of the humoral immune response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230750\">",
"    <span class=\"h2\">",
"     B cell activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to Ag or various polyclonal mitogens activates resting B cells and stimulates their proliferation. Activated B cells lose expression of sIgD and CD21, and acquire expression of other proteins termed activation antigens, which fall into several classes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Growth factor receptors",
"     </li>",
"     <li>",
"      Structures involved in cell-cell interaction",
"     </li>",
"     <li>",
"      Molecules that play a role in the localization and binding of activated B cells within various microenvironments",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific activation antigens include the following proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD71, the transferrin receptor, which is expressed on all proliferating cells.",
"     </li>",
"     <li>",
"      CD25, the 55 kD Tac Ag, is the alpha chain of the IL-2 receptor (high affinity); it is present on activated B cells, T cells and monocytes.",
"     </li>",
"     <li>",
"      CD23, a 45 kD glycoprotein, is the low affinity receptor for IgE; a soluble form is reported to have B cell growth promoting activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31848?source=see_link\">",
"       \"The biology of IgE\"",
"      </a>",
"      .) Monoclonal antibodies against CD23 inhibit IgE production [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CD80 and CD86 are glycoprotein members of the Ig gene superfamily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/63\">",
"       63",
"      </a>",
"      ]. These molecules are ligands for the T cell Ag CD28 and provide a costimulatory signal to T cells critical for optimal T cell activation and proliferation following presentation of antigen in the context of MHC to the T cell receptor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27283?source=see_link\">",
"       \"Major histocompatibility complex (MHC) structure and function\"",
"      </a>",
"      .) This signal leads to augmented cytokine secretion, including IL-2, which optimizes T cell help to B cells. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"       \"The humoral immune response\"",
"      </a>",
"      .) Subsequent to CD28 expression, T cells express CTLA-4, which interacts with CD80 and CD86 to turn off the T cell response.",
"     </li>",
"     <li>",
"      Following activation, B cells also express Fas (CD95), another member of the tumor necrosis factor (TNF) receptor family. Binding of Fas to its natural ligand (Fas ligand, FasL, CD95L), expressed on activated T cells, triggers apoptotic cell death. Thus, Fas regulates clonal expansion of autoreactive B cells. Fas is present on germinal center B cells and B cells in sinusoids of lymphoid tissues, but only weakly on precursor B cells, mature sIgD+ naive B cells, and plasma cells. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5735?source=see_link\">",
"       \"Apoptosis and autoimmune disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1230945\">",
"    <span class=\"h2\">",
"     Maturation of activated B cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paths that B cells follow after activation varies depending on whether they concomitantly receive co-signals from antigen-activated T cells. B-1b and B-2 cells are preferentially activated by T cells. T cell-activated B cells migrate under the influence of chemokines to the mantle zone of germinal centers where they acquire CD5 expression transiently, and then enter the germinal center.",
"   </p>",
"   <p>",
"    Activated germinal center B cells are large rapidly dividing cells that express activation-induced cytosine deaminase (AID) and uracil nucleoside glycosylase (UNG), DNA modifying enzymes that mediate somatic mutation of the Ig genes (somatic hypermutation). However, AID is error-prone and germinal center B cells have a higher than normal mutation rate involving other genomic loci as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/64\">",
"     64",
"    </a>",
"    ]. One gene that is often mutated at a high rate in normal germinal center B cells encodes the transcription factor Bcl-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/64\">",
"     64",
"    </a>",
"    ], a master regulator that is required for the formation of B cell follicles. Follicular B cells re-express CD10 and also turn on expression of several other antigens, such as GCET1, which have been used to sub-classify tumors of follicular B cell origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most follicular B cells die, but a few that express antibodies that recognize antigen with high affinity receive survival signals through the Ig receptor. These cells next undergo Ig class switching, an event also requiring AID that permits B cells to express Ig molecules other than IgM. Class switching is influenced by cytokines; for example, in the presence of high levels of TGF-beta, B cells preferentially switch to IgA heavy chain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/66\">",
"     66",
"    </a>",
"    ]. The hyper-IgM syndrome is a rare human immunodeficiency state characterized by a failure of Ig class switching and a marked hyperplasia of germinal center B cells. It is caused by loss-of-function mutations in AID, UNG, CD40, or CD40L [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/67\">",
"     67",
"    </a>",
"    ]. Following class switching, B cells leave the germinal center and either undergo terminal differentiation into plasma cells or enter into the long-lived memory B cell pool.",
"   </p>",
"   <p>",
"    In the absence of T cell help, activated B cells rapidly mature into short-lived plasma cells without undergoing somatic hypermutation or class switching. As a result, these cells secrete IgM antibodies of low affinity. B cells that fail to receive T cell help do not contribute to memory B cell pools. B-1 B cells may preferentially follow this &ldquo;non-follicular&rdquo; differentiation pathway, as they appear to be much less dependent on T cell help for antibody production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231030\">",
"    <span class=\"h2\">",
"     Plasma cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma cell is large, up to 20 microns in diameter, and secretes antibodies prodigiously, although it has few antibody molecules on its surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/68\">",
"     68",
"    </a>",
"    ]. Plasma cells that arise from follicular B cells are found mainly in the bone marrow and are long-lived (months), whereas plasma cells arising from non-follicular B cells have life spans of only days to a few weeks. Plasma cell differentiation is accompanied by the loss of Bcl-6, Pax-5, CD19, CD20, and B cell activation antigens, and the appearance of the transcription factors X-box binding protein 1 (XBP-1) and PR domain-containing protein 1 (PRDM1, also called B-lymphocyte-induced maturation protein 1 [BLIMP-1] and positive regulatory domain I-binding factor [PRDIBF1]); cytoplasmic Ig (cIg); and the antigens CD38 and syndecan-1 (CD138) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD38 is a cell surface glycoprotein also present on thymocytes, immature myeloid cells, and subsets of hematopoietic stem cells. CD38 is ADP-ribosyl cyclase whose substrate is nicotinamide adenine dinucleotide (NAD). In addition to its enzymatic function, CD38 is involved in Ca",
"      <sup>",
"       ++",
"      </sup>",
"      mobilization, signal transduction, and adhesion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CD138, also called syndecan-1, is a heparan sulphate proteoglycan that acts as an adhesion molecule; it serves as a useful diagnostic marker for plasma cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231087\">",
"    <span class=\"h2\">",
"     Memory B cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The memory B cell is identical in appearance to resting mature B cells. It is unclear what factors influence a B cell to become a memory cell rather than a plasma cell. Memory cells are more sensitive to antigen stimulation, and proliferate and generate plasma cells more rapidly than do mature B cells. These plasma cells are responsible for the rapid appearance of high affinity antibodies in secondary immune responses. The life span of the memory cell is not precisely known, but they may persist for years, if not decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recall that mature na&iuml;ve B cells express surface IgM and IgD. After activation, B cells no longer express IgD. If a memory B cell underwent class-switching in a germinal center (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    ) it will express either IgG, IgA, or IgE on the surface. If not, it retains expression of IgM and IgD (&ldquo;unswitched&rdquo;). Memory B cells also express CD27. CD27 is a member of the TNF receptor superfamily (TNFRSF7) and its ligand, CD70 (TNFSF7), is expressed on activated T and B cells. This interaction modulates memory B cell activation. Using these markers, one may distinguish several subsets of B cells:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mature na&iuml;ve B cells &mdash; IgM+IgD+CD27-",
"     </li>",
"     <li>",
"      Unswitched memory B cells &mdash; IgM+IgD+CD27+",
"     </li>",
"     <li>",
"      Switched memory B cells &mdash; IgM-IgD-CD27+",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alterations in these subsets may have significant clinical associations in some forms of humoral immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9688?source=see_link\">",
"     \"Pathogenesis of common variable immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More information on antigen-dependent B cell development is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231136\">",
"    <span class=\"h1\">",
"     T CELL DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The developmental progression from the hemopoietic stem cell through the various lineages of T cells is discussed here. The genetics of the T cell receptor (TCR), and the cellular interactions in T cell activation and effector mechanisms are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231171\">",
"    <span class=\"h2\">",
"     T cell lineages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority (usually &gt;95 percent) of circulating T cells express a receptor containing chains designated alpha and beta",
"    <span class=\"nowrap\">",
"     (TCRalpha/beta,",
"    </span>",
"    also called TCR2). The remainder expresses receptors comprised of homologous chains called gamma and delta",
"    <span class=\"nowrap\">",
"     (TCRgamma/delta,",
"    </span>",
"    or TCR1) (",
"    <a class=\"graphic graphic_figure graphicRef75287 \" href=\"mobipreview.htm?29/60/30670\">",
"     figure 1",
"    </a>",
"    ). Additional discussion of the alpha, beta, gamma, and delta genes and molecules can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    .) Gamma-delta and alpha-beta T cell development diverge at early stages of intrathymic development, and mature alpha-beta and gamma-delta T cells differ in their tissue distribution, mechanisms of antigen recognition, requirements for activation, and roles in immune responses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vast majority of T cells develop in the thymus, while a distinct population develops in the intestinal lamina propria. The details of extrathymic T cell development and the relationship of extrathymic T cells to their more numerous thymus-derived counterparts are still obscure. T cell development is more completely understood in the mouse due to its widespread use in experimental immunologic studies, but a very similar set of events is believed to occur during the intrathymic development of human T cells. An overall scheme of thymic T cell development, based on work performed in the mouse, is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef76102 \" href=\"mobipreview.htm?21/33/22047\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231244\">",
"    <span class=\"h2\">",
"     Origins of thymocyte progenitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the prethymic phase, pluripotent stem cells develop into lymphoid progenitor cells capable of becoming T cells. Such progenitors initially appear in the liver by about six weeks of gestation, and then shift by about five months of gestation to the bone marrow, which is the major source of T cell progenitors throughout the remainder of life. Progenitor cells reach the thymus via the blood, entering into the thymus through venules near the corticomedullary junction and then migrating to the outer cortex.",
"   </p>",
"   <p>",
"    Certain cell-surface molecules serve as markers of T cell differentiation (",
"    <a class=\"graphic graphic_figure graphicRef76102 \" href=\"mobipreview.htm?21/33/22047\">",
"     figure 2",
"    </a>",
"    ). The marker that is expressed earliest in bone marrow progenitors is CD7. As with very early B cell progenitors, early cells expressing CD7 are not yet committed to the T cell lineage. The role of CD7 in T cell differentiation is unknown. It may be a ligand for a complex family of glycoproteins called galectins, whose physiological functions are still unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/76\">",
"     76",
"    </a>",
"    ]. Some CD7+ cells also express CD34, a marker of hematopoietic stem cells and early T, B, and myeloid cell progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231299\">",
"    <span class=\"h2\">",
"     Intrathymic regulatory factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of highly specialized types of epithelial cells play critical roles in thymic T cell development. They are classified based upon location within the thymus, physical appearance, surface staining characteristics, and secreted products (",
"    <a class=\"graphic graphic_table graphicRef77368 \" href=\"mobipreview.htm?16/56/17291\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. The biology of these cells is still poorly understood, although common progenitors have been identified in mice. If the same is true in humans, it may be possible to use these cells in thymic culture systems to create therapeutic T cells from undifferentiated progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interactions between thymic epithelial cells (TEC) and developing T cells (thymocytes) are mediated by specific membrane ligands, and by secreted factors (a broad array of cytokines and neuropeptides). Among the most important ligands are DLL4 and Jagged2, which activate the Notch1 receptor on early T cell progenitors. Notch signaling is essential for commitment of early progenitors to T cell fate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/82\">",
"     82",
"    </a>",
"    ]. In its absence, T cell differentiation fails to occur and increased B cell development occurs instead within the thymus. Conversely, constitutive activation of Notch1 in the bone marrow compartment leads to a failure of B cell development and ectopic T cell development. The cytokine interleukin-7 (IL-7) is also produced by thymic epithelial cells and contributes to the proliferative burst that occurs early in intrathymic T cell development (",
"    <a class=\"graphic graphic_figure graphicRef76102 \" href=\"mobipreview.htm?21/33/22047\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/83\">",
"     83",
"    </a>",
"    ]. In fact, both B and T cell development is completely blocked in the absence of functional IL-7 receptor, which leads to a form of severe combined immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/84\">",
"     84",
"    </a>",
"    ]. TECs and thymocytes also respond to endocrine and neural signals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/85\">",
"     85",
"    </a>",
"    ]. Thymic development depends upon intact pituitary and thyroid function, while overproduction of gonadal or adrenal steroids may lead to thymic involution due to the steroid sensitivity of developing T cells.",
"   </p>",
"   <p>",
"    Thymic epithelial cells also produce a variety of thymus-specific hormones and cytokines required for T cell differentiation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thymopoietin (TP) refers to three protein isoforms generated by differential mRNA splicing of transcripts expressed from a single gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/86\">",
"       86",
"      </a>",
"      ]. TP promotes T cell development, inhibits B cell development, interacts with acetylcholine receptors, and stimulates release of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/62/2023?source=see_link\">",
"       adrenocorticotropic hormone",
"      </a>",
"      and beta-endorphin by the pituitary gland.",
"     </li>",
"     <li>",
"      The thymosins are a group of low molecular weight (3-4 kD) proteins that also promote thymic T cell differentiation.",
"     </li>",
"     <li>",
"      Thymulin is a zinc-binding nonapeptide that potentiates signaling through the IL-2 receptor, and promotes development of IL-2 receptor-positive thymocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The roles of all of these molecules in T lymphocyte differentiation still require clarification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231468\">",
"    <span class=\"h2\">",
"     Intrathymic T cell development",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general scheme of T cell development in the thymus is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef76102 \" href=\"mobipreview.htm?21/33/22047\">",
"     figure 2",
"    </a>",
"    ). Once early T cell progenitors take up position in the outer cortex, they enlarge and begin to proliferate rapidly. These immature precursors represent only 2 to 3 percent of the total number of cells within the thymus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/87\">",
"     87",
"    </a>",
"    ]. After the proliferative phase, cells take on the appearance of small resting lymphocytes, and migrate through the cortex toward the medulla. In addition to Notch and IL-7, a broad array of additional cytokines and chemokines as well as adhesion molecules and components of the extracellular matrix act in concert to guide thymocyte development and migration through the thymus, a complex process that is still being unraveled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/88\">",
"     88",
"    </a>",
"    ]. Importantly, about 95 percent of cortical cells die as a result of selective processes (see below) before they reach the medulla.",
"   </p>",
"   <p>",
"    Thymocytes at different stages of development can be identified by the expression of various surface molecules. As mentioned above, the most immature thymocytes are CD7+. In addition to these markers (",
"    <a class=\"graphic graphic_figure graphicRef76102 \" href=\"mobipreview.htm?21/33/22047\">",
"     figure 2",
"    </a>",
"    ), early T cell precursors express CD2, an adhesion molecule important in intercellular contacts between T cells and other cells participating in immune responses. As thymocytes mature further they begin to express CD1, a molecule homologous to MHC class I, which may interact with glycolipid antigens and present them to gamma-delta T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/89\">",
"     89",
"    </a>",
"    ]; its role in T cell development is unknown.",
"   </p>",
"   <p>",
"    In the early stages of development, thymocytes are called double negative (DN) since they express neither CD4 nor CD8 (see below). During this time,",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    and beta chain gene rearrangement is occurring. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    .) There are four DN stages (DN1-DN4) distinguished by expression of CD44 and CD25 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/87\">",
"     87",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef76102 \" href=\"mobipreview.htm?21/33/22047\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    CD44 is a hyaluronan receptor and ligand for E-selectin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/90\">",
"     90",
"    </a>",
"    ], while CD25 is the alpha chain of the receptor for IL-2 (IL-2R) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/91\">",
"     91",
"    </a>",
"    ]. The DN3 stage is a critical developmental checkpoint during",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell development. At this stage the cells express the",
"    <span class=\"nowrap\">",
"     RAG1/RAG2",
"    </span>",
"    DNA recombinase and have rearranged their TCR beta genes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .) Cells with productive rearrangements express TCR beta chains in complex with pre-TCR-alpha, a pseudo-alpha chain that functions much like surrogate light chains during pre-B cell development (",
"    <a class=\"graphic graphic_figure graphicRef75287 \" href=\"mobipreview.htm?29/60/30670\">",
"     figure 1",
"    </a>",
"    ). The pre-TCR complex associates with the CD3 complex and transmits signals that drive proliferation and promote cell survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Cells that fail to successfully rearrange their TCR-beta genes arrest and die at the DN3 stage. There are also data to suggest that the presence of an invariant chain of CD3, the delta chain, is essential for T cell development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signaling via the pre-TCR triggers the expression of CD4 and CD8 (ie, the transition to double-positive (DP) stage), allelic exclusion of the TCR beta chain gene locus, rearrangement of the TCR alpha genes, and cellular expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    .) No ligand for the pre-TCR has been identified, and T cells can develop with a pre-TCR that has no external domains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/93\">",
"     93",
"    </a>",
"    ], suggesting that pre-TCR signaling is cell autonomous.",
"   </p>",
"   <p>",
"    If a thymocyte does not produce any functional alpha chains, it cannot develop further, and dies via apoptosis (so-called programmed cell death) after three to four days. If alpha gene rearrangement is successful, alpha chains assemble with beta chains and are expressed on the surface as a complete alpha-beta TCR-CD3 receptor complex. The CD4 and CD8 antigens next appear at low levels on the surface, and the cell has the phenotype TCRloCD3loCD4loCD8lo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231735\">",
"    <span class=\"h2\">",
"     T cell co-receptors CD4 and CD8",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surface antigens CD4 and CD8 distinguish two major subsets of T cells. Normal mature cells express either one of these molecules, but not both. The CD8 antigen is required for T cell interaction with cells expressing MHC class I molecules, while CD4 is necessary for interaction with cells expressing MHC class II. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD4 is a 55 kD transmembrane glycoprotein encoded by a gene on chromosome 12. It is a member of the immunoglobulin (Ig) superfamily and has four extracellular Ig-like domains. The outermost two domains of CD4 interact with a monomorphic determinant of MHC class II molecules.",
"     </li>",
"     <li>",
"      CD8 is made up of two polypeptides designated alpha and beta. Both chains have a Mr of 32 kD and are encoded by genes on chromosome 2. Most CD8 on T cells is in the form of alpha-beta heterodimers, but it also occurs as an alpha2 homodimer. Both forms are functional, but behave differently with respect to signal transduction and their roles in T cell development. CD8 binds to the membrane-proximal domain of MHC class I molecules.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cytoplasmic domains of both CD4 and CD8 are associated with the protein tyrosine kinase Lck, a member of the src family of tyrosine kinases. CD4 and CD8 associate with Lck in slightly different fashions, but both molecules are important co-stimulators in T cell activation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism whereby gamma-delta or alpha-beta lineage commitment is determined is unknown. There are data to suggest that expression of a functional gamma-delta receptor precludes further development along the alpha-beta path [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231784\">",
"    <span class=\"h2\">",
"     Late thymic phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cells that fail to interact with self-MHC die by apoptosis. Following positive selection (see below), the T cells become DP cells (ie, TCRhiCD3hiCD4hiCD8hi). At this stage, alpha gene rearrangement ceases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .) DP cells are the targets of the selective processes that establish the repertoire of TCR specificities. In the final phase of thymic T cell development, cells become single-positive (SP), ie, they express only CD4 (MHC class II-restricted) or CD8 (MHC class I-restricted) (",
"    <a class=\"graphic graphic_figure graphicRef76102 \" href=\"mobipreview.htm?21/33/22047\">",
"     figure 2",
"    </a>",
"    ). What regulates the transition of thymocytes from DP to SP is not known. The process may be either random or controlled by specific cellular interactions. Neither the random nor the instructive models have been firmly established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231827\">",
"    <span class=\"h1\">",
"     T CELL REPERTOIRE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of the T cell repertoire is identical to that of the B cell repertoire. (See",
"    <a class=\"local\" href=\"#H1229513\">",
"     'B cell development'",
"    </a>",
"    above.) However, due to the different ways in which B cells and T cells interact with antigen, the set of antigenic determinants recognized by each cell type is different (although not necessarily mutually exclusive, as some epitopes may be recognized by both) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/95\">",
"     95",
"    </a>",
"    ]. In order for the immune system to be effective, T cells must be able to recognize the multitude of foreign molecules the body encounters without attacking self.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231865\">",
"    <span class=\"h2\">",
"     Positive selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MHC molecules expressed in the thymus determine the spectrum of antigens that T cells can recognize, a limitation referred to as MHC restriction. This same restriction extends to the ability of T cells to cooperate in immune responses, for example, in providing help to B cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MHC restriction results from the process of positive selection in the thymus (positive because T cells live as a result). Positive selection is mediated mainly through weak interactions between TCRs expressed on thymocytes and self-peptides presented through MHC antigens expressed on thymic epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/96\">",
"     96",
"    </a>",
"    ], many of which are of neural crest origin. Positive selection rescues thymocytes from programmed cell death, which is the fate of the vast majority of developing T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231902\">",
"    <span class=\"h2\">",
"     Negative selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative selection results from high affinity interactions of developing T cells with self-peptides presented on MHC antigens. This process prevents the survival of T cells that, if released into the periphery, could activate autoimmune responses. Bone marrow-derived antigen-presenting cells (eg, thymic dendritic cells, macrophages) appear to be important in negative selection.",
"   </p>",
"   <p>",
"    As a result of positive and negative selection, only 1 to 5 percent of thymocytes exit the thymus as mature T cells; the remainder die [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231927\">",
"    <span class=\"h2\">",
"     The mature phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mature thymocytes exit the thymus through venules in the medulla and recirculate through the blood, secondary lymphoid organs and lymph, surveying the body for foreign antigens.",
"   </p>",
"   <p>",
"    Thymic output of T cells can be evaluated with T cell-receptor rearrangement excision circle (TREC) analysis. These are analogous to the kappa rearrangement excision circles (KRECs) described above. (See",
"    <a class=\"local\" href=\"#H1230059\">",
"     'Mature B cells'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    TRECs are formed during TCR rearrangement in the thymus when loops of DNA are excised from the chromosome. These excision circles are stable and are not replicated during subsequent mitoses; hence, they are diluted out in the peripheral blood T cell compartment with each cell division. Cell populations with high numbers of TRECs are recent thymic emigrants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. TREC measurement in dried blood spots is an established method of newborn screening for severe autologous T cell lymphopenia (severe combined immunodeficiency, or SCID) and is already available in several states in the USA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link&amp;anchor=H6#H6\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Newborn screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T cells have a long life span. Upon antigen stimulation, T cells enlarge and undergo rapid proliferation. After stimulation, T cells become effector cells. Some types of T cell may also become memory cells, analogous to memory B cells. These aspects of the antigen-dependent development of T cells are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231972\">",
"    <span class=\"h2\">",
"     Development of gamma-delta cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma-delta receptor-bearing T cells are the first to appear during ontogeny in all species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/94\">",
"     94",
"    </a>",
"    ]. Mature gamma-delta T cells are mainly DN cells (expressing neither CD4 nor CD8) and do not pass through the same DP stage of development as alpha-beta T cells. As with alpha-beta T cells, some speculate that the TCRs of gamma-delta T cells generate autonomous signals that drive cells through certain developmental checkpoints. While the development of gamma-delta T cells clearly requires signals mediated by gamma-delta TCRs, these signals appear to be qualitatively very different from those that drive alpha-beta cell development.",
"   </p>",
"   <p>",
"    Gamma-delta T cells undergo little cellular expansion within the thymus, but may expand considerably in the periphery. The extent to which gamma-delta T cells undergo positive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    negative selection is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/94\">",
"     94",
"    </a>",
"    ]. Some reports support the existence of versions of these processes that are involved in gamma-delta T cell development, but the experimental systems are not clearly physiologic in many instances. One study strongly suggests that an autosomal dominant gene variant expressed in the thymus can mediate positive selection of a population of murine cutaneous gamma-delta T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232021\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF MATURE T CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section applies principally to cells expressing alpha-beta TCRs. Mature T cells are small lymphocytes with an appearance identical to other lymphocyte subpopulations. They recirculate continually from blood to lymphoid tissues to lymph, awaiting contact with antigen presenting cells that bear a complementary peptide-MHC complex.",
"   </p>",
"   <p>",
"    All mature thymocytes and peripheral blood T cells bear the CD2, CD3- T-cell receptor complex, CD5, and CD28 antigens (",
"    <a class=\"graphic graphic_table graphicRef50154 \" href=\"mobipreview.htm?40/17/41243\">",
"     table 5",
"    </a>",
"    ). Other surface molecules such as CD4 and CD8, as well as cytokine and chemokine receptors serve to differentiate several functionally distinct subpopulations of mature T cells. As described above, these subsets may differ in their interactions with various classes of self-histocompatibility proteins. In addition, they may have very different functions in immune responses.",
"   </p>",
"   <p>",
"    Two principal categories of T cells have been defined: T cells that modulate the activity of B cells and other T cells (helper T cells), and effector cells mediating cellular immune responses (cytotoxic T cells). Most regulatory T cells express CD4, and most cytotoxic T cells express CD8, but exceptions exist. Cytotoxic T cells expressing CD4 are prominent in graft rejection and have also been observed in tumor immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/102\">",
"     102",
"    </a>",
"    ]. Cytokine producing cells expressing CD8 may also be seen in certain normal or pathological immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232084\">",
"    <span class=\"h2\">",
"     Cytotoxic T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic T cells (Tc) express mainly CD8, and lyse autologous cells bearing foreign antigen molecules associated with class I histocompatibility proteins or cells that are allogeneic with respect to MHC class I. A discussion of alloreactivity can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232109\">",
"    <span class=\"h2\">",
"     Modulatory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most modulatory T cells express CD4 and recognize antigens associated with self-MHC class II molecules. Subtypes of CD4+ T cells have been defined, including Th1 and Th2 T helper cells, T regulatory cells (Tregs), Th9 cells, and Th17 cells. These cells are distinguished by the cytokines they produce and by certain surface markers. An \"undifferentiated\" mature T cell, referred to as Th0, may develop into various kinds of effector cells, depending upon the cytokines they are exposed to during antigen stimulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232122\">",
"    <span class=\"h3\">",
"     Th1 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th1 cells predominantly generate delayed hypersensitivity reactions, although they also can provide B cell help. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232147\">",
"    <span class=\"h3\">",
"     Th2 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th2 are prominent helpers for antibody production, especially IgE responses, and promote eosinophil development and activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31848?source=see_link&amp;anchor=H264545938#H264545938\">",
"     \"The biology of IgE\", section on 'Regulation of synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232172\">",
"    <span class=\"h3\">",
"     Regulatory T cells (Tregs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tregs are distinguished by expression of the transcription factor FoxP3, which appears to be a \"master\" gene for the development and function of this type of T cell. Tregs also express CD25 (the IL-2 receptor alpha chain) and are dependent on IL-2. CD4+CD25+FoxP3+ Tregs are important in countering the development of allergic and autoimmune disease, as FoxP3 mutant mice and humans develop airway inflammation, eosinophilia, and elevated serum IgE levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25850?source=see_link\">",
"     \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\"",
"    </a>",
"    .) Tregs have also been implicated in the prevention of graft rejection and graft versus host disease (GVHD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/43/44729?source=see_link&amp;anchor=H3#H3\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\", section on 'Regulatory T cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24003629\">",
"    <span class=\"h3\">",
"     Th9 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th9 cells are newcomers to the pantheon of T cell subsets that are still being functionally characterized. These cells express IL-9 and have been implicated in tumor immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232221\">",
"    <span class=\"h3\">",
"     Th17 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th17 cells are proinflammatory T cells implicated in the cell-mediated cytotoxicity of some autoimmune diseases, many of which were formerly thought to be Th1-mediated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. Th17 cells produce IL-17, IL-22, IL-26, IFN-gamma, and CCL20 and express IL-23 receptor and CD45RO. In humans, differentiation of Th0 cells into Th17 cells requires exposure to IL-1beta and either IL-23 or IL-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/110-112\">",
"     110-112",
"    </a>",
"    ]. ROR-gamma t is a transcription factor that regulates this T cell subset. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of cytokines in rheumatic diseases\", section on 'Rheumatoid arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Th17 cells may have some role in certain types of asthma, although patients with Th17-mediated asthma are not atopic and inflammatory cells in the airway are predominately neutrophils, rather than eosinophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/113\">",
"     113",
"    </a>",
"    ]. Th17 cells may also be involved in allergic rhinitis and conjunctivitis, food protein induced enterocolitis, atopic dermatitis, contact dermatitis, and are essential for effective mucosal immunity against fungi (eg, Candida species) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/112,114\">",
"     112,114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1265604\">",
"    <span class=\"h2\">",
"     Na&iuml;ve T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD45, also called &ldquo;leukocyte common antigen,&rdquo; is a protein tyrosine phosphatase that has a critical role in T cell activation via the dephosphorylation of the tyrosine kinase Lck. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .) Different CD45 isoforms are expressed at different stages of lymphocyte development, making it a useful marker for lymphocyte subtyping. Na&iuml;ve T cells express an isoform of CD45 called CD45RA, and are negative for a second isoform, CD45RO, that is expressed following activation (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1263084\">",
"    <span class=\"h2\">",
"     T cell activation markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells express a variety of surface molecules after activation via the antigen receptor. These include CD69, CD40 ligand, CD28, CD25, MHC class II, and an isoform of CD45 called CD4RO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1265553\">",
"    <span class=\"h2\">",
"     Memory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Memory T cells express CD45RO and (like memory B cells) CD27. The proportions of na&iuml;ve vs activated or memory T cells may have clinical applications in the diagnosis of autoimmune or inflammatory conditions and immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/23/31098/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5924629\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary tissues responsible for the initial generation of B and T lymphocytes are the bone marrow and thymus, respectively. Secondary lymphoid tissues include lymph nodes, spleen, tonsils, and lymphoid aggregations in the mucosa of the gastrointestinal and respiratory tracts. Within these secondary lymphoid tissues B and T cells are largely segregated, with B cells mainly localized to follicles and T cells in the interfollicular areas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       B cells",
"      </strong>",
"      &mdash; The earliest recognizable stage is called the B progenitor cell or pre-pro-B cell. Subsequent stages include the pro-B cell; the pre-B cell; the naive or mature B cell; antigen-activated B cell; the plasma cell; and the memory cell. Rearrangement of immunoglobulin heavy and light chain genes is an essential facet not only of mature B cell function but also of all but the earliest stages of B cell development. (See",
"      <a class=\"local\" href=\"#H1229513\">",
"       'B cell development'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All mature B cells have immunoglobulin receptors and express CD19 and CD20, but can be divided into subgroups based on expression of other surface markers (",
"      <a class=\"graphic graphic_table graphicRef68762 \" href=\"mobipreview.htm?17/0/17420\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       T cells",
"      </strong>",
"      &mdash; The vast majority of T cells develop in the thymus, while a distinct population develops in the intestinal lamina propria. The genetics of the T cell receptor (TCR), and the cellular interactions in T cell activation and effector mechanisms are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=see_link\">",
"       \"T cell receptor genetics\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"       \"The adaptive cellular immune response\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Two principal categories of T cells have been defined: T cells that modulate the activity of B cells and other T cells (helper T cells), and effector cells mediating cellular immune responses (cytotoxic T cells). (See",
"      <a class=\"local\" href=\"#H1231827\">",
"       'T cell repertoire'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All mature thymocytes and peripheral blood T cells bear the CD2, CD3- T-cell receptor complex, CD5, and CD28 antigens (",
"      <a class=\"graphic graphic_table graphicRef50154 \" href=\"mobipreview.htm?40/17/41243\">",
"       table 5",
"      </a>",
"      ). Other surface molecules such as CD4 and CD8, as well as cytokine and chemokine receptors serve to differentiate several functionally distinct subpopulations of mature T cells. (See",
"      <a class=\"local\" href=\"#H1232021\">",
"       'Characteristics of mature T cells'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/2\">",
"      Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008; 132:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/3\">",
"      Nu&ntilde;ez C, Nishimoto N, Gartland GL, et al. B cells are generated throughout life in humans. J Immunol 1996; 156:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/4\">",
"      LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008; 112:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/5\">",
"      Bj&ouml;rck P, Kincade PW. CD19+ pro-B cells can give rise to dendritic cells in vitro. J Immunol 1998; 161:5795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/6\">",
"      Dorshkind K, Montecino-Rodriguez E. Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol 2007; 7:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/7\">",
"      Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science 2002; 296:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/8\">",
"      Tedder TF, Zhou LJ, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today 1994; 15:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/9\">",
"      He XY, Antao VP, Basila D, et al. Isolation and molecular characterization of the human CD34 gene. Blood 1992; 79:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/10\">",
"      Melchers F, Karasuyama H, Haasner D, et al. The surrogate light chain in B-cell development. Immunol Today 1993; 14:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/11\">",
"      Schuh W, Meister S, Roth E, J&auml;ck HM. Cutting edge: signaling and cell surface expression of a mu H chain in the absence of lambda 5: a paradigm revisited. J Immunol 2003; 171:3343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/12\">",
"      Yel L, Minegishi Y, Coustan-Smith E, et al. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med 1996; 335:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/13\">",
"      Minegishi Y, Coustan-Smith E, Wang YH, et al. Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med 1998; 187:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/14\">",
"      Minegishi Y, Coustan-Smith E, Rapalus L, et al. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest 1999; 104:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/15\">",
"      Ferrari S, Lougaris V, Caraffi S, et al. Mutations of the Igbeta gene cause agammaglobulinemia in man. J Exp Med 2007; 204:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/16\">",
"      Vetrie D, Vorechovsk&yacute; I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/17\">",
"      Minegishi Y, Rohrer J, Coustan-Smith E, et al. An essential role for BLNK in human B cell development. Science 1999; 286:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/18\">",
"      Schweighoffer E, Vanes L, Mathiot A, et al. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003; 18:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/19\">",
"      Cossman J, Neckers LM, Arnold A, Korsmeyer SJ. Induction of differentiation in a case of common acute lymphoblastic leukemia. N Engl J Med 1982; 307:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/20\">",
"      Nadler LM, Ritz J, Bates MP, et al. Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest 1982; 70:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/21\">",
"      Shipp MA, Richardson NE, Sayre PH, et al. Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci U S A 1988; 85:4819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/22\">",
"      Shipp MA, Vijayaraghavan J, Schmidt EV, et al. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 (\"enkephalinase\"): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A 1989; 86:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/23\">",
"      Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/24\">",
"      Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/25\">",
"      Hemler ME. VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol 1990; 8:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/26\">",
"      Ryan DH, Nuccie BL, Abboud CN, Winslow JM. Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. J Clin Invest 1991; 88:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/27\">",
"      Durie FH, Foy TM, Masters SR, et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994; 15:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/28\">",
"      Armitage RJ, Fanslow WC, Strockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/29\">",
"      Nitschke L, Tsubata T. Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends Immunol 2004; 25:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/30\">",
"      van Zelm MC, van der Burg M, Langerak AW, van Dongen JJ. PID comes full circle: applications of V(D)J recombination excision circles in research, diagnostics and newborn screening of primary immunodeficiency disorders. Front Immunol 2011; 2:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/31\">",
"      GOWANS JL, KNIGHT EJ. THE ROUTE OF RE-CIRCULATION OF LYMPHOCYTES IN THE RAT. Proc R Soc Lond B Biol Sci 1964; 159:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/32\">",
"      Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983; 304:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/33\">",
"      Goldstein LA, Zhou DF, Picker LJ, et al. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 1989; 56:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/34\">",
"      St John T, Meyer J, Idzerda R, Gallatin WM. Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 1990; 60:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/35\">",
"      Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/36\">",
"      Stoolman LM. Adhesion molecules controlling lymphocyte migration. Cell 1989; 56:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/37\">",
"      Tedder TF, Penta AC, Levine HB, Freedman AS. Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. J Immunol 1990; 144:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/38\">",
"      Spertini O, Freedman AS, Belvin MP, et al. Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia 1991; 5:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/39\">",
"      Siegelman MH, van de Rijn M, Weissman IL. Mouse lymph node homing receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains. Science 1989; 243:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/40\">",
"      Springer TA. Adhesion receptors of the immune system. Nature 1990; 346:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/41\">",
"      Astier AL, Xu R, Svoboda M, et al. Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival. Blood 2003; 101:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/42\">",
"      Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010; 120:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/43\">",
"      Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111:3941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/44\">",
"      Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol 2000; 74:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/45\">",
"      Freedman AS, Munro JM, Rice GE, et al. Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science 1990; 249:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/46\">",
"      Li L, Zhang X, Kovacic S, et al. Identification of a human follicular dendritic cell molecule that stimulates germinal center B cell growth. J Exp Med 2000; 191:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/47\">",
"      Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003; 112:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/48\">",
"      Van de Velde H, von Hoegen I, Luo W, et al. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 1991; 351:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/49\">",
"      Bikah G, Carey J, Ciallella JR, et al. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 1996; 274:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/50\">",
"      Youinou P, Jamin C, Lydyard PM. CD5 expression in human B-cell populations. Immunol Today 1999; 20:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/51\">",
"      Nisitani S, Murakami M, Akamizu T, et al. Preferential localization of human CD5+ B cells in the peritoneal cavity. Scand J Immunol 1997; 46:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/52\">",
"      Bofill M, Janossy G, Janossa M, et al. Human B cell development. II. Subpopulations in the human fetus. J Immunol 1985; 134:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/53\">",
"      Hannet I, Erkeller-Yuksel F, Lydyard P, et al. Developmental and maturational changes in human blood lymphocyte subpopulations. Immunol Today 1992; 13:215, 218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/54\">",
"      Lydyard PM, Quartey-Papafio R, Br&ouml;ker B, et al. The antibody repertoire of early human B cells. I. High frequency of autoreactivity and polyreactivity. Scand J Immunol 1990; 31:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/55\">",
"      Chen ZJ, Wheeler J, Notkins AL. Antigen-binding B cells and polyreactive antibodies. Eur J Immunol 1995; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/56\">",
"      Casali P, Notkins AL. Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. Annu Rev Immunol 1989; 7:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/57\">",
"      Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 2010; 10:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/58\">",
"      Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/59\">",
"      Ueki Y, Goldfarb IS, Harindranath N, et al. Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med 1990; 171:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/60\">",
"      Clark EA, Ledbetter JA. Structure, function, and genetics of human B cell-associated surface molecules. Adv Cancer Res 1989; 52:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/61\">",
"      Gordon J. B-cell signalling via the C-type lectins CD23 and CD72. Immunol Today 1994; 15:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/62\">",
"      Stokes J, Casale TB. Rationale for new treatments aimed at IgE immunomodulation. Ann Allergy Asthma Immunol 2004; 93:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/63\">",
"      Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 2009; 229:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/64\">",
"      Liu M, Duke JL, Richter DJ, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008; 451:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/65\">",
"      Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15:5494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/66\">",
"      Islam KB, Nilsson L, Sideras P, et al. TGF-beta 1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes. Int Immunol 1991; 3:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/67\">",
"      Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev 2005; 203:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/68\">",
"      Uckun FM. Regulation of human B-cell ontogeny. Blood 1990; 76:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/69\">",
"      Oracki SA, Walker JA, Hibbs ML, et al. Plasma cell development and survival. Immunol Rev 2010; 237:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/70\">",
"      Nutt SL, Fairfax KA, Kallies A. BLIMP1 guides the fate of effector B and T cells. Nat Rev Immunol 2007; 7:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/71\">",
"      Hu CC, Dougan SK, McGehee AM, et al. XBP-1 regulates signal transduction, transcription factors and bone marrow colonization in B cells. EMBO J 2009; 28:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/72\">",
"      Schuber F, Lund FE. Structure and enzymology of ADP-ribosyl cyclases: conserved enzymes that produce multiple calcium mobilizing metabolites. Curr Mol Med 2004; 4:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/73\">",
"      Gray D. Immunological memory: a function of antigen persistence. Trends Microbiol 1993; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/74\">",
"      Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/75\">",
"      van de Ven AA, van de Corput L, van Tilburg CM, et al. Lymphocyte characteristics in children with common variable immunodeficiency. Clin Immunol 2010; 135:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/76\">",
"      Pace KE, Hahn HP, Pang M, et al. CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000; 165:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/77\">",
"      Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/78\">",
"      Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Molecular biological ontogenesis of the thymic reticulo-epithelial cell network during the organization of the cellular microenvironment. In Vivo 1999; 13:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/79\">",
"      Hadden JW. Thymic endocrinology. Ann N Y Acad Sci 1998; 840:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/80\">",
"      Rossi SW, Jenkinson WE, Anderson G, Jenkinson EJ. Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium. Nature 2006; 441:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/81\">",
"      Bleul CC, Corbeaux T, Reuter A, et al. Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature 2006; 441:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/82\">",
"      Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity 2010; 32:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/83\">",
"      Sch&uuml;ler T, H&auml;mmerling GJ, Arnold B. Cutting edge: IL-7-dependent homeostatic proliferation of CD8+ T cells in neonatal mice allows the generation of long-lived natural memory T cells. J Immunol 2004; 172:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/84\">",
"      Puel A, Leonard WJ. Mutations in the gene for the IL-7 receptor result in T(-)B(+)NK(+) severe combined immunodeficiency disease. Curr Opin Immunol 2000; 12:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/85\">",
"      Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009; 9:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/86\">",
"      Singh VK, Biswas S, Mathur KB, et al. Thymopentin and splenopentin as immunomodulators. Current status. Immunol Res 1998; 17:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/87\">",
"      Haks MC, Oosterwegel MA, Blom B, et al. Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR. Semin Immunol 1999; 11:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/88\">",
"      Anderson G, Harman BC, Hare KJ, Jenkinson EJ. Microenvironmental regulation of T cell development in the thymus. Semin Immunol 2000; 12:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/89\">",
"      Ulrichs T, Porcelli SA. CD1 proteins: targets of T cell recognition in innate and adaptive immunity. Rev Immunogenet 2000; 2:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/90\">",
"      Dimitroff CJ, Lee JY, Rafii S, et al. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001; 153:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/91\">",
"      Gaffen SL. Signaling domains of the interleukin 2 receptor. Cytokine 2001; 14:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/92\">",
"      Dadi HK, Simon AJ, Roifman CM. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med 2003; 349:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/93\">",
"      Irving BA, Alt FW, Killeen N. Thymocyte development in the absence of pre-T cell receptor extracellular immunoglobulin domains. Science 1998; 280:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/94\">",
"      Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/95\">",
"      Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004; 4:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/96\">",
"      von Boehmer H, Aifantis I, Azogui O, et al. The impact of pre-T-cell receptor signals on gene expression in developing T cells. Cold Spring Harb Symp Quant Biol 1999; 64:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/97\">",
"      Palmer E. Negative selection--clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol 2003; 3:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/98\">",
"      Ye P, Kirschner DE. Measuring emigration of human thymocytes by T-cell receptor excision circles. Crit Rev Immunol 2002; 22:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/99\">",
"      van den Dool C, de Boer RJ. The effects of age, thymectomy, and HIV Infection on alpha and beta TCR excision circles in naive T cells. J Immunol 2006; 177:4391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/100\">",
"      Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol 2012; 129:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/101\">",
"      Lewis JM, Girardi M, Roberts SJ, et al. Selection of the cutaneous intraepithelial gammadelta+ T cell repertoire by a thymic stromal determinant. Nat Immunol 2006; 7:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/102\">",
"      Prezzi C, Casciaro MA, Francavilla V, et al. Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur J Immunol 2001; 31:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/103\">",
"      Tsuji-Yamada J, Nakazawa M, Minami M, Sasaki T. Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 2001; 28:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/104\">",
"      Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/105\">",
"      Albert MH, Anasetti C, Yu XZ. T regulatory cells as an immunotherapy for transplantation. Expert Opin Biol Ther 2006; 6:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/106\">",
"      Purwar R, Schlapbach C, Xiao S, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/107\">",
"      Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/108\">",
"      Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007; 6:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/109\">",
"      de Latour RP, Visconte V, Takaku T, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood 2010; 116:4175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/110\">",
"      Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/111\">",
"      Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/112\">",
"      Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. Allergol Int 2008; 57:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/113\">",
"      Amin K, L&uacute;dv&iacute;ksd&oacute;ttir D, Janson C, et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med 2000; 162:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/114\">",
"      McDonald DR. TH17 deficiency in human disease. J Allergy Clin Immunol 2012; 129:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/23/31098/abstract/115\">",
"      Perniola R, Lobreglio G, Rosatelli MC, et al. Immunophenotypic characterisation of peripheral blood lymphocytes in autoimmune polyglandular syndrome type 1: clinical study and review of the literature. J Pediatr Endocrinol Metab 2005; 18:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13933 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31098=[""].join("\n");
var outline_f30_23_31098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5924629\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1229438\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1229463\">",
"      NORMAL LYMPHOID TISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1229488\">",
"      ORIGIN OF LYMPHOID CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1229513\">",
"      B CELL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1229574\">",
"      Role of immunoglobulin gene rearrangements in B cell development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1229599\">",
"      Pro-B cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1229690\">",
"      Pre-B cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1230059\">",
"      Mature B cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1230519\">",
"      B cell subsets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1230750\">",
"      B cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1230945\">",
"      Maturation of activated B cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231030\">",
"      Plasma cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231087\">",
"      Memory B cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231136\">",
"      T CELL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231171\">",
"      T cell lineages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231244\">",
"      Origins of thymocyte progenitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231299\">",
"      Intrathymic regulatory factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231468\">",
"      Intrathymic T cell development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231735\">",
"      T cell co-receptors CD4 and CD8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231784\">",
"      Late thymic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231827\">",
"      T CELL REPERTOIRE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231865\">",
"      Positive selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231902\">",
"      Negative selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231927\">",
"      The mature phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231972\">",
"      Development of gamma-delta cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1232021\">",
"      CHARACTERISTICS OF MATURE T CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232084\">",
"      Cytotoxic T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232109\">",
"      Modulatory T cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1232122\">",
"      - Th1 cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1232147\">",
"      - Th2 cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1232172\">",
"      - Regulatory T cells (Tregs)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24003629\">",
"      - Th9 cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1232221\">",
"      - Th17 cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1265604\">",
"      Na&iuml;ve T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1263084\">",
"      T cell activation markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1265553\">",
"      Memory T cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5924629\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/13933\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13933|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/60/30670\" title=\"figure 1\">",
"      Structure T cell receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/33/22047\" title=\"figure 2\">",
"      Scheme thymic T cell development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13933|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/8/40076\" title=\"table 1\">",
"      Immunoglobulin genes in B cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/55/31613\" title=\"table 2A\">",
"      B cell surface markers I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/30/4589\" title=\"table 2B\">",
"      B cell surface markers II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/0/17420\" title=\"table 3\">",
"      B cell subsets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/56/17291\" title=\"table 4\">",
"      Characteristics TEC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/17/41243\" title=\"table 5\">",
"      Surface markers resting mature T cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9688?source=related_link\">",
"      Pathogenesis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31242?source=related_link\">",
"      The development of immune cells in the fetus and neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_23_31099="Viral hepatitis prevention";
var content_f30_23_31099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Viral hepatitis prevention board",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Seven points consensus on hepatitis B as an occupational hazard",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Occupational hepatitis B vaccination programs should apply equally to employees in both the public and private sectors, self-employed staff, students, contract workers and voluntary workers.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The employer must ensure that the risk of occupational transmission is assessed. The assessment should be based on work practices and should be independent of job title or status.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If the assessment shows the worker is at risk of contamination, the employer has the obligation to inform the worker at risk.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Information, training and education must be provided by the employer for the above workers on the measures to be taken to protect them from risk.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The employer must offer the above workers vaccination free of charge.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The employer has an obligation to ensure that exposed workers are correctly vaccinated. Employees who decline vaccination must be counseled and sign a refusal form.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Current practices should be improved by providing information to increase awareness and change attitudes, thereby improving acceptance of vaccination. Information and education should be targeted at occupational health professionals, employers and managers, workers, health and safety representatives and unions.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Hallower J, Kane M, McCloy E (Eds). Eliminating Hepatitis B as an occupational hazard. London medical imprint 1993. p.114.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31099=[""].join("\n");
var outline_f30_23_31099=null;
var title_f30_23_31100="Benign EEG variants";
var content_f30_23_31100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Benign EEG variants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Patient: age / state",
"      </td>",
"      <td class=\"subtitle1\">",
"       Waveform: morphology / frequency",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration",
"      </td>",
"      <td class=\"subtitle1\">",
"       Distribution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Benign spike-like patterns",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Small sharp spikes",
"      </td>",
"      <td>",
"       Adults / drowsiness and light sleep",
"      </td>",
"      <td>",
"       Monophasic or diphasic spikes",
"      </td>",
"      <td>",
"       Phase &lt;50 msecs",
"      </td>",
"      <td>",
"       Bi-hemispheric maximal-anterior / mid temporal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Wicket spikes",
"      </td>",
"      <td>",
"       Adults / drowsiness and light sleep",
"      </td>",
"      <td>",
"       Sharply contoured arch shaped / 6 to 11 Hz",
"      </td>",
"      <td>",
"       Few seconds",
"      </td>",
"      <td>",
"       Bilateral anterior / mid temporal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       14- and 6-Hz positive bursts",
"      </td>",
"      <td>",
"       Children and adolescents / drowsiness and light sleep",
"      </td>",
"      <td>",
"       Arch shaped positive sharp component / 4-7 Hz and 13-17 Hz range",
"      </td>",
"      <td>",
"       Less than 1 to 2 seconds",
"      </td>",
"      <td>",
"       Bilateral posterior temporal / parietal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       6 Hz spike and wave",
"      </td>",
"      <td>",
"       Adolescents and young adults / relaxed wakefulness and drowsiness",
"      </td>",
"      <td>",
"       Low voltage spike-high amplitude slow wave / 5 to 7 Hz",
"      </td>",
"      <td>",
"       1 to 2 seconds",
"      </td>",
"      <td>",
"       Generalized / at times maximal anterior or posterior",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Rhythmic patterns with an epileptiform morphology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rhythmic temporal theta bursts of drowsiness",
"      </td>",
"      <td>",
"       Adolescents and young adults / relaxed wakefulness and drowsiness",
"      </td>",
"      <td>",
"       Notched flat topped / 5 to 7 Hz",
"      </td>",
"      <td>",
"       Seconds",
"      </td>",
"      <td>",
"       Bilateral temporal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Subclinical rhythmic EEG discharge in adults",
"      </td>",
"      <td>",
"       Adults &gt;50 / hyperventilation, drowsiness",
"      </td>",
"      <td>",
"       Rhythmic sharply contoured / 5 to 6 Hz",
"      </td>",
"      <td>",
"       40 to 80 seconds",
"      </td>",
"      <td>",
"       Bilateral parietal / posterior temporal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Midline theta rhythm",
"      </td>",
"      <td>",
"       Children and adults / awake, drowsy",
"      </td>",
"      <td>",
"       Sinusoidal, arciform / 5 to 7 Hz",
"      </td>",
"      <td>",
"       4 to 20 seconds",
"      </td>",
"      <td>",
"       Midline, maximal centrally",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mushtaq, R, Van Cott, AC, Benign EEG variants. Am J Electroneurodiagnostic Technol 2005; 45:88. Copyright &copy;2005 American Society of Electroneurodiagnostic Technologists.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31100=[""].join("\n");
var outline_f30_23_31100=null;
var title_f30_23_31101="CHA2DS2-VASc score and stroke risk";
var content_f30_23_31101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    CHA2DS2-VASc score and stroke risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Risk factors for stroke and thromboembolism in non-valvular AF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Major risk factors",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Clinically relevant non-major risk factors",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Previous stroke, TIA, or systemic embolism",
"        </p>",
"        Age &ge;75 years",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         Heart failure or moderate to severe LV systolic dysfunction (eg, LV EF &le;40 percent)",
"        </p>",
"        <p>",
"         Hypertension - diabetes mellitus",
"        </p>",
"        <p>",
"         Female sex - age 65 to 74 years",
"        </p>",
"        Vascular disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Risk factor-based approach expressed as a point based scoring system, with the acronym CHA",
"        <sub>",
"         2",
"        </sub>",
"        DS",
"        <sub>",
"         2",
"        </sub>",
"        -VASc",
"        <br/>",
"        (Note: maximum score is 9 since age may contribute 0, 1, or 2 points)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Risk factor",
"       </td>",
"       <td class=\"subtitle2\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Congestive heart failure/LV dysfunction",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Hypertension",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Age &ge;75",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Diabetes mellitus",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Stroke/TIA/thrombo-embolism",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Vascular disease*",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Age 65 to 74",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"2\">",
"        Sex category (ie, female sex)",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"2\">",
"        <strong>",
"         Maximum score",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         9",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Adjusted stroke rate according to CHA",
"        <sub>",
"         2",
"        </sub>",
"        DS",
"        <sub>",
"         2",
"        </sub>",
"        -VASc score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        CHA",
"        <sub>",
"         2",
"        </sub>",
"        DS",
"        <sub>",
"         2",
"        </sub>",
"        -VASc score",
"       </td>",
"       <td class=\"subtitle2\">",
"        Patients",
"        <br/>",
"        (n = 7329)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Adjusted stroke rate",
"        <br/>",
"        (percent/year)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        422",
"       </td>",
"       <td class=\"centered\">",
"        1.3 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        1230",
"       </td>",
"       <td class=\"centered\">",
"        2.2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        1730",
"       </td>",
"       <td class=\"centered\">",
"        3.2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        1718",
"       </td>",
"       <td class=\"centered\">",
"        4.0 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        1159",
"       </td>",
"       <td class=\"centered\">",
"        6.7 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        679",
"       </td>",
"       <td class=\"centered\">",
"        9.8 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td class=\"centered\">",
"        294",
"       </td>",
"       <td class=\"centered\">",
"        9.6 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        82",
"       </td>",
"       <td class=\"centered\">",
"        6.7 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td class=\"centered\">",
"        15.2 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AF: atrial fibrillation; EF: ejection fraction (as documented by echocardiography, radionuclide ventriculography, cardiac catheterization, cardiac magnetic resonance imaging, etc); LV: left ventricular; TIA: transient ischaemic attack.",
"     <br>",
"      * Prior myocardial infarction, peripheral artery disease, aortic plaque. Actual rates of stroke in contemporary cohorts may vary from these estimates.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Based on Lip, et al.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369. By permission of the European Society of Cardiology. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31101=[""].join("\n");
var outline_f30_23_31101=null;
var title_f30_23_31102="XRT thyroid cancer survival";
var content_f30_23_31102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    External radiation therapy and thyroid cancer survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 451px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    154 patients over the age of 45 with microscopic residual papillary cancer after surgery. Ninety patients received external radiation; 64 did not. The cause-specific survival was 100 percent at 10 years in patients given external radiation compared&nbsp;with 95.3 percent if RT was not prescribed. The local recurrence-free rate was 94.2 percent if given external radiation, compared with 83.9 percent if not.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James D Brierley, MB, BS, FRCP, FRCR, FRCPC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31102=[""].join("\n");
var outline_f30_23_31102=null;
var title_f30_23_31103="Rash in Staphylococcal toxic shock syndrome";
var content_f30_23_31103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rash in Staphylococcal toxic shock syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous maculopapular eruption on the abdomen in a patient with staphylococcal toxic shock syndrome (TSS). The erythroderm of TSS can be subtle and resemble a sunburn.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_23_31103=[""].join("\n");
var outline_f30_23_31103=null;
